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Abstract 
Bromotyrosine-derived natural products are a fascinating class of compounds that are 
produced by marine sponges of the order Verongida. Furthermore, they exhibit a rich 
variety of chemical structures and display a diverse range of bioactivities which 
makes them of great interest to both the chemical and biological research 
communities.  
This thesis is divided into four Chapters and describes the total syntheses of five 
bromotyrosine-derived natural products and analogues thereof. The anticancer activity 
of these compounds was also investigated. In addition, studies towards the total 
syntheses of the ceratamines are reported. 
The first Chapter gives a general introduction into the history, biosynthesis, structures 
and biological activities of bromotyrosine-derived natural products. A background 
into the anticancer properties of ceratamines A and B is also provided.  
The research in Chapter two is concerned with bromotyrosine-derived oximes and is 
divided into two parts. The syntheses of the natural products (5)-bromoverongamine, 
ianthelline and JBIR-44 are described in Part one and the structure-activity 
relationship studies into these products is described in Part two. 
The total syntheses of subereamollines A and B are discussed in Chapter three. 
Furthermore, both enantiomers of the natural products were accessed and their 
absolute stereochemistry was unambiguously assigned. 
The first section of Chapter four provides an in-depth review of the research carried 
out by the Andersen and Coleman groups into the ceratamines. This is followed by an 
account of the Ley group approach towards the syntheses of these natural products.  
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2 
1.1 Perspective 
Global research efforts have led to remarkable advances in our understanding of 
cancer biology in recent years. However, as the incidence of cancer rises, the disease 
presents major health problems for ever-widening populations, bringing in turn, 
increasing strain on healthcare systems. Huge investments in research have been made 
to try and tackle these problems. One aspect of the solution lies in the need for new 
anticancer drugs and more effective treatment strategies. Cancer therapy has already 
had some success generated by this momentum, particularly with mechanism-based 
drugs that interact with protein kinases and their signalling pathways e.g. Gleevec. 
However, the continued search for improved cytotoxic agents that act on ubiquitous 
targets such as DNA (e.g. cisplatins) or tubulin (e.g. natural products) continues. As 
the major types of solid human tumours are multi-causal in nature, there is a 
movement towards treatments that involve combinations of signal transduction 
inhibitors (mechanism-based) with improved and more specific cytotoxic drugs. 
The search for lead compounds is an essential component of pharmaceutical research, 
and for many thousands of years natural products have made enormous contributions 
to human health. However, it was not until the 1950s that, as a result of a concerted 
effort made by the NCI in the United States supporting screening programmes, the 
speed of discovery of new naturally occurring anticancer agents began to surge. The 
range of natural products with striking anticancer profiles is quite remarkable.1 
Indeed, natural product-derived anticancer therapies are now relatively common 
treatments in the clinic e.g. paclitaxel and vinorelbine. Newer anticancer therapies 
such as the combretastatins2 are in late stage clinical trials, and an epothilone 
analogue (ixabepilone) has recently been approved for clinical use.3  
Sadly, in spite of this, the use of natural products and their importance as a source of 
molecular diversity has been overshadowed by various industry-favoured approaches 
including high-throughput screening and combinatorial approaches for generating 
synthetic small molecules. However, drug discovery from natural sources has a robust 
historical justification and good biochemical and chemical rationales. Natural 
products will continue to serve as an inspiration for the discovery of new drugs. 
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1.2 Marine Natural Products 
Marine life differs from terrestrial life in many respects and this has implications on 
the natural product diversity observed in these environments. It has been established 
that while terrestrial life is far richer in species, marine life is richer in phyla. In 
examining the higher taxa, there is greater biodiversity exhibited in the sea.4 This is 
paralleled in the increased diversity in the molecular frameworks possessed by marine 
natural products. The members of this chemically diverse family of natural products 
also exhibit a broad spectrum of bioactivities. Indeed, some of the most toxic 
compounds known to man are of marine origin.5  
The last few years have seen an unprecedented rise in the number of newly discovered 
marine natural products that have been reported in the literature. To put this in 
context, over 1000 new compounds were identified in both 2008 and 2009.6 In part, 
this increase is testament to recent scientific advances in the collection, isolation and 
structural elucidation of these substances; many of the stereochemical and 
connectivity problems encountered when trying to unravel complex chemical 
structures have been solved by the emergence of new techniques in nuclear magnetic 
resonance, mass spectrometry and X-ray crystallography.  
This rise in the number of reported compounds can also be attributed to the interest 
that marine natural products generate within the scientific community. Besides the 
obvious desire that pharmaceutical companies have in transforming novel bioactive 
entities into marketable drugs, synthesis chemists revel in the challenge of 
constructing complex molecular architectures and biochemists need new chemical 
tools that aid in delineating biological pathways and the identification of new 
biological targets. 
1.3 Bromotyrosine-Derived Natural Products 
Seawater is known for its high chloride ion concentration (∼0.5 M); however, the 
occurrence of the other halides is often overlooked. Bromide (the fourth most 
abundant anion in seawater) is the second most abundant halide ([Br]– ∼0.8 mM), 
followed by fluoride ([F]– ∼70 µM) and then iodide ([I]– ∼0.4 µM).7 These halide ions 
are believed to originate from minerals that have been washed out of the ground and 
carried into the sea by rivers–a process known as continental weathering. 
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Unlike terrestrial organisms, marine organisms are constantly exposed to halide ions 
and, as a consequence of this, have evolved to incorporate halogens into the 
biosyntheses of compounds that they use for defensive armament against predation. 
These halogenated natural products (also known as secondary metabolites) are most 
commonly found in red algae and sponges and in terms of structure, range from one-
carbon species, such as iodomethane and carbon tetrabromide,8 to much more 
complex substances, for example thyrsiferyl acetate (1) (Figure 1).9 Interestingly, the 
first halogenated secondary metabolite to be reported was diiodotyrosine (2), isolated 
from the coral Gorgonia cavolii by Drechsel in 1896.10  
NH2
OH
O
OH
II
2
O
O
O
Br
OH
OH
O
OAc
1
HH
 
Figure 1 Structures of thysiferyl acetate (1) and diiodotyrosine (2). 
Although the concentration of bromide is much lower than that of chloride, the 
number of naturally occurring organochlorine compounds (2320*) that have been 
identified only slightly exceeds the number of natural organobromine compounds 
(2050*).11 This non-statistical outcome is due to the fact that it is easier for marine 
organisms to incorporate bromide into organic compounds; the standard oxidation 
potential of bromide is –1.07 V compared to –1.36 V for chloride.12 The research 
described herein focuses on bromotyrosine-derived natural products, a specific class 
of brominated secondary metabolites. 
Bromotyrosine-derived natural products are produced by horny sponges of the order 
Verongida. These sponges possess an unusual biochemistry and, as a result, have 
promoted much biological and chemical interest. Characteristics of these sponges 
include a lack of terpenes, production of large amounts of sterol that contain the 
aplystane skeleton† and an ability to synthesise bromotyrosine derivatives. Further to 
this, as bromotyrosine metabolites occur in virtually all Verongida sponges they have 
been used as chemotaxonomic markers to correctly identify different species due to 
the difficulty of identifying sponges on their morphology alone.13 
                                                
* 2004 estimate (See Ref 10). 
† There is an extra methyl group at C-26 in steroids containing the aplystane skeleton. 
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Following the first reported isolation of 3,5-dibromotyrosine (3) from two species of 
coral by Morner in 1913,14 over half a century passed before the first bromotyrosine 
derivative, verongiaquinol (4), was discovered (Figure 2).15 Since then, knowledge of 
these fascinating compounds has grown immensely as a consequence of their diverse 
bioactivity (Section 1.3.3). To date, over 300 of these secondary metabolites have 
been reported in the literature. 
NH2
OH
O
OH
BrBr
3
O
BrBr
HO
NH2
O
4
Morner (1913) Sharma and Burkholder (1967)  
Figure 2 Structures of 3,5-dibromotyrosine (3) and verongiaquinol (4). 
1.3.1 Biosynthesis: Vanadium Bromoperoxidases 
Biosynthetically, enzymes collectively known as the vanadium bromoperoxidases 
(VBPO) are believed to install the bromine functionality within bromotyrosine-
derived secondary metabolites.16 They are able to do this by catalysing the bromide-
assisted disproportionation of hydrogen peroxide to an electrophilic brominating 
species and water (Scheme 1, equation 1). This is followed by concomitant 
bromination of the organic substrate held in the active site (Scheme 1, equation 2). 
H2O2 + H+ + Br– → HOBr + H2O (equation 1) 
HOBr + Org-H → Org-Br + H2O (equation 2) 
Scheme 1 Process catalysed by VBPOs illustrated in the simplest form. 
These enzymes have attracted much interest due to their ability to introduce bromine 
atoms into aromatic compounds and their dependence on the transition metal 
vanadium.17 Vanadium bromoperoxidases are dodecameric in structure with each of 
the 12 protein subunits containing cationic vanadium(V) (Figure 3).18  
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Figure 3 Left: dodecameric structure of Corallina VBPO; right: ribbon diagram of a single 
subunit (vanadate shown in purple). Images taken from J. Inorg. Biochem., 2009, 103, 617 
and J. Biol. Inorg. Chem., 2005, 10, 275. 
As previously mentioned, bromination reactions catalysed by these enzymes proceed 
via an electrophilic mechanism and not a radical process.19 The actual electrophilic 
brominating species is thought to be either a free halogenating agent such as Br2, Br3–, 
or HOBr, or an enzyme–Br complex e.g. Venz–OBr.20 A combination of mechanistic 
and X-ray diffraction studies has helped to elucidate the intricacies of the catalytic 
bromination process.21  
V
N
OH
O
O
O
His
N
His
V
N
O
O
N
His
O
O
H
Lys NH3
Br
H2O2, 2H
+
2H2O
Br
HOBr
H2O
H+
5
6  
Figure 4 Simplified diagram representative of the VBPO catalytic cycle.  
In the resting state of the enzyme, the vanadate(V) ion housed in the active site is 
bound to the protein by a histidine residue (Figure 4). Hydrogen peroxide can 
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coordinate to the resting state 5 to form an oxoperoxo vanadium(V) species (6). This 
species is hydrogen bonded to a lysine residue and this is thought to assist in the 
oxidation of the bromide by increasing the oxidation potential. The bromide ion held 
in the active site‡ reacts with 6 to form the oxidised halogen intermediate (HOBr in 
this case), which can then act to brominate the desired organic substrate that is also 
held in the active site.  
The stage at which bromination takes place in the biosynthesis of bromotyrosine-
derived natural products is still unclear. One theory, as their name suggests, is that 
they are assembled from subunits of either monobromotyrosine (8) or 
dibromotyrosine (9) that come from the bromination of the amino acid L-tyrosine (7) 
(Scheme 2). However, since the substrates for vanadium bromoperoxidases are only 
required to be phenolic in nature,22 it could be envisaged that more complex 
intermediates may well be brominated at later stages of a biosynthetic pathway. 
NH2
OH
O
OH
Br
8
NH2
OH
O
OH
Tyrosine (7)
Vanadium Bromoperoxidase
Br–, H2O2
NH2
OH
O
OH
BrBr
9
and
 
Scheme 2 Bromination of tyrosine (7) 
The research described within this thesis relates to compounds derived from a 
dibromotyrosine subunit. 
1.3.2 Structures of Bromotyrosine-Derived Natural Products 
The 300 or so bromotyrosine-derived natural products that are currently known 
exhibit a rich variety of chemical structures and this has led to them being classified 
into six main categories: simple bromotyrosine derivatives, oximes, bastadins, 
spirocyclohexadienylisoxazolines, spirooxepineisoxazolines, and other structural 
classes.23 To review all these classes in detail would be excessive and beyond the 
scope of this thesis; however, by way of a few examples some of the important 
structural features are worth mentioning (Figure 5). 
 
                                                
‡ Recently, Littlechild and co-workers have unambiguously shown that in the VBPO of Corallina 
piluifera, the bromide ion is held in the active site by an arginine residue and positioned within 
hydrogen bonding distance to the vanadate ion (J. Inorg. Biochem., 2009, 103, 617). 
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Figure 5 Examples of structures from the six classes of bromotyrosine products. 
The simple derivatives contain a single bromotyrosine subunit and are products of 
degradation, reduction, hydroxylation, alkylation or esterification with simple 
functional groups; 3,5-dibromo-4-methoxyphenethylamine (10) is a member of this 
class.24 Oxidation of the tyrosine amino functionality give rises to the oxime 
derivatives, e.g. psammaplin A (14),25 and these will be discussed in greater depth in 
Chapter 2.  
Members of the bastadins are predominantly macrocyclic in structure as exemplified 
by bastadin-19 (12).26 To date, around 30 members of this class have been identified 
from natural sources and they consist of four bromotyrosine subunits stitched together 
by amide and biaryl ether linkages. Some bastadins are currently used as biochemical 
tools to study calcium ion channels as they are novel allosteric modulators of the 
ryanodine receptor 1/FKBP12 complex, responsible for releasing Ca2+ ions from the 
sarcoplasmic reticulum.27  
The spirocylcohexadienylisoxazolines all contain a [6,5]-spirocyclic unit of the type 
possessed by compound 11. They are further catagorised as either mono- or bis-
spirocylcohexadienylisoxazolines depending on whether they contain one or two of 
these units, respectively. As a consequence of their biosynthesis the relative 
Chapter 1: Introduction 
9 
stereochemistry between the hydroxyl group at C-1 and oxygen in the oxazoline ring 
is conserved (Section 3.1.1), however, both absolute configurations at C-1 and C-6 are 
possible. A more detailed insight into these compounds will be provided in Chapter 3. 
Bromotyrosine-derived natural products bearing a spirooxepineisoxazoline core 
(compound 13) make up the smallest class with the identification of only 10 members 
to date: the psammaplysins A-G and ceratinamides A and B.28 Biosynthetically, 
oxidation of a tyrosine precursor 18 by an epoxidase yields 19. This then undergoes a 
rearrangement to give 20 which subsequently reacts with the hydroxyl group of the 
oxime to give the spirooxepineisoxazoline 21 (Scheme 3).  
20 21
OH
Br Br
N
OH
ORO
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OH
Br Br
O
N
HO
OR
O
19
O
OH
Br Br
N
HO
OR
O
H
O
OH
Br Br
O
N
O
OR
 
Scheme 3 Mechanism of the formation of spiroketal 21. 
The final class of natural products is a miscellany of compounds that bear no apparent 
structural relationship to one another; their common feature being that they are 
derived from bromotyrosine. When more is known about these compounds in the 
future, it may be possible to further categorise them. From a synthesis chemist’s 
perspective these molecules are perhaps the most intriguing with regards to their 
structure, as is illustrated by geodiamolide J29 (15), aplysillin A30 (16) and 
prepolycitrin A31 (17). The ceratamines (Section 1.3.4 and Chapter 4), a family of 
novel heterocyclic marine alkaloids, also fall into this category. 
1.3.3 Biological Activities 
Like terrestrial plant life, marine sponges have evolved a sophisticated chemical 
defense system to protect against their perilous environment. In addition to the 
obvious threat of predation, sponges may also be compromised by biofouling,§ 
pathogenic infections and the overgrowth of other marine invertebrates. Up to 40% of 
the total biomass in Verongida sponges is made up from bacteria, suggesting that 
                                                
§ Biofouling is the undesired attachment of microorganisms, plants, algae and animals to a surface. 
Sponges are filter-feeders and the build-up of organisms on their surface can be particularly damaging 
because the flow of water through the body of the sponge is reduced.     
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brominated secondary metabolites may also have a role in controlling bacterial 
colonisation.**32 
A particularly interesting facet of this defense mechanism is the response of these 
sponges to wounding. Typically, the chemical defense strategies of marine 
invertebrates are constitutive and rely on the accumulation of preformed toxins in 
tissues. These are either constantly secreted into the surrounding marine environment 
or are released upon wounding.33 In addition to this, Verongida sponges have an 
activated defense system that is highly dynamic and responds within seconds if said 
sponge comes under attack. Evidence suggests that if damaged is inflicted on the 
sponge, enzymes will convert high molecular weight isoxazoline bromotyrosine 
derivatives (Chapter 3) into lower molecular weight metabolites that exhibit greater 
bioactivities. Proksch and co-workers demonstrated that extracts of the sponge 
Aplysina aerophoba were able to convert several isoxazoline derivatives, including 
aerophobin-2 (22), into (+)-aeroplysinin-1 (23) which in turn was converted into 
verongiaquinol (4) (Scheme 4).34 It has since been postulated that the latter 
transformation is catalysed by a nitrile hydratase.35 
Br
Br
MeO
O
N
OH
H
N
O
N
H
N
NH2
BrBr
OMe
HO
OH
NC
O
BrBr
HO
NH2
O
22 (+)-23 4  
Scheme 4 Bioconversion of aerophobin-2 (22) to aeroplysinin-1 (23) and verongiaquinol (4). 
This process was complete within 40 seconds of mechanical wounding and both 23 
and 4 were found to have an increased ability to deter fish relative to 22. Around the 
same time Woerdenbag and co-workers discovered that 23 and 4 could form 
semiquinone radicals which could also contribute to their cytotoxic activity and 
concluded that, “compound 23 will generate free radicals after metabolic activation by 
the predator’s cells, which results in an antifeedant effect. Simultaneously, the 
dienone 4 is liberated, which immediately yields free radicals in the water 
surrounding the sponge, thereby shielding the sponge from further predation or 
attack”.36  
                                                
** Recent work by Becerro and co-workers found a significant positive correlation between 
bromotyrosine products and certain bacterial strains suggesting that bacteria could either be involved in 
their production or be directly affected by them (Appl. Environ. Microbiol., 2011, 77, 862). 
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Consistent with their role as defensive agents, bromotyrosine-derived products 
isolated from Verongida sponges exhibit a rich diversity of biological activities that 
include: antiviral,37 Na+/K+ ATPase inhibition,38 anti-HIV,39 HDAC inhibition,40 
antifouling,41 histamine H3 antagonism,42 antifungal,43 thrombin receptor 
antagonism,30 mycothiol S-conjugate amidase inhibition,44 and isoprenylcysteine 
carboxy methyltransferase (Icmt) inhibition.45 In addition, the vast majority of 
bromotyrosine secondary metabolites also possess significant antimicrobial 
activities.23 For example, both enantiomers of 23 show activity against both Gram-
positive and Gram-negative bacteria.46 Furthermore, 23 has been found to inhibit the 
growth of Plasmodium falciparum (IC50 17.7 µM) and Trypanosoma cruzi (IC50 37.7 
µM).47 
The anticancer activity of bromotyrosine-derived natural products has also been 
investigated and a significant number of compounds have been found to elicit 
cytotoxic responses in cancer cells both in vitro and in vivo. The anticancer properties 
of oxime and spirocyclohexadienylisoxazoline-type derivatives will be reviewed in 
Chapters 2 and 3, respectively, but by way of an example, aeroplysinin (23) has been 
shown to be cytotoxic towards numerous neoplastic cell lines that have a marked 
dependence on growth factors.48  
In particular, the growth inhibitory activity of 23 against L5178y cells (IC50 0.5 µM) 
is greater than other agents such as bleomycin (IC50 0.9 µM) and distamycin (IC50 
13.1 µM). Further studies by Kreuter and co-workers found that (+)-23 could inhibit 
EGF receptor tyrosine protein kinase and block the EGF-dependent proliferation of 
both MCF-7 and ZR-75-1 human breast cancer cells.49 More recently, it has come to 
light that (+)-23 is also a potent antiangiogenic†† agent, with the ability to inhibit the 
growth, migration and invasion of endothelial cells.50 Following on from this, Plumet 
and co-workers synthesised a library of analogues in an attempt to optimise these 
antiangiogenic properties. 51 Using 23 as a starting point they sought to increase the 
ratio of sprouting inhibition/cytotoxicity–their lead compound exhibited a ratio of 
921:1 (cf. 54:1 for 23). 
                                                
†† Angiogenesis is growth of new blood vessels from pre-existing vessels. As tumour growth is 
dependent on the formation of new blood vessels, targetting angiogenesis with antiangiogenic agents is 
a recognised therapeutic strategy.  
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Historically, bromotyrosine compounds were screened against a variety of cell lines 
as a means of quantifying their cytotoxic activity; however, the mode of action of 
many of these products is still unknown. The reasons for this are multifactorial but the 
availability of natural material and lack of the appropriate biochemical assays were 
probably the main cause. Nowadays, an understanding of a molecule’s cellular target 
is vital given the highly stringent nature of current drug approval guidelines. 
Therefore, it is clear that further collaborative research will be required in order for 
the full potential of these fascinating compounds to be realised in a cancer setting. 
1.3.4 The Ceratamines 
The inspiration for the research discussed in this thesis stemmed from a family of 
bromotyrosine-derived products whose members were unique in terms of both 
structure and biological activity. Extracts of the marine sponge Pseudoceratina sp. 
collected around Papua New Guinea showed promising activity in a cell-based assay‡‡ 
designed to detect new antimitotic natural product chemotypes.52 The active 
components of the sponge were isolated using bioassay guided fractionation, which 
yielded two heterocyclic alkaloids: ceratamine A (24) and B (25) (Figure 6).53 
OMe
Br Br
N
O
N
N
N
H
R
R = Me: 
R = H:
Ceratamine A (24)
Ceratamine B (25)
Me
18
19
 
Figure 6 Structures of ceratamine A and B. 
The presence of signals for slowly interconverting forms in the 1H and 13C NMR 
spectra indicated the ceratamines existed preferentially as one of two tautomeric 
forms (4:1 ratio). Scalar coupling observed between Me-19 and NH-18 suggested the 
major tautomer was of that illustrated in Figure 6. Structurally, the ceratamines are 
unlike any bromotyrosine-derived products previously isolated; the characteristic 3,5-
                                                
‡‡ This assay quantitatively determined antimitotic activity by detecting MCF-7 cells halted in mitosis 
by an Enzyme-Linked ImmunoSorbant Assay (ELISA) using the monoclonal antibody TG-3 (See Ref 
52). 
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dibromo-4-methoxybenzyl motif is appended to a novel imidazo[4,5,d]azepine core.§§ 
Commencing with a tyrosine–histidine dipeptide (26) the proposed biosynthesis is 
depicted in Scheme 5. Following bis-bromination (by a VBPO) and methylation, the 
amino functionality is oxidised to give oxime 27. Subsequent decarboxylation forms 
the Z-enamide 28 and it is also possible that the aminomethyl group is installed at this 
stage. Finally, an oxidative cyclisation between C-4 and C-5 furnishes the natural 
product.  
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Scheme 5 Proposed biosynthesis of the ceratamines. 
In order to fully appreciate the biological activity of the ceratamines, it is necessary to 
describe their biological target, microtubules, in more depth. 
1.3.4.1 Microtubules as an Anticancer Target 
Microtubules are highly dynamic filamentous polymeric proteins that are key 
components of the eukaryotic cytoskeleton. They are involved in the development and 
maintenance of cell shape, cell motility, and cell surface specialisation.54,55 They also 
act as intracellular highways, trafficking organelles such as mitochondria and vesicles 
through the highly congested cytoplasm.56 A key cellular function of microtubules is 
the role they play in the assembly of the mitotic spindle and thus the separation of 
duplicated chromosomes during mitosis.57 Microtubules are composed of tight α- and 
                                                
§§ Interestingly, Andersen and co-workers claimed, “The…core heterocycle in the ceratamines appears 
to have no precedent at any oxidation level among known natural products or synthetic compounds.” In 
fact, Waly and co-workers were the first to report the synthesis of a imidazo[4,5,d]azepine ring system 
(J. Prakt. Chem., 1994, 336, 86). 
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β-tubulin heterodimeric units that are arranged head to tail in a polar fashion into 
linear protofilaments (Figure 7). 
        
Figure 7 Left: structure of a microtubule; right: the αβ-tubulin heterodimer. Images taken 
from http://vbaulin.front.ru/research/a_microtub.html and http://cryoem.berkeley.edu/papers/ 
cyto_review/index.html. 
In order for microtubules to perform their many tasks in maintaining a fully functional 
cell, they exhibit complex non-equilibrium dynamics.58 Modulation of the sensitive 
non-equilibrium dynamics by external stimuli has a profound and detrimental effect 
on the structure and function of microtubules. Thus, exploiting the dependence of 
cellular processes such as mitosis on this dynamic behaviour makes microtubules an 
important target for anticancer agents.  
Mitosis is a sequential series of cellular events that leads to the duplication and 
synchronous separation of sister chromatids to generate two identical daughter nuclei 
(Figure 8). It is an exquisitely sensitive process that relies on proper spindle function 
throughout out all stages. 
Upon the onset of mitosis, the interphase microtubule network disassembles and is 
replaced by a new microtubule population which is responsible for the formation of 
the mitotic spindle. This new population exhibits high levels of dynamic instability.59 
Following breakdown of the nuclear membrane in the prophase, microtubules sprout 
out from their centrosomal anchor in an attempt to capture kinetochores to form the 
bipolar metaphase spindle (prometaphase).60  
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As this spindle provides the structural framework for segregation of duplicated 
chromosomes, failure of even a single chromosome to achieve bipolar attachment to 
the spindle can lead to cell cycle arrest and the onset of the apoptotic cascade.61 Thus, 
disruption of these sensitive dynamics has critical consequences for cell fate and 
makes microtubules a valuable therapeutic target, especially in oncology. 
 
Figure 8 Microtubules are important in all phases of mitosis. Image reproduced from 
http://kvhs.nbed.nb.ca/gallant/biology/mitosis_phases.html. 
Microtubule-targeted antimitotic drugs can be categorised into two distinct functional 
classes based on their mechanistic ability to disrupt microtubule polymerisation. 
Microtubule destabilising agents inhibit microtubule polymerisation and comprise of 
a large number of structural chemotypes such as the Vinca alkaloids (vinblastine), 
halichondrin B, estramustine, spongistatin 1, colchicine and combretastatin. In 1979, 
Horwitz and co-workers discovered that the potent biological activity of paclitaxel 
arose from its ability to stabilise microtubules, a previously uncharacterised mode of 
action.62 To date, there are approximately ten known microtubule-stabilising 
chemotypes and therefore are far less numerous than their destabilising counterparts. 
Significantly, all naturally-occurring stabilising agents have complex architectures 
that contain multiple stereocentres. As a consequence, synthesising the gram/kilogram 
quantities required for clinical trials and global distribution following approval is 
technically demanding and therefore costly. This expense is then reflected in the price 
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of the drug and ultimately prevents some patients gaining access to a potentially life-
saving treatment. However, industrial and academic efforts to discover non-natural 
microtubule-stabilising chemotypes have proved unsuccessful*** and currently, 
microtubule-stabilising agents are either natural products or semi-synthetic 
derivatives. Arguably the most famous example is the taxanes with others including 
the epothilones, discodermolides, sarcyodyctins and eleutherosides.1  
The taxanes represent some of the most important drugs in cancer chemotherapy and 
are testament to the relevance of microtubules as a therapeutic target.63 However, sub-
optimal pharmaceutical properties such as poor solubility, undesirable side effects and 
more crucially the development of resistance, limits their effectiveness and 
emphasises the need for a new generation of superior microtubule-stabilising agents. 
1.3.4.2 Ceratamines: Biological Activity 
The ceratamines were found to be capable of directly promoting the polymerisation of 
microtubules in vitro.64 These are reportedly the first heterocyclic alkaloids of marine 
or terrestrial origin known to stabilise microtubules, the inference being that small 
achiral drug-like molecules may be able to modulate microtubule dynamics though 
microtubule stabilisation.  
Both ceratamine A and B inhibited proliferation of MCF-7 cells (breast cancer) at low 
micromolar concentrations (IC50 2 µM and 3 µM, respectively) Treatment of cells 
with ceratamine A and B for 16 hours resulted in a concentration-dependent 
accumulation of cells with condensed mitotic chromosomes. Flow cytometry showed 
that these cells were halted in M phase and not G2 of the cell cycle thus proving the 
ceratamines are genuine antimitotic agents. Microtubule turbidity assays showed that, 
24 and 25 could promote polymerisation at a concentration of 100 µM. Despite the 
fact this was to a lesser extent and at a ten-fold higher concentration than paclitaxel it 
was still a remarkable result. Furthermore there is a possibility that ceratamines bind 
to a previously unidentified site on tubulin as it was observed that a 25-fold excess of 
ceratamine A failed to displace [3H]-paclitaxel from it’s binding site on β-tubulin.  
                                                
*** The exception being the discovery of GS-164, a novel small synthetic molecule, reported to 
polymerise microtubules in vitro and in HeLa cells. (Cancer Chemother. Pharmacol., 1997, 40, 513).   
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 Immunofluorescence microscopy revealed that ceratamines produced some 
interesting effects at the cellular level that have not been observed with other 
microtubule-stabilising agents. At 20 µM, ceratamine A disrupted the interphase 
microtubule network of MCF-7 cells by causing a pronounced accumulation of 
microtubules that partially or completely encircled the nucleus (Figure 9 b and d).  
A B C D
E F G H
 
Figure 9 Effect of ceratamine A (20 µM) on cellular microtubules. (a & c) Untreated 
interphase cells; (b & d) treated interphase cells; (e) mitotic spindle of untreated cell; (f) 
alignment of chromatids in untreated mitotic cells; (g) treated mitotic cell showing no 
alignment of chromatids; (h) treated mitotic cell showing multiple foci of staining. 
Microtubules stained with β-tubulin E7 monoclonal antibody (a-e and h); DNA stained with 
Hoechst 33258 (f and g). Images reproduced from Cancer Res., 2005, 65, 3040.  
In mitotic cells, the condensed sister chromatids were not equatorially aligned and 
there was no evidence of a mitotic spindle (Figure 9 g and h, respectively). Instead, 
multiple foci of β-tubulin staining were scattered throughout the cell, which on cross 
sectional analysis revealed them to be pillar like structures that spanned the entire 
thickness of the cell. 
These biological properties made it clear that the ceratamines were worthy of further 
investigation. However, due to the limited amounts of 24 (8 mg), and 25 (14 mg) 
obtained from the natural source, total synthesis represented the only viable way of 
accessing material on which to conduct further testing. During the course of this 
project, the groups of Andersen and Coleman have disclosed synthesis strategies 
towards the ceratamines.65 These will be reviewed in Chapter 4 prior to a discussion 
of the Ley group approach.  
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Compound Numbering 
In this chapter, the numbering of the carbon atoms in (5)-bromoverongamine and 
ianthelline is according to the convention outlined by Braekman and co-workers 
(Figure 10).1 
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Figure 10 Atom labeling of (5)-bromoverongamine and ianthelline. 
When discussing JBIR-44, the numbering system outlined by Fujiwara et al. will be 
adopted (Figure 11).2 
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Figure 11 Atom labeling of JBIR-44. 
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2.1.1 Oxime Bromotyrosine Derivatives 
Bromotyrosine compounds that possess oxime functionalities represent a fascinating 
class of compounds since naturally occurring oxime derivatives are relatively rare. 
Bromotyrosine-derived oximes are categorised into three subgroups* based on their 
structure: oxime–histamines, oxime–disulfides, and oxime–tyramines. 
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Figure 12 Structural classes of bromotyrosine-derived oximes. The (E)-2-(hydroxyimino)-N-
alkylamide functionality is highlighted in red. 
Upon isolation, the majority of these derivatives have been shown to possess a (E)-2-
(hydroxyimino)-N-alkylamide functional motif (Figure 12). However, in 1987, 
Schmitz and co-workers reported the isolation of (E,E)-psammaplin A (1.18 g) along 
with much smaller quantities of (E,Z)-psammaplin A (1) (19 mg), the first 
bromotyrosine derivative known to possess the corresponding Z-isomeric motif.3 The 
geometry of the oxime groups could be assigned on the basis of the 1H and 13C NMR 
chemical shifts corresponding to the methylene carbons (C-7 and C-7′) α to the 
oximes (Figure 13).  
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Figure 13 Structure of (E,Z)-psammaplin A (1) showing the signature chemical shifts. 
The shift of C-7′ (δC 35.7 ppm) is significantly downfield with respect to C-7 (δC 27.7 
ppm) because, in the case of the E-oxime, the oxime hydroxyl and C-7 are in a cis 
relationship and this results in a phenomenon known as steric compression.4 The 
opposite trend is observed for the chemical shifts of the methylene protons (H-7′, δH 
                                                
* The bastadins also contain oxime functionalities but due to their unique macrocyclic structures, 
constitute their own group (see Section 1.3.2). 
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3.68 ppm; H-7, δH 3.87 ppm). 1H NMR studies conducted by Karbatsos and co-
workers showed that the α-methylene protons cis to an oxime hydroxyl are deshielded 
and appear further downfield than α-methylene protons trans to an oxime hydroxyl.5 
Interestingly, it was discovered that a sample of 1 had isomerised to the 
corresponding (E,E)-isomer over the course of a couple of weeks; during this time it 
had been necessary to heat the sample to facilitate the evaporation of deuterated 
solvents. This led Schmitz and co-workers to postulate that the natural metabolite was 
in fact the (Z,Z)-isomer and that isomerisation occurred during the isolation 
procedure. It is therefore possible that all reported structures of bromotyrosine-
derived oximes are, in fact, artifacts from isolation procedures. Despite the obvious 
implications, the scientific community has largely ignored this finding.  
However, in 2010, Crews and co-workers isolated (E,Z)-bastadin-19 (2a) along with 
the previously reported (E,E)-bastadin-19 (2b) (Scheme 6) and agreeing with the 
hypothesis put forward by Schmitz, they sought to carry out further investigations.6 
They were able to affect the photoisomerisation of 2b to 2a (310–330 nm) and 
showed that upon standing in d6-DMSO (720 hours), 2a reverted to the more 
thermodynamically stable 2b.† Molecular mechanics calculations on a simplified 
structure showed that, where intramolecular H-bonding is minimised due to solvation, 
the E-oxime is lower in energy than the corresponding Z-oxime by 4.0 kJ/mol. 
Furthermore, a plausible biosynthetic pathway was proposed‡ for the bastadins and 
psammaplins which accounted for the initial formation of the Z-oxime (Scheme 6). 
Initially, it is thought two successive hydroxylations of the amine give intermediate 3. 
Next, elimination of water from the oxyanion amide resonance forms the nitroso 
species 4 and this can then undergo base-catalysed tautomerisation to furnish Z-oxime 
5.  
                                                
† Oximes are known to exhibit configurational stability in the solid state. In solution, there exists an 
equilibrium between the E and Z isomers and over time, the thermodynamically favoured isomer 
predominates.  
‡ It is an extension of the proposed pathway for the biosynthesis of nocardicin A (J. Bacteriol. 2005, 
187, 739).  
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Scheme 6 Left: structures of 2a and 2b; right: biosynthetic pathway of psammaplins and 
bastadins proposed by Crews and co-workers.6 
Given that the neighbouring amide facilitates the specific elimination of the anti 
hydroxyl group, it would appear this biosynthetic pathway is applicable to all 
bromotyrosine derivatives that contain the α-oximino amide motif. This then raises 
the pertinent issue regarding which oxime geometry is of biological relevance to the 
parent sponge. Investigations examining the bioactivity of bromotyrosine derivatives 
as a function of oxime geometry have not been undertaken, however, one would 
assume that by altering the spatial arrangement (E vs. Z) of a hydrogen bond donor, 
the activity of the derivative would be significantly affected.  
2.1.2 Biological Activity of Bromotyrosine-Derived Oximes 
2.1.2.1 Antifouling Activity 
Biofouling is the growth and accumulation of macro and microorganisms on the 
surface of submerged objects.7 This process is largely undesirable and the cost to 
industry, caused by the build-up of crustaceans (in particular barnacles) and 
microorganisms on man-made structures, runs in to billions of dollars on an annual 
basis. For example, it has been estimated that biofouling can reduce the speed of a 
ship by 10% and that 40% more fuel is needed to overcome the added drag.8   
Traditionally, surfaces were coated with paint that contained toxic agents such as 
tributyltin and triphenyltin compounds to prevent the accumulation of marine 
organisms. However in recent years, the use of these organotin compounds has been 
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phased out§ and therefore, there is a need for the development of new non-toxic 
antifouling agents. Over the last decade, the search for novel compounds that fulfill 
this criteria has focused on marine sponges since it is well known that their surfaces 
the are devoid of biofouling organisms (Section 1.3.3). Two excellent reviews by 
Fusetani focus on the ecological roles of antifouling marine natural products together 
with their industrial applications.9 
Recent studies by Proksch and co-workers identified the oxime moiety as the 
common pharmacophore of bromotyrosine compounds that inhibited the settlement of 
barnacle larvae (Balanus improvisus).10 Hemibastadin-1 (6), psammaplin A (10) and 
aplysamine-2 (9), along with several bastadin derivatives, were shown to inhibit 
settlement in a dose-dependent fashion (1–10 µM). Several analogues of 6 were 
synthesised to evaluate the basic structure–activity relationship (Figure 14). The 
dibromo analogue 7 exhibited the same potency (MIC 10 µM) whereas the desbromo 
analogue 8 was significantly less active (MIC 100 µM); the analogue lacking the 
oxime functionality (11) had no effect on larvae settlement. 
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Figure 14 Structures of antifouling natural products and analogues. 
Whilst the mode of action of these antifouling agents is still unknown,** the 
antifouling activities of 6 are currently being tested in a more relevant environment.11  
                                                
§ In 2008, the use of organotin compounds for antifouling purposes was prohibited. 
** It has been suggested that either the oxime may be converted to nitric oxide, or, these derivatives 
directly perturb the levels of intracellular Ca2+ in barnacle larvae.  
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2.1.2.2 Anticancer Activity 
A number of bromotyrosine oximes including purealidin A12 and C,13 aplysamines 3–
5,14 purpuramines I and J,15 and bastadin 4, 8, and 916 are known to exhibit 
cytotoxicity in a variety of cancer cell lines. In particular, purealidin N (12) (an 
oxime–histamine) showed significant cytotoxicity against murine lymphoma L1210 
cells (EC50 147 nM) and KB human epidermoid carcinoma cells (EC50 155 nM) 
(Figure 15).17 In addition to these cytotoxic products, compounds with more specific 
modes of action, relevant to preventing cancer progression have also been discovered.  
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Figure 15 Structures of purealidin N (12) and spermatinamine (13). 
Isoprenylcysteine carboxyl methyl transferase (Icmt) is a relatively new enzyme 
target in anticancer drug discovery. Icmt catalyses the methylation of the C-terminal 
prenylcysteine found on prenylated proteins; this is required for the correct 
localisation and functions of these proteins, most notably GTPases in the Ras 
superfamily. Ras is an oncogene and its hyperactivation is thought to contribute to 
carcinogenesis, therefore, inhibiting post-translational modification and preventing 
correct localisation of this family of proteins is attractive. Whilst several small-
molecule inhibitors have been reported in the literature, spermatinamine (13) was the 
first natural product inhibitor of Icmt (IC50 1.9 µM) to be discovered (Figure 15).18 
Since then, aplysamine 6 (another bromotyrosine derivative) has also been found to 
inhibit Icmt to a similar degree (IC50 14 µM).19 
Psammaplin A (10) (Figure 14) is an oxime disulfide that is cytotoxic (EC50 180–980 
nM) towards human lung, ovarian, CNS, skin and colon cancer cell lines. 
Furthermore it was found to be a potent inhibitor (IC50 4.2 ± 2.4 nM) of histone 
deacetylase (HDAC), an enzyme that modulates the levels of histone acetylation. In 
fact, 10 is more potent than the canonical HDAC inhibitor trichostatin A. HDAC 
inhibition by 10 in human endometrial cancer cells caused increased levels of 
acetylated histone H3 and H4, cell cycle arrest, and induction of an apoptotic 
pathway.20 Mechanistically, it is thought the disulfide bond is cleaved in the reducing 
Chapter 2 Part I: Total Syntheses of (5)-Bromoverongamine, Ianthelline and JBIR-44  
 29 
environment of the cell and that the resulting sulfhydryl group coordinates a zinc ion 
in the HDAC active site.21 
Over recent years, research into this class of compounds has gathered pace given their 
diverse biological activity profile, and it is clear that they warrant further investigation 
as potential anticancer lead compounds. The research within this chapter describes the 
synthesis of three bromotyrosine-derived oximes and analogues thereof. Their 
cytotoxic activities were then evaluated on human cancer cell lines. 
2.1.3 (5)-Bromoverongamine, Ianthelline and JBIR-44 
2.1.3.1 Isolation and Biological Activity 
(5)-Bromoverongamine (14) (Figure 16) was isolated in 1998 from a Pseudoceratina 
sp. and was reported to inhibit the settlement of barnacle larvae at 10 mg/mL (IC50 
1.03 mg/mL).1 More recently, 14 has also been shown to be bactericidal towards 
methicillin-resistant Staphylococcus aureus (MRSA) (MIC 0.0625-0.5 mg/L).22 The 
isolation of ianthelline (15) (Figure 16) from Ianthella ardis was reported in 1986 and 
it exhibited moderate activity as an antibacterial and antifungal agent against S. 
aureus and Candida albicans.23 It has since been isolated from at least two more 
species of sponge and was also shown to be an antifouling agent by inhibiting 
bacterial attachment to agar blocks.24,25 A virtual screen has also suggested that 15 
may be a SARS-coronavirus proteinase inhibitor.26 
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Figure 16 Structures of (5)-bromoverongamine (14) and ianthelline (15). 
Structurally, 14 and 15 are analogous and possess the signature 3,5-dibromo-4-
methoxyaryl group and E-oxime. They differ only at C-14, with 15 having an 
exocyclic amino group at this position. Furthermore, they are purported to share a 
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biogenetic relationship with ceratamines A and B (Section 1.3.4) and could be 
envisaged as cyclisation precursors (Scheme 7).††  
N
H
O
N
HN
OMe
CO2H
BrBr
R
N
HO
N
H
O
N
HN
OMe
BrBr
R
N
R = H: 
R = NH2:
(5)-Bromoverongamine
Ianthelline
HO
N
H
O
OMe
BrBr
N
HO
N
H
N
R
ReductionDecarboxylation
 
Scheme 7 Part of the proposed biosynthetic pathway of 14 and 15. The oxime geometry is 
drawn as E to avoid confusion. 
These two products were attractive synthetic targets for a number of reasons. Firstly, 
no total syntheses had been reported therefore, access to synthetic material would 
allow confirmation of the proposed structures. More importantly, despite their 
biogenetic relationship to the ceratamines and structural similarity to purealidin N 
(Figure 15) the anticancer properties of 14 and 15 had not been explored. Taking 
these considerations into account, both 14 and 15 warranted further investigation. 
In 2009, during the course of the research into 14 and 15, the isolation of JBIR-44 
(16) from Psammaplysilla purpurea was reported. It was shown to exhibit cytotoxic 
activity in a dose-dependent manner against a human cervical cancer cell line (HeLa, 
EC50 3.7 µM, 48 h) (Figure 17). Therefore, in light of this biological activity, and, as 
the left-hand portion of 16 is identical to that of both 14 and 15, the total synthesis of 
16 was also undertaken.  
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Figure 17 Structure of JBIR-44 (16). 
 
 
 
                                                
†† It is not yet known if either 14 or 15 are direct biosynthetic precursors to the ceratamines.  
Chapter 2 Part I: Total Syntheses of (5)-Bromoverongamine, Ianthelline and JBIR-44  
 31 
2.1.3.2 Synthetic Strategy 
Retrosynthetically, it was envisaged that all three natural products could be accessed 
by elaboration of a common α-oximino acid (17) intermediate which in turn could be 
obtained in three steps from the commercially available 3,5-dibromo-4-
hydroxybenzaldehyde (23) (Scheme 8). Amide coupling of 17 with the amine salts 
18, 19 or 20 followed by the removal of the PMB protecting group would furnish the 
desired bromotyrosine-derivatives 14, 15, and 16, respectively. 
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Scheme 8 Retrosynthetic analysis for the proposed synthesis of 14, 15, and 16 involving a 
common α-oximino acid intermediate 17. 
Synthetic routes to α-oximino acids, esters and amides closely related to 17 have been 
widely discussed in the literature. In addition to the most common approach via an 
azlactone intermediate (Scheme 9a),27 other pathways include cyano ylide couplings 
(Scheme 9b)28 and conversion of either amines (Scheme 9c),29 or α-keto compounds 
(Scheme 9d)30 directly to their corresponding oxime derivative. A more elegant 
approach employed a Horner–Wadsworth–Emmons reaction to couple Nakamura’s α-
OTBS-functionalised dimethyl phosphonate (22) to an elaborated aldehyde (21) 
(Scheme 9e). This has been used to good effect in the synthesis of purealidin N (12)31 
and bastadin analogues.32 
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Scheme 9 Different approaches to α-oximino compounds closely related to 17. 
Reagents and conditions: (a) Ba(OH)2·8H2O, BnONH2·HCl, 1,4-dioxane/H2O, 60 ºC, 34%; 
(b) EDCI, CH2Cl2, 82%; (c) O3, CH2Cl2, –78 ºC; (d) RNH2, t-BuOH; (e) NH2OH·HCl, 
NaOAc, EtOH, 52% three steps; (f) Na2WO4·2H2O, EtOH, H2O2, H2O, 25 ºC, 4 h, 68%; (g) 
NH2OH·HCl, NaOAc, EtOH, rt, 57%; (h) LDA, THF, –78 ºC, 92%; (i) HF·Et3N, MeOH then 
NH2OH·HCl, rt, 90%. 
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2.1.4 Results and Discussion 
2.1.4.1 Synthesis of α-Oximino Acid 17 
The α-oximino acid intermediate 17 was accessed in three steps from the 
commercially available 3,5-dibromo-4-hydroxybenzaldehyde (23) (Scheme 10). 
Methylation of the phenol 23 was achieved with methyl iodide in the presence of 
potassium carbonate.33 Then, azlactone 25 was subsequently formed by the treatment 
of 24 with N-acetylglycine and sodium acetate in acetic anhydride (Erlenmeyer 
conditions).34  
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23 24 25  
Scheme 10 Synthesis of azlactone 25. 
Reagents and conditions: (a) MeI, K2CO3, acetone, reflux, 6 h; (b) N-acetylglycine, NaOAc, 
Ac2O, 120 ºC, 90 min, 82% over 2 steps. 
These two steps proceeded in an overall yield of 82% and the geometry of 25 was 
confirmed by X-ray crystallographic analysis to be the thermodynamically favoured 
Z-isomer (Figure 18). 
 
Figure 18 X-ray crystal structure of azlactone 25. 
Prior to formation of 17, it was necessary to prepare O-para-methoxybenzyl (PMB) 
hydroxylamine hydrochloride (26) using a modified literature procedure (Scheme 
11).35 Protection of the free hydroxyl group of N-hydroxyphthalimide (27) with PMB 
chloride gave 28 in 59% yield. Removal of the phthalimide group with hydrazine 
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hydrate released the free hydroxylamine which, upon treatment with methanolic 
hydrogen chloride, furnished the desired hydrochloride salt 26. 
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Scheme 11 Synthesis of protected hydroxylamine 26. 
Reagents and conditions: (a) PMB-Cl, Et3N, DMF, 90 ºC, 59%; (b) hydrazine hydrate, 
DMF/MeOH (1:2), 60 ºC, then 1.25 M MeOH in HCl, 77%. 
The one-pot saponification of the crude azlactone 25 with barium hydroxide 
octahydrate and subsequent condensation with 26 afforded the α-oximino acid 
intermediate (17) (Scheme 12). Furthermore, this reaction could be performed on a 
multi-gram scale with an isolated yield of up to 54%.  
Chromatographic purification was problematic and co-elution of the product (17) with 
the unconsumed hydroxylamine 26 could not be prevented. Removal of excess 26 
prior to the purification was attempted, however, several acidic/basic work up 
procedures were unsuccessful, as was the use of scavenger resins (PS-isocyanate or 
QP-SA). The reaction was also performed on purified 25 but no improvement was 
observed. Nevertheless, the isolated yield was an improvement on the literature 
precedent of 35% reported for similar systems.27 
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Scheme 12 Synthesis of α-oximino acid 17. 
Reagents and conditions: (a) Ba(OH)2·8H2O, 1,4-dioxane/H2O (1:1), 60 ºC, 30 min then 26, 6 
h, 54%. 
With a view to shortening the synthesis, it was investigated whether the PMB 
protection of the oxime was required. Following the saponification of 25 as 
previously described, hydroxylamine hydrochloride was used in place of 26 for the 
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subsequent condensation. However, efforts to isolate the desired product proved 
unsuccessful due to the intractability‡‡ of the crude reaction mixture.  
2.1.4.2 Synthesis of (5)-Bromoverongamine  
With 17 in hand, the first task was to undertake the synthesis of (5)-
bromoverongamine (14) as the required amine coupling partner was commercially 
available. Amide coupling of 17 and histamine dihydrochloride (18) with DCC and 
HOBt furnished O-PMB-(5)-bromoverongamine (29) in 81% yield (Scheme 13). 
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Scheme 13 Synthesis of (5)-bromoverongamine (14). 
Reagents and conditions: (a) Histamine dihydrochloride, DCC, HOBt, iPr2EtN, CH2Cl2, rt, 18 
h, 81%; (b) AlCl3, anisole, CH2Cl2, rt, 5 min, 78%. 
The final step of the synthesis involved removal of the PMB protecting group. 
Investigations by Day and co-workers27 on similar substrates found that an aluminium 
trichloride/anisole mixture cleanly unmasked PMB protected oximes whereas 
treatment with either DDQ or TMSCl/NaI led to decomposition. However, in our case 
there was a concern that these Lewis acidic conditions may also lead to demethylation 
of the activated para-methoxy functionality on the dibrominated aryl unit. Pleasingly, 
treatment of 29 with the aluminium trichloride/anisole mixture led to complete 
conversion after only 5 minutes§§ to furnish the natural product in 78% yield.  
Whilst the 1H NMR spectral data of synthetic 14 matched with that reported for the 
natural material, the assignment of the C-12 quaternary centre (δC 134.0 ppm) in the 
natural material did not correlate with the shift of C-12 (δC 135.9 ppm) in the 
synthetic material (see appendix).*** However, X-ray crystallographic analysis 
confirmed that the structure of synthetic 14 matched with that proposed for the natural 
                                                
‡‡ Given the already polar nature of PMB-oxime acid 17, the additional polarity gained by the 
introduction of an unprotected oxime meant that purification was not possible by normal-phase 
chromatography. 
§§ No demethylation was observed even up to a reaction time of 3 hours. 
*** The original 13C NMR spectrum for the natural material was kindly provided by Professor Jean 
Claude Braekman for comparison and is included in the appendix of this chapter. 
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material (Figure 19). Furthermore, this data also confirmed the E-geometry of the 
oxime and the tautomeric form of the imidazole ring. 
 
Figure 19 X-ray crystal structure of (5)-bromoverongamine (14). 
2.1.4.3 Synthesis of Ianthelline 
As mentioned previously, ianthelline is structurally analogous to 14, differing only by 
the presence of an exocyclic amino group on the imidazole ring. However, the 
required 2-aminohistamine (19) coupling partner was neither inexpensive nor widely 
available from commercial sources. Coupling partner 19 could be synthesised by 
heating 1,4-diamino-2-butanone dihydrochloride (33) with excess cyanamide but it 
was not possible to isolate the product (Scheme 14) and using the crude mixture in the 
subsequent coupling reaction was unreliable. In an alternative strategy,36 Nω-
acetylhistamine was coupled to the diazonium species formed in-situ from sodium 
nitrite and p-bromoaniline (30) to form the desired 2-arlyazo derivative 31, along with 
the undesired 4-arylazo regioisomer and bis-adduct in a 3.4:2.4:1 ratio. Reductive 
cleavage of the azo-linkage with hydrogen over a platinum oxide catalyst initially 
gave the hydrobromide salt of 32 which could be freebased using a Dowex 50W X8 
ion exchange resin to yield 32 in 14%. The acetate group was then hydrolysed with 6 
N HCl to give 19 quantitatively.  
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Scheme 14 Synthesis of 19. 
Reagents and conditions: (a) NaNO2, HCl, 0 ºC, 30 min then Nω-acetylhistamine, NaHCO3, 
52%; (b) PtO2, H2, 4 bar, rt, 42 h, 14%; (c) 6 N HCl, 100 ºC, 14 h, 100%; (d) cyanamide 50% 
w/w in H2O, H2O, pH 6, 60 ºC, 2 h. 
With quantities of 19 in hand, the synthesis of 15 could be realised (Scheme 15). A 
DCC/HOBt mediated coupling between 17 and 19 gave O-PMB-ianthelline (34) in 
41% yield. PMB removal was achieved using the conditions previously mentioned to 
furnish ianthelline (15) in 44% yield. The 1H and 13C NMR spectral data of synthetic 
ianthelline (15) were identical with those reported for the natural material (see 
appendix). 
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Scheme 15 Synthesis of ianthelline (15). 
Reagents and conditions: (a) Histamine dihydrochloride, DCC, HOBt, iPr2EtN, CH2Cl2, rt, 
18 h, 41%; (b) AlCl3, anisole, CH2Cl2, rt, 5 min, 44%. 
2.1.4.4 Synthesis of JBIR-44 
The synthesis of dibromotyrosine side chain 20 had been reported previously in the 
literature. Following the procedure by Hamann and co-workers,37 treatment of 
tyramine (35) with excess bromine in acetic acid only yielded a mixture of the desired 
product 20, mono-brominated product and starting material in a 1:1:1.45 ratio. 
However, the synthesis of the amine side chain of JBIR-44 could be achieved in one 
step by heating 35 with bromine in methanol for 14 hours (Scheme 16).38  
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Scheme 16 Synthesis of 20. 
Reagents and conditions: (a) MeOH, Br2, 60 ºC, 14 h, 68%. 
The side chain 20 could then be coupled to acid 17 under the conditions described 
previously to furnish O-PMB-JBIR-44 (36) in moderate yield; alternative protocols 
(EDCI/HOBt, ®T3P) were unsuccessful in improving this coupling. Removal of the 
PMB moiety proceeded cleanly to furnish JBIR-44 (16) in 85% yield (Scheme 17). 
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36 16  
Scheme 17 Synthesis of JBIR-44 (16). 
Reagents and conditions: (a) 20, DCC, HOBt, iPr2EtN, CH2Cl2, rt, 18 h, 42%; (b) AlCl3, 
anisole, CH2Cl2, rt, 5 min, 85%. 
The 1H and 13C NMR spectra for synthetic 16 matched those reported for the natural 
materials. However, the original assignments of C-8 (δC 153.8 ppm) and C-3 (δC 
152.0 ppm) should be reversed on the basis of HMBC spectroscopy (Figure 20). For 
natural 16, Fujiwara and co-workers reported a strong m-coupling between the 
aromatic protons H-1 and H-5 (δH 7.52 ppm) and the aromatic carbon (δC 152.0 ppm) 
and also observed the long range coupling of methylene protons H-7 (δH 3.87 ppm) to 
C-8 (δC 153.8 ppm). In the synthetic sample, we observed a strong m-coupling 
between aromatic protons H-1 and H-5 (δH 7.52 ppm) and the signal at (δC 153.8 
ppm) which we have assigned to C-3. We also observed a long range coupling of the 
methylene protons H-7 (δH 3.87 ppm) to the signal at (δC 152.0 ppm) which we have 
assigned to C-8. Unfortunately, the HMBC spectrum for natural 16 was not available 
for direct comparison. 
Chapter 2 Part I: Total Syntheses of (5)-Bromoverongamine, Ianthelline and JBIR-44  
 39 
OMe
BrBr
N
O
N
H
HO
Br
Br
OHH H
H
H
C-8 !C 152.0
C-3 !C 153.8
H-1/5 !H 7.52
H-7 !H 3.87
 
Figure 20 1H 13C HMBC correlations for synthetic JBIR-44 (16). 
2.1.4.5 Improving the Synthesis of α-Oximino Acid 17  
On completing the syntheses of 14, 15 and 16 we wanted to investigate the possibility 
of improving the transformation of azlactone 25 to α-oximino acid 17 (due to its 
moderate yield and troublesome purification) as an efficient procedure would be 
necessary for analogue development. Instead of a one-pot procedure, a two-step 
procedure was envisaged as it is known that azlactones hydrolyse efficiently with acid 
under refluxing conditions to furnish the corresponding phenylpyruvic acid 
derivative39 and that these can then be converted directly to the corresponding oxime 
by treatment with an appropriate hydroxylamine (Scheme 9d).  
In the literature, the reaction times reported for the hydrolysis of azlactones to their 
phenylpyruvic acid derivatives vary from 3-48 h depending on the aryl substituents. 
Mechanistically, the acidic hydrolysis of azlactones proceeds via an α-(aroylamino) 
cinammic acid intermediate that in turn hydrolyses to the phenylpyruvic acid 
derivative. In our case, hydrolysis of 25 to the α-(aroylamino) cinammic acid 37 
occurred within 1 hour. However, the subsequent hydrolysis of 37 to acid 38 was 
much slower (Table 1). Monitoring the reaction by 1H NMR††† indicated the reaction 
had gone to completion after 20 hours and, following a standard work-up, 38 was 
obtained in excellent yield. 
 
 
 
 
 
                                                
††† In d4-MeOH, 38 existed exclusively in the enol tautomeric form. Furthermore, the sample 
decomposed after standing in d4-MeOH at room temperature for 24 h. 
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Table 1 Reaction progress for the acidic hydrolysis of azlactone 25 to 38. 
OMe
BrBr
O
N
O
OMe
BrBr
OMe
BrBr
OH
HO O
H
N
O OH
O
25 37 38
SLOWFAST
3 N HCl, reflux
 
Entry Time (h) Ratio of 37:38a Yield 
1 1.5 6:1 – 
2 6 1:4.3 – 
3 20 0:1 92% 
a Product ratios were calculated by 1H NMR. 
It is important to note that when crude 25 was used in the reaction, the product (38) 
was an orange solid and although no impurities were visible by NMR, it was not pure 
by microanalysis. Attempts to purify this product by chromatography resulted in 
decomposition. Hydrolysis of purified 25 (chromatography) furnished 38 as a white 
solid which required no subsequent purification. Furthermore, it was possible to 
obtain crystals of 38 from diethyl ether and the structure and the geometry about the 
enol double bond could be confirmed by X-ray diffraction (Figure 21). 
 
Figure 21 X-ray crystal structure of 38. The diethyl ether co-solvent has been hidden. 
Next, condensation of 38 with a stoichiometric amount of hydroxylamine 26 in the 
presence of sodium acetate furnished α-oximino acid 17 without the need for 
purification (Scheme 18). The overall yield of 93% for this two-step transformation 
(from 25) represents a significant improvement on the 54% yield from the one-pot 
procedure (Scheme 12). Using this improved procedure, it was also possible to access 
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the free oxime 39 in quantitative yield. Accordingly, it was demonstrated that this 
unprotected congener of 17 could be coupled to histamine dihydrochloride using 
DCC/HOBt to furnish 14 albeit in 30% yield (not shown).‡‡‡ 
OMe
BrBr
OH
O
38
OMe
BrBr
N
39: R = H
17: R = PMB
OH
O
RO
a or b
HO
 
Scheme 18 Synthesis of α-oximino acids 17 and 39. 
Reagents and conditions: (a) Hydroxylamine hydrochloride, NaOAc, EtOH, rt, 19 h, quant; 
(b) 26, NaOAc, EtOH, rt, 19 h, quant. 
2.1.4.6 Biological Screening 
The three natural products and their PMB-protected congeners were screened against 
human cancer cell lines in order to evaluate their cytotoxicity (Table 2). In the MTS 
assays that were conducted, JBIR-44 (16) was found to be cytotoxic against cervical 
(HeLa) and ovarian (SK-OV-3) cancer cell lines (EC50 14 µM§§§ and 22 µM). 
Ianthelline (15) exhibited moderate cytotoxicty against HeLa cells (EC50 35 µM) but 
had lower activity against SK-OV-3 cells (EC50 >50 µM). (5)-Bromoverongamine 
(14) was the least active (EC50  >50 µM) although loss of cell viability was observed 
in all three cell lines between 70 and 100 µM. 
In the case of 14 and 15, PMB-protection of the oxime resulted in a marked increase 
in potency. Following the trend in activity for the corresponding natural products, 29 
(EC50 23 µM) was more cytotoxic than 34 (EC50 30–45 µM) with the inference being 
that the exocyclic amino functionality at C-14 improves the interaction of the 
molecule with its cellular target. Interestingly, 36 (the PMB-protected counterpart of 
JBIR-44) showed no activity against HeLa or SK-OV-3 cell lines. Because the 
intracellular target for 36 is not known, accounting for the observed trends can only 
be hypothesised upon. Protecting a free oxime moiety with a PMB group is known to 
increase the cLogP value by approximately two units, thereby drastically altering the 
pharmacokinetic and pharmacodynamic properties of the molecule concerned.  
                                                
‡‡‡ Unprotected α-oximino acids are known to form nitriles by loss of carbon dioxide and water 
(Synthesis, 2010, 181). 
§§§ This value agreed with that reported for the natural material against the same cell line (IC50 3.7 µM). 
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Table 2 MTS assay results for the natural products and their PMB protected derivatives. 
Screened against SK-OV-3, HeLa, TR-175 and HUVEC cells. Drug incubations were for 48 h  
Cell Line (EC50/µM) 
Compound 
HeLa 
(cervical) 
SK-OV-3 
(ovarian) 
TR-175 
(ovarian) 
HUVECs 
5-Bromoverongamine (14) >50 >50 >50 36 
Ianthelline (15) 35 >50 – 74 
JBIR-44 (16) 14 22 – 24 
29 45 40 30 – 
34 – 23 – – 
36 N/A N/A – – 
N/A (not active); – (not tested) 
In the case of JBIR-44, an already lipophilic molecule (cLogP 4.98), the introduction 
of a PMB group may either prevent the compound from exiting the cell membrane**** 
or from binding in the active site of its target protein. Alternatively, protection of the 
free oxime would negate its ability to hydrogen bond donate to a protein target. This 
latter explanation may be more likely given the importance of the free oxime in 
eliciting the antifouling properties in similar compounds (Section 2.1.2.1).  
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O
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16: R = H
36: R = PMB
14: R = H
29: R = PMB
15: R = H
34: R = PMB
cLogP = 1.83
cLogP = 3.82
cLogP = 2.03
cLogP = 4.02
cLogP = 4.98
cLogP = 6.97  
Figure 22 cLogP values of tested compounds. 
On the other hand, the natural products 14 and 15 are more polar (cLogP 2.03 and 
1.83, respectively) due to the imidazole moiety in their side chain. For these 
compounds, the introduction of a lipophilic (PMB) group may be favourable as a 
result of improving their pharmacokinetic and pharmacodynamic properties. In 
general, increasing a compound’s lipophilicity can aid its diffusion across cell 
membranes and improve binding to an intracellular target by exploiting hydrophobic 
pockets. Following on from this, lipophilic molecules often lack specificity for a 
                                                
**** Highly lipophilic molecules have a reduced ability to exit the cell membrane as they tend to get 
retained due to their increased affinity for the phospholipid bilayer (Expert Opin. Drug Discov., 2010, 
235). 
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particular target. It is this promiscuity that is often linked to an increase in general 
toxicity due to off-target effects.40 Taking this into account it is likely that the 
cytotoxicity observed for 29 and 34 is directly related to the increase in lipophilicity, 
gained by the introduction of a PMB group.  
Since aeroplysinin-1 (Section 1.3.3) was reported to inhibit the proliferation of bovine 
arterial endothelial cells (IC50 ~2µM) 14, 15 and 16 were also screened against human 
umbilical vein endothelial cells (HUVECs).†††† These cells are an established model 
of tumour vascular endothelium and are used to investigate the antiangiogenic 
properties of molecules. In these assays, all three compounds were found to be 
cytotoxic to HUVECs in the micromolar range (EC50 24–74 µM).  
2.1.5 Conclusion 
In conclusion, the total syntheses of the related bromotyrosine-derived natural 
products (5)-bromoverongamine, ianthelline, and JBIR-44 have been achieved in 
yields of 58, 17 and 33%, respectively from the commercially available 3,5-dibromo-
4-hydroxybenzaldehyde. In addition, a robust and efficient route to α-oximino acid 17 
has been established which can be readily exploited for analogue development. The 
cytotoxicity of JBIR-44 was confirmed in HeLa and SK-OV-3 cancer cell lines. 
Ianthelline was also biologically active in HeLa cells. Furthermore, all three natural 
products were cytotoxic towards HUVECs. These biological results prompted us 
explore the SAR of these molecules in greater depth, the details of which can be 
found in part II of this chapter.  
 
 
 
 
 
 
 
                                                
†††† These assays were performed by Thomas M. Beale Esq. 
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2.1.6 Chemistry: Experimental 
General Experimental Details  
All non-aqueous reactions were performed under an atmosphere of argon in oven-
dried glassware cooled under vacuum unless otherwise stated. Reagents were used as 
supplied from commercial sources. All reactions were performed at room temperature 
unless otherwise stated. Following extraction, the organic phase was dried with 
anhydrous magnesium sulfate. For mixtures of solvents, the ratios given refer to the 
volumes used. Analytical TLC was carried out on Merck 60 F254 silica gel plates and 
visualised by UV irradiation (254 nm) and developed with either acidic aqueous 
ammonium molybdate(IV) solution or alkaline potassium permanganate solution, and 
appropriate heating. Flash column chromatography was performed using Merck 
Kieselgel (230-400 mesh). All chromatography solvents were distilled before use 
except methanol, ether, water, formic acid and acetic acid which were used as 
supplied. “Petrol” refers to petroleum ether b.p. 40-60 ºC.  
NMR spectra were recorded at room temperature on Bruker DPX-400, Bruker DRX-
500 or Bruker DRX-600 spectrometers using the deuterated solvent as internal 
deuterium lock; 1H spectra at 400, 500 and 600 MHz respectively, and 13C spectra at 
100, 120 and 150 MHz. Chemical shifts are reported in parts per million (ppm) and 
internal references were the residual protic solvent: for d1-chloroform, δH = 7.26 ppm 
and δC = 77.0 ppm; for d4-methanol, δH = 3.31 ppm and δC = 49.0 ppm; for d6-acetone 
δH = 2.05 ppm and δC = 29.8 ppm. Coupling constants (J) are reported in Hz and 
recorded to the nearest 0.1 Hz. In reporting the spectral data, the following 
abbreviations were used: br = broad, s = singlet, d = doublet, t = triplet, q = quartet, 
dd = doublet of doublets. Spectra were assigned with information gained from DEPT 
135, COSY, HMBC and HMQC experiments.  
IR spectra were recorded on a Perkin-Elmer Spectrum I FTIR spectrometer. Samples 
were applied neat. Only selected absorbances (νmax) are reported and relative 
intensities are indicated as s - strong; m - medium; w - weak and br - broad. Peaks are 
reported in wavenumbers (cm−1). 
HRMS were recorded using a Waters Micromass LCT Premier spectrometer or by 
Paul Skelton at the Department of Chemistry, University of Cambridge and are 
reported in units of m/z.  
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Melting points were measured either on an automated Stanford Research Systems 
MPA100 (Optimelt) melting point machine or a Reichert hot stage apparatus 
equipped with a digital thermometer.  
Microanalysis was performed in the microanalytical laboratories at the Department of 
Chemistry, University of Cambridge, using an Exeter analytical elemental analyzer, 
model CE-440. X-ray structure determination was performed by Dr John E. Davies at 
the Department of Chemistry, University of Cambridge using a Nonius Kappa CCD 
detector. 
cLogP values were calculated using the OSIRIS Property Explorer, 
http://www.organic-chemistry.org/prog/peo/. 
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3,5-Dibromo-4-methoxybenzaldehyde (24) 
OMe
Br Br
O
15
4
7
1
 
To a stirred solution of 3,5-dibromo-4-hydroxybenzaldehyde (23) (10.1 g, 36.1 mmol) 
in acetone (200 mL) was added anhydrous K2CO3 (6.74 g, 48.8 mmol). The resulting 
mixture was stirred for 30 min then treated with iodomethane (4.48 mL, 71.9 mmol) 
and heated under reflux for a further 6 h. After this time, acetone and excess 
iodomethane were removed in vacuo and the resulting residue was partitioned 
between EtOAc (200 mL) and H2O (200 mL). The organic layer was separated and 
the aqueous layer was extracted with EtOAc (3 x 200 mL). The combined organic 
extracts were washed with brine, dried and concentrated in vacuo. The residue was 
purified by flash column chromatography (20% Et2O/Petrol) to furnish 24 (9.60 g, 
32.7 mmol, 91%) as a white crystalline solid. 
Rf 0.50 (20% Et2O/Petrol); νmax (thin film)/cm-1 1685s, 1547m, 1469m, 1260s, 980s; 
δH (400 MHz, CDCl3) 9.86 (1H, s, H-7), 8.03 (2H, s, H-2/6), 3.97 (3H, s, H-15); δC 
(100 MHz, CDCl3) 188.3 (C-7), 159.1 (C-4), 134.2 (C-1), 133.9 (C-2/6), 119.3 (C-
3/5), 60.9 (C-15); m.p. 83-85 ºC (lit.,41 87-88 ºC); elem. anal. C8H6Br2O2 (79Br) 
requires C 32.69%, H 2.06%, Br 54.37%, found C 32.75%, H 2.03%, Br 53.88%. 
Consistent with literature data.42 
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(Z)-4-(3,5-Dibromo-4-methoxybenzylidene)-2-methyloxazol-5(4H)-one (25) 
OMe
Br Br
15
4
8
1
O
N
O
1' 2'
 
A mixture of aldehyde 24 (6.86 g, 23.3 mmol), N-acetylglycine (3.55 g, 30.3 mmol), 
sodium acetate (2.49 g, 30.4 mmol) and acetic anhydride (11 mL, 116 mmol) were 
heated at reflux for 1.5 h. After cooling to room temperature, H2O (400 mL) and 
CH2Cl2 (400 mL) were added. The organic layer was separated and washed with H2O 
(400 mL), brine (400 mL), dried and concentrated in vacuo. The residue was purified 
by flash column chromatography (40% CH2Cl2/Petrol) to furnish 25 (7.86 g, 21.1 
mmol, 91%) as a yellow solid.  
Rf 0.32 (10% Et2O/Petrol); νmax (thin film)/cm-1 1806s, 1792s, 1765s, 1660s, 1260s; 
δH (400 MHz, CDCl3) 8.24 (2H, s, H-2/6), 6.90 (1H, s, H-7), 3.92 (3H, s, H-15), 2.43 
(3H, s, H-2'); δC (100 MHz, CDCl3) 167.3 (C-1'), 167.1 (C-9), 155.9 (C-4), 135.8 (C-
2/6), 133.7 (C-8). 131.7 (C-1), 127.1 (C-7), 118.5 (C-3/5), 60.8 (C-15), 15.7 (C-2'); 
m/z (ESI+) found 373.9029, [M+H]+ C12H10Br2NO3 (79Br) requires 373.9027; m.p. 
167-168 ºC (lit.,43 154-155 ºC); elem. anal. C12H9Br2NO3 requires C 38.43%, H 
2.42%, N 3.73%, found C 38.31%, H 2.30%, N 3.60%. 
Crystals of 25 were obtained by slow evaporation of CDCl3. The structure was 
confirmed by X-ray crystallographic analysis and given the unique identifier sl1031. 
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(Z)-3-(3,5-Dibromo-4-methoxyphenyl)-2-hydroxyacrylic acid (38) 
OMe
Br Br
OH
HO O
15
4
9
7
1
 
A suspension of azlactone 25 (2.39 g, 6.37 mmol) and 3 N HCl (50 mL) were heated 
to reflux for 20 h. The mixture was cooled to room temperature and the white 
precipitate was isolated by filtration, washed with H2O (20 mL) and evaporated to 
dryness in vacuo to furnish 38 (2.09 g, 5.94 mmol, 93%) as a white solid. 
νmax (thin film)/cm-1 3469s, 2939br, 1674s, 1446s, 1248s; δH (600 MHz, CD3OD) 
7.96 (2H, s, H-2/6), 6.33 (1H, s, H-7), 3.84 (3H, s, H-15); δC (150 MHz, CD3OD) 
167.5 (C-9), 153.9 (C-4), 135.6 (C-1), 134.4 (C-2/6). 118.6 (C-3/5), 107.8 (C-7), 61.1 
(C-15); m.p. 186-188 ºC; elem. anal. C10H8Br2O4 requires C 34.12 %, H 2.29 %, 
found C 34.01 %, H 2.16 %. 
Crystals of 38 were obtained by slow evaporation of Et2O. The structure was 
confirmed by X-ray crystallographic analysis and given the unique identifier sl1033. 
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(E)-3-(3,5-Dibromo-4-methoxyphenyl)-2-(hydroxyimino)propanoic acid (39) 
OMe
Br Br
15
8
1
N
HO
OH
O
9
 
To a stirred solution of 38 (348 mg, 0.989 mmol) and hydroxylamine hydrochloride 
(68.7 mg, 0.99 mmol) in EtOH (10 mL) was added sodium acetate (243 mg, 2.96 
mmol). After 19 h, H2O (150 mL) was added, the mixture was acidified (pH 0) by the 
addition of aqueous HCl (3 N) and extracted with EtOAc (3 × 100 mL). The 
combined organic extracts were dried and evaporated to dryness in vacuo to furnish 
39 (363 mg, 0.99 mmol, 100%) as a white solid. 
Rf 0.10 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 3064br, 1694s, 1471s, 1030s, 
698s; δH (400 MHz, CDCl3) 7.47 (2H, s, H-2/6), 3.95 (2H, s, H-7), 3.85 (3H, s, H-
15); δC (100 MHz, CDCl3) 165.6 (C-9), 153.3 (C-4), 148.9 (C-8), 133.38 (C-2/6), 
133.35 (C-1), 118.2, (C-3/5), 60.6 (C-15), 29.3 (C-7); m/z (ESI+) found 387.8799, 
[M+Na]+ C10H10Br2NO4Na (79Br) requires 387.8796. m.p. 171-173 ºC (lit.,29 142-145 
ºC). 
Consistent with literature data.29 
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(E)-3-(3,5-Dibromo-4-methoxyphenyl)-2-(((4-ethoxybenzyl)oxy)imino)propanoic 
acid (17) 
OMe
Br Br
15
8
1
N
O
OH
O
MeO
9
1'
8'
5'
2'
 
Procedure 1: A mixture of azlactone 25 (6.83 g, 18.2 mmol) and Ba(OH)2·8H2O 
(17.2 g, 54.5 mmol) in dioxane (100 mL) and H2O (100 mL) were stirred at 60 ºC. 
After 1 h, O-para-methoxybenzyl hydroxylamine hydrochloride (26) (3.45 g, 18.2 
mmol) was added and the mixture was stirred vigorously. After 6 h, the reaction 
mixture was cooled to 0 ºC and acidified (pH 0) with aqueous 3 N HCl. The mixture 
was extracted with EtOAc (3 × 400 mL) and the combined organic extracts were 
dried and concentrated in vacuo. The residue was purified by flash column 
chromatography (0:100:0.1-2:100:0.1 MeOH/CH2Cl2/AcOH) to furnish 17 (4.81 g, 
9.87 mmol, 54%) as a white solid.  
Procedure 2: To a stirred solution of 38 (297 mg, 0.844 mmol) and O-para-
methoxybenzyl hydroxylamine hydrochloride (26) (160 mg, 0.844 mmol) in EtOH 
(8.40 mL) was added sodium acetate (207 mg, 2.52 mmol). After 19 h, the mixture 
was acidified (pH 0) with aqueous 3 N HCl. The mixture was extracted with EtOAc 
(3 × 100 mL) and the combined organic extracts were dried and evaporated to dryness 
in vacuo to furnish 17 (409 mg, 0.84 mmol, quant.) as a white solid. 
Rf 0.43 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 2934br, 1702s, 1513s, 1473s, 
1256s; δH (400 MHz, CDCl3) 7.38 (2H, s, H-2/6), 7.28 (2H, d, J 8.6 Hz, H-3'/7'), 6.93 
(2H, d, J 8.6 Hz, H-4'/6'), 5.24 (2H, s, H-1'), 3.85 (3H, s, H-15), 3.83 (3H, s, H-8'), 
3.80 (2H, s, H-7); δC (100 MHz, CDCl3) 164.2 (C-9), 160.0 (C-5'), 152.9 (C-4), 148.6 
(C-8), 133.7 (C-1), 133.3 (C-2/6), 130.4 (C-3'/7'), 127.4 (C-2'), 117.9 (C-3/5), 114.1 
(C-4'/6'), 78.5 (C-1'), 60.6 (C-15), 55.3 (C-8'), 29.1 (C-7); m/z (ESI+) found 507.9391, 
[M+Na]+ C18H17Br2NO5Na (79Br) requires 507.9371; m.p. 101-103 ºC. 
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2-((4-Methoxybenzyl)oxy)isoindoline-1,3-dione (28) 
N
O
O
O
OMe
1
12
13
9
8
 
A mixture of N-hydroxyphthalimide (27) (26.1 g, 160 mmol), 4-methoxybenzyl 
chloride (21.7 mL, 160 mmol), and Et3N (53.0 mL, 380 mmol) in DMF (400 mL) was 
heated at 90 ºC. After 40 min, the reaction was quenched by the addition of ice-cold 
water (500 mL). The orange precipitate was washed with H2O and the resulting white 
solid was taken up in CH2Cl2 (300 mL), washed with H2O (300 mL), brine (300 mL), 
dried and evaporated to dryness in vacuo to furnish 28 (26.6 g, 94.0 mmol, 59%) as a 
beige solid which was used without further purification.  
Rf 0.35 (40% Et2O/Petrol); νmax (thin film)/cm-1 1785w, 1724s, 1611m, 1515m; δH 
(400 MHz, CDCl3) 7.80 (2H, dd, J 5.4, 3.1 Hz, H-12/13), 7.72 (2H, dd, J 5.4, 3.1 Hz, 
C-11/14), 7.45 (2H, d, J 8.5 Hz, C-4/6), 6.88 (2H, d, J 8.5 Hz, C-3/7), 5.15 (2H, s, C-
8), 3.80 (3H, s, C-1); δC (100 MHz, CDCl3) 163.5 (C-9/16), 160.3 (C-2), 134.3 (C-
12/13), 131.6 (C-4/6), 128.8 (C-10/15), 125.7 (C-5), 123.4 (C-11/14), 113.8 (C-3/7), 
79.9 (C-8), 55.2 (C-1); m/z (ESI+) found 306.0736, [M+Na]+ C16H13NO4Na requires 
306.0737; m.p. 125-127 ºC (lit.,44 129-130 ºC).  
Consistent with literature data.45  
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O-(4-Methoxybenzyl)hydroxylamine hydrochloride (26)  
NH2 O
OMe
1
8
.HCl  
To a stirred solution of 28 (32.5 g, 115 mmol) in DMF/MeOH (460 mL, 1:2) at 60 ºC 
was added hydrazine hydrate (17.4 mL, 358 mmol). After 5 min, the reaction was 
cooled to room temperature and quenched by the addition of H2O (150 mL). Excess 
solvent was removed in vacuo and the resulting residue was extracted with EtOAc (3 
x 500 mL). The combined organic layers were washed with brine (500 mL), dried and 
concentrated in vacuo. Methanolic hydrogen chloride (1.25 M, 100 mL) was added 
dropwise to the residue at 0 ºC with stirring. The resulting precipitate was isolated via 
filtration and washed with Et2O to furnish 26 (16.7 g, 88.1 mmol, 77%) as white 
platelets.  
νmax (thin film)/cm-1 2803w, 2650m, 1611m, 1504m, 1255m; δH (400 MHz, CD3OD) 
7.37 (2H, d, J 8.5 Hz, H-4/6), 6.98 (2H, d, J  8.5 Hz, H-3/7), 4.95 (2H, s, H-8), 3.82 
(3H, s, H-1); δC (100 MHz, CD3OD) 162.7 (C-5), 132.8 (C-4/6), 126.6 (C-2), 115.7 
(C-3/7), 78.4 (C-8), 56.2 (C-1); m/z (ESI+) found 137.0604, [M+H]+ C8H9O2 requires 
137.0597; m.p. decomp. 200-202 ºC (lit.,46 decomp. 196-197 ºC); elem. anal. 
C8H12O2Cl requires C 50.67% H 6.38%, N 7.39%, Cl 18.69%, found C 50.69%, H 
6.34%, N 7.25%, Cl 18.75%.  
Consistent with literature data.47  
Chapter 2 Part I: Total Syntheses of (5)-Bromoverongamine, Ianthelline and JBIR-44  
 53 
(E)-N-(2-(1H-Imidazol-4-yl)ethyl)-3-(3,5-dibromo-4-methoxyphenyl)-2-(((4-
methoxybenzyl)oxy)imino)propanamide (29) 
OMe
Br Br
15
8
1
N
O
N
H
O
MeO
9
1'
8'
5'
2'
12
14
N
H
N
 
To a stirred solution of acid 17 (42.0 mg, 86.2 µmol) in CH2Cl2 (2 mL) were added 
N,N′-dicyclohexylcarbodiimide (21.0 mg, 0.102 mmol) and N-hydroxybenzotriazole 
(13.8 mg, 0.102 mmol). After stirring for 5 min, histamine dihydrochloride (28.0 mg, 
0.152 mmol) and iPr2EtN (43.0 µL, 0.250 mmol) were added. After 24 h, the solvent 
was removed in vacuo and the residue partitioned between H2O (20 mL) and EtOAc 
(20 mL). The organic layer was separated and the aqueous layer was extracted with 
EtOAc (3 × 20 mL). The combined organic extracts were washed with brine (20 mL), 
dried and concentrated in vacuo. The residue was purified by flash column 
chromatography (1-10% MeOH/CH2Cl2) to furnish 29 (40.6 mg, 70.0 µmol, 81%) as 
a white foam.  
Rf  0.43 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 3283br, 2929w, 1734w, 1661s, 
1611s, 1512s, 1256s, 980s; δH (600 MHz CDCl3) 7.56 (1H, s, H-14), 7.38 (2H, s, H-
2/6), 7.24 (2H, d, J 8.6 Hz, H-3'/7'), 6.89 (2H, d, J 8.6 Hz, H-4'/6'), 6.78 (1H, s, H-13), 
5.10 (2H, s, H-1'), 3.81 (3H, s, H-15), 3.80 (3H, s, H-8'), 3.78 (2H, s, H-7), 3.59 (2H, 
apparent q, J 6.6 Hz, H-10), 2.84 (2H, t, J 6.6 Hz, H-11); δC (150 MHz, CDCl3) 162.3 
(C-9), 159.7 (C-5'), 152.5 (C-4), 150.9 (C-8), 135.5 br (C-12), 134.9 (C-1), 134.8 (C-
14), 133.4 (C-2/6), 130.1 (C-3' and C-7'), 128.4 (C-2'), 117.6 (C-3/5), 116.0 br (C-13), 
114.0 (C-4'/6'), 77.3 (C-1'), 60.5 (C-15), 55.2 (C-8'), 39.2 (C-10), 28.6 (C-7), 27.0 (C-
11); m/z (ESI+) found 579.0240, [M+H]+ C23H25Br2N4O4 (79Br) requires 579.0243. 
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(E)-N-(2-(1H-Imidazol-4-yl)ethyl)-3-(3,5-dibromo-4-methoxyphenyl)-2-
(hydroxyimino)propanamide. (5)-Bromoverongamine (14) 
OMe
Br Br
15
8
1
N
HO
N
H
O
9 12
14
N
H
N
 
To a stirred solution of amide 29 (78.0 mg, 0.134 mmol) and anisole (146 µL, 1.34 
mmol) in CH2Cl2 (5 mL) was added aluminium trichloride (179 mg, 1.34 mmol). 
After 5 min, a saturated aqueous solution of NaHCO3 (15 mL) was added followed by 
a saturated aqueous solution of Rochelle’s salt (25 mL). After stirring for 10 min the 
aqueous phase was extracted with CH2Cl2 (3 × 25 mL) and the combined organic 
layers were dried, and concentrated in vacuo. The residue was purified by flash 
column chromatography (2-10% MeOH/CH2Cl2) to furnish 14 (48.1 mg, 0.105 mmol, 
78%) as a white foam. 
Rf 0.10 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 1655s, 1542m, 1471s, 1421s, 
1259s; δH (600 MHz CD3OD) 7.57 (1H, s, H-14), 7.47 (2H, s, H-2/6), 6.82 (1H, s, H-
13), 3.83 (2H, s, H-7), 3.80 (3H, s, H-15), 3.49 (2H, t, J 7.1 Hz, H-10), 2.79 (2H, t, J 
7.1 Hz, H-11); δC (150 MHz, CD3OD) 165.3 (C-9), 153.8 (C-4), 152.1 (C-8), 137.3 
(C-1), 136.1 (C-14), 135.9 br (C-12), 134.5 (C-2/6), 118.5 (C-3/5), 117.9 br (C-13), 
61.0 (C-15), 40.3 (C-10), 28.8 (C-7), 27.7 (C-11); m/z (ESI+) found 458.9682, 
[M+H]+ C15H17Br2N4O3 (79Br) requires 458.9667; m.p. 100-102 ºC. 
Crystals of 14 were obtained by slow evaporation of a solution of Et2O/Petrol/EtOH. 
The structure was confirmed by X-ray crystallographic analysis and given the unique 
identifier sl1006. 
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(E)-N-(2-(2-((4-Bromophenyl)diazenyl)-1H-imidazol-5-yl)ethyl)acetamide (31) 
N
H
N
H
N
N
12
14
10
O N
Br
2'
3'
6'
 
To a stirred solution of bromoaniline (30) (3.84 g, 22.3 mmol) in aqueous HCl (2 N, 
120 mL) was added, via cannula, a solution of sodium nitrite (1.54 g, 22.3 mmol) in 
H2O (32 mL) over 30 min, ensuring the temperature did not exceed 0 ºC. After this 
time, the mixture was added to a vigorously stirred solution of Nω-acetylhistamine 
(4.00 g, 26.1 mmol) in aqueous NaHCO3 (10% w/w, 200 mL) at 0 ºC. After 24 h at 4 
ºC the orange solid was isolated via filtration and purified by flash column 
chromatography (1-20% MeOH/CH2Cl2) to furnish 31 (3.91 g, 11.6 mmol, 52%) as a 
yellow solid. 
Rf 0.44 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 3057w, 2314w, 1618m, 1570m, 
1460s; δH (400 MHz, CD3OD) 7.82 (2H, d, J 8.7, H-4′ and H-8′), 7.71 (2H, d, J 8.7, 
H-5′ and H-7′), 7.15 (1H, s, H-13), 3.49 (2H, t, J 6.9, H-10), 2.87 (2H, t, J 6.9, H-11), 
1.93 (3H, s, H-2′); δC (125 MHz, CD3OD) 173.4 (C-1′), 155.4 (C-14, br) 152.7 (C-3′), 
133.7 (C-5′ and C-7′), 130.1 (C-12, br), 126.8 (C-6′), 125.4 (C-4′ and C-8′), 118.0 (C-
13, br), 40.1 (C-10), 29.2 (C-11, br), 22.5 (C-2′); m/z (ESI+) Found: 336.0456, 
[M+H]+ C13H15BrN5O (79Br) requires 336.0460; m.p. 102-106 ºC. 
Consistent with literature data. 48 
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N-(2-(2-Amino-1H-imidazol-5-yl)ethyl)acetamide (32) 
N
H
N
H
N
NH2
12
14
10
O
2'  
A solution of diazo compound 31 (4.55 g, 13.5 mmol) in absolute ethanol (100 mL) 
was hydrogenated over PtO2 (455 mg, 2.00 mmol) under an H2 atmosphere (4 bar). 
After 24 h, a second batch of PtO2 (455 mg) was added. After 18 h, the PtO2 was 
removed via filtration through celite and the reaction mixture was concentrated in 
vacuo. The residue was partitioned between H2O (100 mL) and EtOAc (100 mL). The 
aqueous layer was extracted with EtOAc (2 x 100 mL) and passed through a Dowex 
50W X8 column which was eluted with aqueous ammonium hydroxide (10%, 200 
mL). This was evaporated to dryness in vacuo to furnish 32 (326 mg, 1.94 mmol, 
14%) as a brown oil. 
νmax (thin film)/cm-1 3299br, 1632s, 1568s; δH (400 MHz, CD3OD) 6.29 (1H, s, H-
13), 3.34 (2H, t, J 7, H-10), 2.58 (2H, t, J 7, H-11), 1.92 (3H, s, H-2′); δC (100 MHz, 
CD3OD) 173.2 (C-1′), 150.8 (C-14), 132.0 (C-12), 112.1 (C-13), 40.4 (C-10), 28.0 
(C-11), 22.5 (C-2′); m/z (ESI+) found 169.1090, [M+H]+ C7H13N4O requires 
169.1084.  
Consistent with literature data.48  
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5-(2-Aminoethyl)-1H-imidazol-2-amine dihydrochloride (19) 
H2N N
H
N
NH2
.2HCl
12
14
10
 
A stirred solution of amide 32 (39.0 mg, 0.232 mmol) and aqueous HCl (6 N, 6 mL) 
was heated at 100 ºC for 14 h. After this the mixture was evaporated to dryness in 
vacuo to furnish 19 (46.2 mg, 0.232 mmol, 100%) as a brown solid which was used 
without further purification. 
νmax (thin film)/cm-1 3326s, 3233s, 1565s; δH (400 MHz CD3OD) 6.74 (1H, s, H-13), 
3.23 (2H, t, J 7.0 Hz, H-10), 2.95 (2H, t, J 7.0 Hz, H-11); δC (100 MHz, CD3OD) 
123.3 (C-14), 117.7 (C-12), 112.0 (C-13), 39.0 (C-10), 23.7 (C-11); m/z (ESI+) found 
127.0982, [M–H–2Cl]+ C5H11N4 requires 127.0982. 
Consistent with literature data.48 
Chapter 2 Part I: Total Syntheses of (5)-Bromoverongamine, Ianthelline and JBIR-44  
 58 
(E)-N-(2-(2-Amino-1H-imidazol-4-yl)ethyl)-3-(3,5-dibromo-4-methoxyphenyl)-2-
(((4-methoxybenzyl)oxy)imino)propanamide (34) 
OMe
Br Br
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MeO
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To a stirred solution of acid 17 (380 mg, 0.780 mmol) in CH2Cl2/DMF (1:1, 15 mL) 
were added N,N′-dicyclohexylcarbodiimide (218 mg, 1.06 mmol) and N -
hydroxybenzotriazole (143 mg, 1.06 mmol). After stirring for 5 min, a solution of 
aminohistamine dihydrochloride (19) (168 mg, 0.844 mmol) and iPr2EtN (290 µL, 
1.69 mmol) in CH2Cl2/DMF (1:1, 15 mL) were added. After 24 h, the mixture was 
concentrated in vacuo and the residue was purified by flash column chromatography 
(15:9:0.5:0.5 EtOAc/acetone/H2O/formic acid) to furnish 34 (190 mg, 0.319 mmol, 
41%) as a brown oil. 
Rf 0.63 (15:9:1:1 EtOAc/acetone/H2O/formic acid); νmax (thin film)/cm-1 2929w, 
1666s, 1513s, 1470s, 1247s; δH (400 MHz CD3OD) 7.36 (2H, s, H-2/6), 7.25 (2H, d, J 
8.6 Hz, H-3'/7'), 6.90 (2H, d, J 8.6 Hz, H-4'/6'), 6.50 (1H, s, H-13), 5.17 (2H, s, H-1'), 
3.81 (3H, s, H-15), 3.80 (3H, s, H-8'), 3.77 (2H, s, H-7), 3.49 (2H, t, J 6.8 Hz, H-10), 
2.71 (2H, t, J 6.8 Hz, H-11); δC (125 MHz, CD3OD) 164.8 (C-9), 161.3 (C-5'), 154.0 
(C-8), 152.5 (C-4), 148.9 (C-14), 136.8 (C-1), 134.5 (C-2/6), 131.2 (C-3'/7'), 129.9 
(C-2'), 126.4 (C-12), 118.6 (C-3/5), 115.0 (C-4'/6'), 110.8 (C-13), 78.5 (C-1'), 61.0 
(C-15), 55.7 (C-8'), 39.1 (C-10), 29.6 (C-7), 25.9 (C-11); m/z (ESI+) found 594.0346, 
[M+H]+ C23H26Br2N5O4 (79Br) requires 594.0352. 
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(E)-N-(2-(2-Amino-1H-imidazol-4-yl)ethyl)-3-(3,5-dibromo-4-methoxyphenyl)-2-
(hydroxyimino)propanamide (15) 
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Br Br
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To a stirred solution of amide 34 (140 mg, 0.235 mmol) and anisole (102 µL, 0.939 
mmol) in CH2Cl2 (5 mL) was added aluminium trichloride (125 mg, 0.939 mmol). 
After 5 min, a saturated aqueous solution of NaHCO3 (10 mL) was added followed by 
a saturated aqueous solution of Rochelle’s salt (20 mL). After stirring for 10 min the 
aqueous phase was extracted with CH2Cl2 (3 × 20 mL) and the combined organic 
layers were dried and concentrated in vacuo. The residue was purified by flash 
column chromatography (15:9:1:1, EtOAc/acetone/H2O/formic acid) to furnish 15 
(48.9 mg, 0.103 mmol, 44%) as a white solid. 
Rf 0.29 (15:9:1:1 EtOAc/acetone/H2O/formic acid); νmax (thin film)/cm-1 3162br, 
1678s, 1532s, 1471s, 1420s, 1257s; δH (400 MHz CD3OD) 7.47 (2H, s, H-2/6), 6.50 
(1H, s, H-13), 3.83 (2H, s, H-7), 3.81 (3H, s, C-15), 3.47 (2H, t, J 7.0 Hz, H-10), 2.70 
(2H, t J 7.0 Hz, H-11); δC (100 MHz, CD3OD) 165.6 (C-9), 153.8 (C-4), 152.0 (C-8), 
148.8 (C-14), 137.4 (C-1), 134.5 (C-2/6), 126.0 (C-12), 118.6 (C-3/5), 110.6 (C-13), 
61.0 (C-15), 38.9 (C-10), 28.8 (C-7), 25.8 (C-11); m/z (ESI+) found 473.9761, 
[M+H]+ C15H18Br2N5O3 (79Br) requires 473.9776. 
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4-(2-Aminoethyl)-2,6-dibromophenol hydrobromide (20) 
HBr•NH2
OH
Br
Br3
6
1
 
To a stirred suspension of tyramine (35) (1.00 g, 7.29 mmol) in MeOH (20 mL) was 
added bromine (750 µL, 14.6 mmol). The mixture was heated to 60 ºC for 14 h and 
then cooled to room temperature after which the precipitate was isolated by filtration, 
washed with Et2O (20 mL) and dried in vacuo to furnish 20 (1.85 g, 4.92 mmol, 68%) 
as a brown powder. 
νmax (thin film)/cm-1 2985w, 2915w, 1601w, 1472s, 1143s, 1133s; δH (400 MHz, d6-
DMSO) 9.77 (1H, br s, OH), 7.84 (3H, br s, NH3), 7.46 (2H, s, H-4/8), 3.03 (2H, br q, 
J 6.2 Hz, H-1), 2.80 (2H, t, J 7.5 Hz, H-2); δC (100 MHz, d6-DMSO) 149.4 (C-6), 
132.5 (C-4/8), 131.7 (C-3), 112.0 (C-5/7), 39.6 (C-1), 31.1 (C-2); m.p. 208-210 ºC. 
elem. anal. C8H10Br3O requires C 25.56% H 2.68%, N 3.73%, found C 25.56%, H 
2.57%, N 3.56%.  
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(E)-N-(3,5-Dibromo-4-hydroxyphenethyl)-3-(3,5-dibromo-4-methoxyphenyl)-2-
(((4-methoxybenzyl)oxy)imino)propanamide (36) 
OMe
Br Br
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To a stirred solution of acid 17 (287 mg, 0.589 mmol) in CH2Cl2 (10 mL) were added 
N,N′-dicyclohexylcarbodiimide (132 mg, 0.64 mmol) and N-hydroxybenzotriazole 
(86.5 mg, 0.640 mmol). After stirring for 5 min, a solution of amine 20 (240 mg, 0.64 
mmol) and iPr2EtN (223 µL, 1.28 mmol) were added. After 19 h, H2O (20 mL) was 
added, the organic layer separated and the aqueous layer was extracted with CH2Cl2 
(3 × 20 mL). The combined organic extracts were washed with brine, dried and 
concentrated in vacuo. The residue was purified by flash column chromatography 
(10-50% Et2O/Petrol) to yield 36 (189 mg, 0.247 mmol, 42%) as a white foam.  
Rf 0.38 (50% Et2O/Petrol); νmax (thin film)/cm-1 3391w, 2930w, 1664s, 1513s, 1471s, 
1245s; δH (400 MHz, CDCl3) 7.41 (2H, s, H-1/5), 7.28 (2H, s, H-13/17), 7.22 (2H, d, 
J 8.7 Hz, H-3'/7'), 6.90 (2H, d, J 8.7 Hz, H-4'/6'), 6.75 (1H, t, J 6.0 Hz, NH), 5.96 
(1H, s, OH), 5.12 (2H, s, H-1'), 3.83 (3H, s, H-18), 3.82 (3H, s, H-8'), 3.80 (2H, s, H-
7), 3.50 (2H, apparent q, J 6.8 Hz, H-10), 2.73 (2H, t, J 7.0 Hz, H-11); δC (100 MHz, 
CDCl3) 162.2 (C-9), 159.7 (C-5'), 152.6 (C-3), 150.9 (C-8), 148.2 (C-15), 134.7 (C-
6), 133.4 (C-1/5), 133.3 (C-12), 132.2 (C-13/17), 130.0 (C-3'/7'), 128.2 (C-2'), 117.7 
(C-2/4), 114.0 (C-4'/6'), 109.9 (C-14/16), 77.4 (C-1'), 60.5 (C-18), 55.3 (C-8'), 40.4 
(C-10), 34.2 (C-11), 28.6 (C-7); m/z (ESI+) found 760.8492, [M+H]+ C26H25Br4N2O5 
(79Br) requires 760.8492. 
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(E)-N-(3,5-Dibromo-4-hydroxyphenethyl)-3-(3,5-dibromo-4-methoxyphenyl)-2-
(hydroxyimino)propanamide. JBIR-44 (16) 
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Br Br
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To a stirred solution of amide 36 (152 mg, 0.199 mmol) and anisole (108 µL, 0.995 
mmol) in CH2Cl2 (5 mL) was added aluminium trichloride (133 mg, 0.995 mmol). 
After 5 min, a saturated aqueous solution of NaHCO3 (10 mL) was added followed by 
a saturated aqueous solution of Rochelle’s salt (20 mL). After stirring for 10 min the 
aqueous phase was extracted with CH2Cl2 (3 × 20 mL) and the combined organic 
layers were dried, and concentrated in vacuo. The residue was purified by flash 
column chromatography (20-50% Et2O/hexanes) to furnish 16 (109 mg, 0.169 mmol, 
85%) as a white foam.  
Rf 0.30 (50% Et2O/Petrol); νmax (thin film)/cm-1 3220br, 2928w, 1655s, 1623m, 
1533s, 1471s; δH (400 MHz, CD3OD calibrated to 7.52) 7.52 (2H, s, H-1/5), 7.36 (2H, 
s, H-13/17), 3.87 (2H, s, H-7), 3.86 (3H, s, H-18), 3.46 (2H, t, J 7.25 Hz, H-10), 2.74 
(2H, t, J 7.23 Hz, H-11); δC (100 MHz, CD3OD) 165.5 (C-9), 153.9 (C-3), 152.1 (C-
8), 150.8 (C-15), 137.3 (C-6), 134.6 (C-12), 134.5 (C-1/5), 133.6 (C-13/17), 118.6 (C-
2/4), 112.1 (C-14/16), 61.0 (C-18), 41.7 (C-10), 34.9 (C-11), 28.8 (C-7); m/z (ESI+) 
found 640.7936, [M+H]+ C18H17Br4N2O4 (79Br) requires 640.7922; m.p. 67-69 ºC 
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2.1.7 Biology: Experimental  
Cell lines and cell culture: SK-OV-3, TR175, and HeLa cell lines were obtained 
from Cell Services (CRUK LRI). Cell lines were grown in T75 flasks (NUNC™). SK-
OV-3 cells were maintained in RPMI-1640 medium (Gibco) supplemented with 10% 
(v/v) FBS, at 37 ºC in humidified air containing 5% CO2. In a similar manner, TR175 
cells were maintained in HAMS-F12 (Gibco) and HeLa cells were maintained in 
DMEM (Gibco).  
MTS assay: Cell viability was assessed using the Promega CellTiter 96® AQueous 
One Solution Cell Proliferation Assay. Single cell suspensions were prepared and 
seeded into 96 well plates (96F Nunclon Delta microwell) with 3 × 103 cells/mL (90 
µL/well). Cells were cultured for 24 h before the addition of agent in culture medium 
(10 µL) at the desired concentration. Drug samples were dissolved in DMSO (to form 
a 0.1 M stock solution) and diluted with the culture medium to the required 
concentrations. The final DMSO concentration did not exceed 0.1% to the total 
incubation solution (v/v) and a vehicle control was conducted with 0.1% DMSO 
concentration in each assay. Cells were incubated at 37 ºC for 48 h. MTS reagent was 
aliquoted to each well (20 µL) and the plates were incubated at 37 ºC for 2 h. 
Absorbance at 490 nm was determined for each well using a TECAN infinite M200. 
Each experimental point was performed in quadruplicate. Dose-response curves were 
generated using Microsoft Excel. 
xCELLigence impedance assay HUVECs were isolated, cultured and defrosted 
immediately prior to use using standard procedures.49 The background impedance of 
the E-plate 96 was determined with pre-warmed EGM-2 (50 µL), followed by 
addition of HUVEC cell suspension in EGM-2 (40 µL, 7.5 × 103 cells/well). Plates 
were returned to the Real-Time Cell Analyzer (RTCA) station and incubated for 5 h, 
with impedance measured every 10 min. Drug compound was then added in EGM-2 
(10 µL, 10× concentrations to give appropriate 1× plate concentrations). The plates 
were returned to the RTCA and incubated for a further 40 h, with impedance 
measured every 40 s for 3 h, then every 30 min for 37 h. Data was obtained as cell 
index values which are calculated as measured impedance minus background 
impedance, divided by 15. These values were normalised using the cell index value 
obtained immediately prior to drug addition. Dose-response curves at the required 
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timepoint were generated and used to determine EC50 values, which were calculated 
using a variable slope dose-response curve with Hill slope constrained to > –2.0 using 
GraphPad Prism version 5.0c for Mac, GraphPad Software, San Diego California 
USA, www.graphpad.com. 
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2.1.8 Appendix 
2.1.8.1 NMR Data of Natural Products 
18 
17 
16 
15 
14 
13 
12 
11 
10 
9 8 7 6 5 4 3 2 1 
A
tom
 
– – – 
61.3 
136.2 
118.0 
134.0 
27.9 
40.6 
165.6 
152.4 
29.1 
134.8 
118.8 
154.2 
118.8 
134.8 
137.7 
N
at. 14 
13C
 
62.8 
M
H
z 
– – – 
61.0 
136.1 
117.9 
136.0 
27.7 
40.3 
165.4 
152.1 
29.0 
134.5 
118.5 
153.8 
118.5 
134.5 
137.4 
Syn. 14 
13C
 
150 
M
H
z 
 
– – – 
3.80 s 
7.62 s 
6.84 s 
– 
2.79 t 
3.49 t 
– – 
3.82 s 
7.46 s 
– – – 
7.46 s 
– 
N
at. 14 
1H
 
300 
M
H
z 
– – – 
3.80 s 
7.57 s 
6.82 s 
– 
2.79 t 
3.49 t 
– – 
3.83 s 
7.47 s 
– – – 
7.47 s 
– 
Syn. 14 
1H
 
600 
M
H
z 
– – – 
61.0 
148.6 
110.7 
126.0 
25.7 
38.9 
165.6 
152.1 
28.8 
134.4 
118.5 
153.8 
118.5 
134.4 
137.2 
N
at. 15 
13C
 
62.8 
M
H
z 
– – – 
61.0 
148.8 
110.6 
126.0 
25.8 
38.9 
165.6 
152.0 
28.8 
134.5 
118.6 
153.8 
118.6 
134.5 
137.4 
Syn. 15 
13C
 
100 
M
H
z 
– – – 
3.81 s 
– 
6.50 s 
– 
2.69 t 
3.47 t 
– – 
3.81 s 
7.46 s 
– – – 
7.46 s 
– 
N
at. 15 
1H
 
300 
M
H
z 
– – – 
3.82 s 
– 
6.50 s 
– 
2.70 t 
3.48 t 
– – 
3.83 s 
7.47 s 
– – – 
7.47 s 
– 
Syn. 15 
1H
 
400 
M
H
z 
61.0 
133.6 
112.1 
150.7 
112.1 
133.6 
134.6 
34.9 
41.7 
165.4 
153.8 
28.7 
137.3 
134.4 
118.6 
152.0 
118.6 
134.4 
N
at. 16 
13C
 
125 
M
H
z 
61.0 
133.6 
112.1 
150.8 
112.1 
133.6 
134.6 
34.9 
41.7 
165.5 
152.1 
28.8 
137.3 
134.5 
118.6 
153.9 
118.6 
134.5 
Syn. 16 
13C
 
100 
M
H
z 
3.85 s 
7.36 s 
– – – 
7.36 s 
– 
2.73 t 
3.45 t 
  
3.87 s 
 
7.52 s 
– – – 
7.52 s 
N
at. 16 
1H
 
500 
M
H
z 
3.86 s 
7.36 s 
– – – 
7.36 s 
– 
2.74 t 
3.46 t 
– – 
3.87 s 
– 
7.52 s 
– – – 
7.52 s 
Syn. 16 
1H
 
400 
M
H
z 
Table 3 Comparison of the NMR data (CD3OD) of natural and synthetic (5)-
bromoverongamine (14),1 ianthelline (15),1 and JBIR-44 (16).2 Discrepancies in the original 
assignment are highlighted in bold. 
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2.1.8.2 NMR Spectra of Natural Products 
1H NMR (CD3OD 600 MHz) spectrum of (5)-bromoverongamine (synthetic material) 
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13C NMR (CD3OD 150 MHz) spectrum of (5)-bromoverongamine (synthetic material) 
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13C NMR (CD3OD 62.8 MHz) (5)-bromoverongamine (natural material) 
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1H NMR (CD3OD 400 MHz) spectrum of ianthelline (synthetic material) 
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13C NMR (CD3OD 100 MHz) spectrum of ianthelline (synthetic material) 
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1H NMR (CD3OD 400 MHz) spectrum of JBIR-44 (synthetic material) 
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13C NMR (CD3OD 100 MHz) spectrum of JBIR-44 (synthetic material) 
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HMBC spectrum of JBIR-44 (synthetic material) 
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2.1.8.3 Crystal Structure Data 
(Z)-4-(3,5-Dibromo-4-methoxybenzylidene)-2-methyloxazol-5(4H)-one (25) 
 
Crystal data and structure refinement for sl1031 
  
Identification code    sl1031 
Empirical formula    C12H9Br2NO3 
Formula weight    375.02 
Temperature     180(2) K 
Wavelength     0.71073 Å 
Crystal system    Monoclinic 
Space group     P2(1)/c 
Unit cell dimensions    a = 11.5810(3) Å α = 90º 
     b = 14.3132 Å  β = 94.95(3)º 
      c  = 7.6379 Å  γ = 90º 
Volume     1261.35(8) Å3 
Z      4 
Density (calculated)    1.975 Mg/m3 
Absorption coefficient   6.425 mm–1 
F(000)      728 
Crystal size     0.23 × 0.14 × 0.07 mm3 
Theta range for data collection  3.53 to 33.17º 
Index ranges     -17<=h<=17, -21<=k<=21, -11<=1<=11 
Reflections collected    18106 
Independent reflections   4733 [R(int) = 0.0493] 
Completeness to theta = 33.17º  98.3% 
Absorption correction    Semi-empirical from equivalents 
Max. and min. transmission   0.658 and 0.323 
Refinement method    Full-matrix least-squares on F2 
Data / restraints / parameters   4733 / 0 / 165 
Goodness-of-fit on F2    1.036 
Final R indices [I>2sigma (I)]  R1 = 0.0328, wR2 = 0.0698 
R indices (all data)    R1 = 0.0504, wR2 = 0.0757  
Largest diff. peak and hole   0.406 and –0.726 e. Å–3 
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(Z)-3-(3,5-Dibromo-4-methoxyphenyl)-2-hydroxyacrylic acid (38) 
 
Crystal data and structure refinement for sl1033 
  
Identification code    sl1033 
Empirical formula    C14H18Br2O5 
Formula weight    426.10 
Temperature     180(2) K 
Wavelength     0.71073 Å 
Crystal system    Monoclinic 
Space group     P2(1)/n 
Unit cell dimensions    a = 15.1400(3) Å α = 90º 
      b = 15.0183(3) Å β = 101.805(1)º 
      c  = 15.3495(4) Å γ = 90º 
Volume     3416.31(13) Å3 
Z      8 
Density (calculated)    1.657 Mg/m3 
Absorption coefficient   4.762 mm–1 
F(000)      1696 
Crystal size     0.42 × 0.23 × 0.12 mm3 
Theta range for data collection  3.55 to 27.89º 
Index ranges     -19<=h<=19, -18<=k<=19, -19<=1<=20 
Reflections collected    20026 
Independent reflections   8006 [R(int) = 0.0372] 
Completeness to theta = 27.89º  98.2% 
Absorption correction    Semi-empirical from equivalents 
Max. and min. transmission   0.451 and 0.354 
Refinement method    Full-matrix least-squares on F2 
Data / restraints / parameters   8006 / 14 / 340 
Goodness-of-fit on F2    1.023 
Final R indices [I>2sigma (I)]  R1 = 0.0530, wR2 = 0.1249 
R indices (all data)    R1 = 0.0811, wR2 = 0.1424  
Largest diff. peak and hole   1.127 and –0.702 e. Å–3 
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(5)-Bromoverongamine. (E)-N-(2-(1H-Imidazol-5-yl)ethyl)-3-(3,5-dibromo-4-
methoxyphenyl)-2-(hydroxyimino)propanamide (14)  
 
Crystal data and structure refinement for sl1006 
  
Identification code    sl1006 
Empirical formula    C15H16Br2N4O3 
Formula weight    460.14 
Temperature     180(2) K 
Wavelength     0.71073 Å 
Crystal system    Monoclinic 
Space group     P2(1)/n 
Unit cell dimensions    a = 8.9668(2) Å α = 90º 
     b = 21.2760 Å  β = 100.246(1)º 
      c  = 9.3347(2) Å γ = 90º 
Volume     1752.45(6) Å3 
Z      4 
Density (calculated)    1.744 Mg/m3 
Absorption coefficient   4.647 mm–1 
F(000)      912 
Crystal size     0.23 × 0.18 × 0.12 mm3 
Theta range for data collection  3.60 to 30.01º 
Index ranges     -12<=h<=12, -29<=k<=29, -12<=1<=12 
Reflections collected    15914 
Independent reflections   5050 [R(int) = 0.0586] 
Completeness to theta = 30.01º  98.7% 
Absorption correction    Semi-empirical from equivalents 
Max. and min. transmission   0.580 and 0.362 
Refinement method    Full-matrix least-squares on F2 
Data / restraints / parameters   5050 / 0 / 222 
Goodness-of-fit on F2    0.991 
Final R indices [I>2sigma (I)]  R1 = 0.0378, wR2 = 0.0927 
R indices (all data)    R1 = 0.0600, wR2 = 0.0991  
Largest diff. peak and hole   0.587 and –0.955 e. Å–3 
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2.2.1 Introduction 
Whether it is in industry or academia, the discovery of a novel bioactive natural 
product is commonly followed-up by a synthesis programme that serves to confirm 
the structural assignment and provide material for further biological studies. Once a 
robust synthesis route has been developed, a medicinal chemistry approach 
traditionally involving SAR analysis is adopted in order to establish the key 
pharmacophoric elements. Developing a pharmacophore model for a biological target 
is vital because it can be used in lead-optimisation and rational design scenarios, 
thereby accelerating the drug-discovery process. 
Intriguingly, there is very little by way of SAR studies into bromotyrosine 
derivatives.1 This is in spite of their rich bioactivity profiles and the relative ease in 
which their structural architectures can be accessed. Historically, brominated 
molecules, especially those containing multiple bromine atoms, would have been 
considered unattractive drug-leads due to their undesirable physicochemical 
properties. Understandably, these compounds run the risk of violating the molecular 
weight and LogP boundaries outlined in Lipinski’s Rules.2 Nevertheless, the use of 
bromine (and the other halogens) should not be disregarded when embarking on drug-
discovery programmes. 
Perhaps surprisingly, around half of the molecules entered into high-throughput 
screening programmes are halogenated3 and as a consequence of this, an ever-
increasing number of drugs and drug candidates in development are halogenated 
structures. The vast majority of these contain fluorine and/or chlorine atoms.* In the 
past, the introduction of halogen atoms (particularly fluorine) has been used to block 
metabolically labile positions since carbon-halogen bonds are not readily metabolised 
by cytochrome p450 enzymes. Furthermore, halogenation is also known to improve a 
compound’s oral permeability, blood-brain-barrier penetration, and selectivity for a 
particular target. In an attempt to improve potency, installation of a halogen atom at a 
tolerated site within a molecule is a common strategy employed by medicinal 
chemists. Until recently, it was believed that an increase in potency was purely due to 
a steric effect–the basis of this argument being that the halogen could exploit a 
                                                
* From 1988 to 2006, 57% of halogenated drugs were fluorinated and 38% were chlorinated. In 
comparison, 4% of halogenated drugs contained bromine and only 1% contained iodine (Curr. Drug. 
Targets, 2010, 11, 1).  
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hydrophobic pocket in the biological target and this additive binding would thus 
increase the affinity of the ligand to its target. In fact, it has now come to light that 
halogen atoms have the ability to engage with functional groups in a protein and form 
intermolecular bonding interactions. These electrostatic interactions are termed 
halogen bonds and although they are a familiar concept and have been extensively 
characterised in the area of supramolecular chemistry, investigations into the 
importance of this phenomenon in a biological setting is very much in its infancy.  
In the simplest of terms, halogen bonding is analogous to hydrogen bonding and 
involves and interaction between an electronegative atom (e.g. O or N) and the 
electropositive cap (termed “sigma hole”) at the end region of halogen atoms (Cl, Br, 
I) along the C-X axis. As the halogen atom can be viewed as the electrophilic partner 
in this interaction, the strength of the halogen bond is positively correlated with the 
electrostatic potential of the cap; the strength of the interaction follows the trend 
I>Br>Cl.  
The biological relevance of this interaction was first analysed in detail by Auffinger 
and co-workers. By surveying the Protein Data Bank (July 2004 release), they were 
able to identify 113 distinct halogen-protein interactions.4 In 2008, this number had 
risen to 248 and consisted of 47% Cl•••O, 22% Br•••O, and 31% I•••O interactions 
with backbone carbonyl oxygens or side chain hydroxyl and carboxyl oxygens. 5 In 
the same study, halogen bonding was shown to play an important role in inhibitor 
recognition and binding in protein kinases. 
It is clearly evident that halogen bonding is a valid and important interaction that 
needs to be considered when working with halogenated molecules in a medicinal 
chemistry setting. To put this in context, IDD 594 is a highly selective aldolase 
reductase inhibitor6; this selectivity is necessary to avoid the toxicity associated with 
off-target effects that include inhibition of aldehyde reductase enzymes. Co-
crystallisation of IDD 594 with aldose reductase revealed a short contact (<3 Å) that 
turned out to be responsible for the observed selectivity (Figure 23).  
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Figure 23 Halogen bonding of IDD 594 to aldolase reductase through Thr 113 residue. 
In the Ley group, we are undertaking research in the area of halogen bonding after 
discovering that replacing meta-methoxy groups in the A-ring of the natural product 
combretastatin A-4 with halogen atoms leads to analogues that have equal or superior 
potency against cancer cells and HUVECs.7 Whilst these analogues retained both the 
antitubulin and antimitotic effects of the parent compound, intriguingly, the 
dibrominated compound (at 100 nM) caused the accumulation of interphase 
microtubules around the nucleus of HeLa cells (not shown). This phenomenon was 
also observed in MCF-7 cells that had been treated with ceratamine A (Chapter 1 
Figure 9d); combretastatin A-4 did not elicit this response.  
Curiously, the degree of biological activity exhibited by these analogues follows a 
distinct trend, for example, the antimitotic activity of the analogues increased in the 
order F<<Cl≈OMe<Br<I (Figure 24). This trend correlates well with both halogen 
Van der Waal’s radii and the calculated strength of halogen bonding. We believe the 
steric effect cannot be used to explain this trend because the Van der Waal’s radii of 
bromine (1.85 Å) and iodine (1.98 Å) are smaller than that of a methoxy substituent 
(2.60 Å). Therefore, to account for these observations, we hypothesise that halogen 
bonding interactions can arise between tubulin and the dibromo and diiodo analogues 
which, in turn, increases the binding affinity. 
Initial computational investigations into the binding of these halogenated 
combretastatin A-4 analogues to the tubulin heterodimer appear to support this 
hypothesis. Multiple rounds of energy minimisation of the ligand in the presence of 
the protein have shown that the free energy of binding for the diiodo analogue is 
greater than that for the dibromo analogue and combretastatin A-4. Furthermore, 
molecular docking supports this data, which shows that the halogenated portion of the 
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diiodo analogue is embedded further into the binding site when compared with the A-
ring of combretastatin A-4 and other analogues.† 
OMe
OH
MeO
R
R
A
B
No treatment
R = Cl
R = OMe
R = Br
R = I
 R = OMe;  Combretastatin A-4
 
Figure 24 Antimitotic activity of analogues represented by histograms of DNA profiles 
showing G1 and G2/M populations. 
To complement this research on the combretastatin A-4 analogues, we sought to 
investigate the importance of the 3,5-dibromo-4-methoxyaryl motif on the anticancer 
activities exhibited by the bromotyrosine derivatives in the first part of this chapter. 
To this end, we planned to synthesise analogues of (5)-bromoverongamine and JBIR-
44 with the aryl ring substitution patterns (40 to 44) outlined in Figure 25. This library 
of compounds would enable us to probe the SAR of these natural products in a 
systematic fashion–to our knowledge, this traditional medicinal chemistry approach 
towards understanding the biological relevance of the 3,5-dibromo-4-methoxyaryl 
motif in bromotyrosine derivatives has not been reported in the literature. 
OH
BrBr
N
O
HO
44
OMe
H H MeO
OMe
OMe
OMe
Cl Cl
OMe
I I
N N N N
OOOO
HO HO HO HO
40 41 42 43  
Figure 25 Desired phenyl ring substitutions on (5)-bromoverongamine and JBIR-44.  
                                                
† Personal communication with Thomas M. Beale Esq. 
Chapter 2 Part II: (5)-Bromoverongamine and JBIR-44: Structure-Activity Relationship Analysis 
 85 
2.2.2 Results and Discussion 
It was our aim to synthesise these analogues in a similar vein to the natural products, 
whereby an α-oximino acid is coupled to the amine side chain, with the oxime 
functionality unmasked by removal of the PMB group (Scheme 8). Furthermore, it 
was envisaged that the collection of α-oximino acids which possessed the desired aryl 
ring substitutions could be accessed in short order by making use of the chemistry 
developed in the first part of this chapter (Scheme 19).  
To recap, aldehydes of type 45 can be converted to the corresponding azlactones (46) 
using conditions described by Erlenmeyer. Finally, the phenylpyruvic acid derivatives 
(47), obtained from the acidic hydrolysis of 46, can be condensed with a (O-
protected) hydroxylamine to furnish the corresponding α-oximino acids (48). In this 
strategy, it is necessary for the 3,5-aryl substituents to be installed at the beginning of 
the synthesis and therefore the R1 functionality in 48 is dependent on the starting 
aldehyde. Importantly, this route is not just limited to variations at R1; diversity can 
also be introduced by modifying the phenolic substituent (R2) or by using a range of 
O-protected hydroxylamines (R3).  
OR2
O
R1 R1
OR2
R1 R1
O
N
O
OR2
R1 R1
O
OH
OR2
R1 R1
N
R3O
O
OH
45 46 47 48
a b c
HO
 
Scheme 19 General route to α-oximino acids of type 48. 
Reagents and conditions: (a) N-acetylglycine, NaOAc, Ac2O, 120 ºC; (b) 3 N HCl, reflux; (c) 
NH2OR3·HCl, NaOAc, EtOH. 
The starting aldehydes necessary for the analogue syntheses are shown in Figure 26. 
3,5-Dichloro-4-methoxybenzaldehyde (51) and 3,5-diiodo-4-methoxybenzaldehyde 
(52) were not available from commercial sources and therefore had to be synthesised.  
OMe
I I
O
OMe
Cl Cl
O
51 52
OMe
H H
O
49
OMe
MeO OMe
O
50
OH
Br Br
O
23  
Figure 26 Starting aldehydes.  
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2.2.2.1 Synthesis of 3,5-Dichloro-4-methoxy Benzaldehyde (51) 
3,5-Dichloro-4-methoxybenzaldehyde (51) is a naturally occurring halometabolite 
produced de novo from glucose by fungi of the phylum Basidiomycota.8 Yet, despite 
its structural simplicity, a convenient synthetic method to access 51 has yet to be 
reported. In 1923, Durrans was able to isolate 51 from a neat mixture of sulfuryl 
chloride (SO2Cl2) and anisaldehyde (49) that had been left at room temperature for 
three days (Scheme 20).9 Using this information as a start point, we began by 
investigating the chlorination of 49 and 4-hydroxybenzaldehyde (53) with sulfuryl 
chloride. 
OMe
O
OMe
O
Cl Cl
49 51
a
 
Scheme 20 Durrans’ method for producing 51. 
Reagents and conditions: (a) SO2Cl2, rt, neat, 3 days. 
Sulfuryl chloride is a source of Cl2 and is often used instead of the gas because it is 
more convenient to handle. Although the reactivity of the halogens increases in the 
order I2<Br2<Cl2<F2, performing multiple electrophilic aromatic substitution reactions 
on a phenyl ring using chlorine is not trivial and can require forcing conditions and 
the presence of a catalyst.10 This is because the introduction of a second chlorine atom 
is disfavoured because of the deactivating effect the first chlorine atom imparts 
towards the next electrophilic substitution. In our case, it soon became apparent that 
whilst monochlorination of both substrates occurred rapidly, chlorination of the 3-
chloroanisaldehyde (from 49, results not shown) proved difficult. Therefore, the 
following discussion will describe the optimisation to find conditions to affect the bis-
chlorination of 53 to 3,5-dichloro-4-hydroxybenzaldehyde (54) (Table 4). Once 
accessed, it was hoped 54 could then be methylated to access the desired aldehyde 51.  
In the beginning, 53 and SO2Cl2 (2.5 eq.) in CH2Cl2 were heated at 60 ºC under 
microwave conditions for 10 minutes (Table 4, entry 1). By 1H NMR analysis, the 
ratio of monochloro (55) to dichloro product (54) was 19.5:1. Next, the amount 
SO2Cl2 was increased in an attempt to improve this ratio (entries 2 and 3). From this 
experimentation, it was decided that 10 equivalents would be used for further 
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optimisation.‡ By lengthening the reaction time to 2 hours (entry 4) and increasing the 
temperature to 80 ºC (entry 5), the product ratio was eventually pushed in favour of 
the bis-chlorinated aldehyde 54. An extended reaction time of 10 hours at 80 ºC 
finally gave a more acceptable ratio of 55:54 (1:7); however, this reaction time was 
not ideal from the perspective of microwave chemistry.  
Table 4 Conditions for the chlorination of 53 with sulfuryl chloride. 
 
OH
O
OH
O
OH
O
Cl Cl Cl
53 55 54
chlorination conditions
+
 
Entry Solvent SO2Cl2 (eq.) Temp/ºC Time/h Ratioa 55:54 
1 CH2Cl2 2.5 60b 0.2 19.5:1 
2 CH2Cl2 7.5 60b 0.2 9.5:1 
3 CH2Cl2 10 60b 0.2 7.2:1 
4 CH2Cl2 10 60b 2 2.2:1 
5 CH2Cl2 10 80b 2 1:1.33 
6 CH2Cl2 10 80b 10 1:7 
7 MeCN 10 rt 1.67 1:0.425 
8 MeCN 10 rt 5 1:1.5 
9 MeCN 10 rt 6 1:2.4 
10 MeCN 10 rt 20 0:1 
11 MeCN 2.5 rt 18 1.2:1 
12 MeCN 2.5 rt 48 1:1 
13 EtOAc 10 80 5 0:1 imp 
14 EtOAc 10 65 1 1:5.34 
15 EtOAc 10 65 2 0:1 
16 EtOAc 5 65 2 1:4.88 
17 EtOAc 2.5 65 2 2.7:1 
a Product ratios were calculated by 1H NMR; b Heated under microwave irradiation.  
As chlorination is known to be much more rapid in polar solvents, acetonitrile was 
used in place of dichloromethane.11 A rapid evolution of gas was observed upon the 
addition of SO2Cl2 to a solution of 53 in MeCN and in view of safety, the mixture was 
not heated (entries 7-10). Although full conversion to 54 was observed after 20 hours, 
a major impurity appeared to be present by 1H NMR analysis.§ This was confirmed 
when the mass recovery was far greater than anticipated following an aqueous work-
up. The impurity was identified as 2,2,2-trichloroacetamide by X-ray crystallographic 
analysis. It is thought the chlorine liberated in situ reacted with the acetonitrile solvent 
                                                
‡ As these reactions were performed in sealed microwave vials, increasing the stoichiometry above 10 
equivalents was prohibitive due to the volumes of SO2Cl2 that would have been required.  
§ This was characterised by two broad peaks at 6.62 and 6.30 in the 1H NMR spectrum.   
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to form 2,2,2-trichloroacetonitrile which upon work-up, hydrolysed under the acidic 
conditions to give the corresponding acetamide. The stoichiometry of SO2Cl2 was 
reduced in an effort to limit this side reaction however this prevented full conversion 
to the bis-chlorinated product (entries 11 and 12). 
In 2009, Terasaki and co-workers reported the chlorination of para-hydroxybenzoate 
esters with SO2Cl2 in ethyl acetate at 80 ºC.12 In our hands, full conversion of 53 to 54 
was achieved by heating (conventional) the mixture to 80 ºC for 5 hours in a sealed 
tube, however, a significant by-product was formed–this was derived from the 
aldehyde 54 and although not formally characterised was presumed to be the 
trichlorinated product (entry 13). Pleasingly, by reducing the temperature and reaction 
time, the formation of this by-product could be minimised without compromising the 
conversion of 53 to 54 (entries 14 and 15). Under these conditions (65 ºC, 2 hours), 
attempts to lower the equivalents of SO2Cl2 without affecting the conversion proved 
unsuccessful (entries 16 and 17). 
Methylation of the crude products from entries 6 and 15 was performed using the 
conditions described previously in Part I of this chapter (Scheme 21) to give 51 in 
40% (entry 15) and 69% (entry 6) yields in two steps from 4-hydroxybenzaldehyde.** 
OH
O
OMe
O
Cl Cl
54 51
a
ClCl
 
Scheme 21 Methylation of the crude products from Table 4, entries 6 and 15. 
Reagents and conditions: (a) MeI, K2CO3, acetone, 60 ºC, 3 h, 40% (entry 15) and 69% (entry 
6) from 53. 
 
 
 
                                                
** Despite the lower yield, scale up of material was performed using the conditions described in entry 
15. These conditions proved to be more convenient since the chlorination reactions could be run in 
parallel when using conventional heating.  
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2.2.2.2 Synthesis of 3,5-Diiodo-4-methoxy Benzaldehyde (52) 
As previously mentioned, electrophilic aromatic iodination is the least facile of the 
halogenation substitutions due to the low electrophilic strength of molecular iodine. 
With the exception of highly reactive substrates (anilines or phenolate anions), 
iodination of aromatic species often requires the use of an activated iodinating 
species. Common approaches involve the use of I+ reagents,13 iodides,14 or molecular 
iodine in combination with an oxidising agent.15  
Again, 4-hydroxybenzaldehyde (53) was chosen instead of anisaldehyde as the 
starting substrate given its greater propensity to undergo electrophilic substitution 
reactions. Of direct relevance to this, the mono and bis-iodination of phenols is 
heavily precedented in the literature. Research into this area has been driven in part by 
the importance of this process in the fields of radiopharmaceuticals16 and thyroid 
hormones.17  
Starting with a mild and efficient iodination procedure, treatment of 53 with 
bis(pyridine)iodonium tetrafluoroborate (Barluenga’s reagent) for 2 hours at room 
temperature exclusively gave 57 in 95% yield after purification (Table 5, entry 1).18 
Although this transformation was high yielding, the cost of the iodinating reagent†† 
and need for purification meant an alternative procedure was desirable. Sudalai and 
co-workers developed a NaIO4/KI/NaCl system for the in situ generation of iodine 
monochloride that was shown to affect the bis-iodination of 53 in excellent yield after 
only 15 minutes at room temperature. 19 In our hands, no conversion of 53 to either 56 
or 57 was observed (by 1H NMR) after this timeframe (entry 2); however, after 24 h, 
partial conversion to the desired product 57 was evident (entry 3). Full conversion 
occurred after 96 hours and, following an aqueous work-up with sodium thiosulfate, 
57 (>10 g) was obtained in 98% yield and excellent purity (entry 4). 
 
 
 
 
                                                
††At the time of this research, the in-house preparation of bis(pyridine)iodonium tetrafluoroborate was 
not feasible as it involved the use of mercury(II) oxide. However, Davies and co-workers recently 
developed a safe and scalable preparation using silver as a substitute for mercury (Org. Synth., 2010, 
87, 288). 
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Table 5 Conditions for the iodination of 53. 
 
OH
O
OH
O
OH
O
I I I
53 56 57
iodination conditions
+
 
Entry Reagent Solvent Temp/ºC Time/h Ratio
a 
53:56:57 
1 I(Py)2BF4 CH2Cl2 rt 2 0:0:1 
2 KI, NaIO4, NaCl 
AcOH/H2O 
(9:1) rt 0.25 
No 
conversion 
3 KI, NaIO4, NaCl 
AcOH/H2O 
(9:1) rt 24 1:1.9:7.1 
4 KI, NaIO4, NaCl 
AcOH/H2O 
(9:1) rt 96 0:0:1 
a Product ratios were calculated by 1H NMR. 
Methylation of 57 proceeded smoothly using the conditions described previously to 
give 52 in 90% yield after purification (Scheme 22). It is worth noting that a 
significant by-product formed when the reaction time was extended to 7.5 hours (cf. 
3.5 hours). This was identified as the β-hydroxy carbonyl compound 58–the aldol 
product of acetone with aldehyde 52.  
 
OH
O
OMe
O
I I
57 52
a
II
OMe
I I
58
OH
O
 
Scheme 22 Methylation of 57. 
Reagents and conditions: (a) MeI, K2CO3, acetone, 60 ºC, 3.5 h, 90%. 
2.2.2.3 Synthesis of α-Oximino Acid Derivatives 
With the required collection of aldehydes now in hand, the syntheses of the 
corresponding α-oximino acid derivatives 69 to 73 could be realised. Formation of 
the azlactones 59 to 63 was achieved using the previously described Erlenmeyer 
conditions. In the case of 63, the 4-hydroxy functionality in the parent aldehyde (23) 
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was acetylated under the reaction conditions (Scheme 23).‡‡ Although the acidic 
hydrolyses of azlactones 59 (22 hours), 60 (37 hours), 61 (17 hours), and 63 (10 
hours) were high yielding, the trimethoxy azlactone 62 decomposed when subjected 
to these conditions (~2 hours). This was somewhat unexpected since Wong and co-
workers reported the acidic hydrolysis of 62 to 67 using identical conditions (3 N 
HCl, 100 ºC, 4 hours, 78%).20 Nevertheless, the trimethoxy α-oximino acid 73 could 
be accessed directly from 62 following saponification of the azlactone with barium 
hydroxide and subsequent condensation with O-PMB hydroxylamine hydrochloride 
(26), albeit in a 30% yield. For the other substrates, condensation of O-PMB 
hydroxylamine hydrochloride with the phenylpyruvic acid derivatives 64, 65, 66 and 
68 in the presence of sodium acetate gave the corresponding α-oximino acids 69 to 72 
in excellent yields and purities. 
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Scheme 23 Syntheses of α-oximino acids 69 to 73. 
Reagents and conditions: (a) N-acetylglycine, NaOAc, Ac2O, 120 ºC; (b) 3 N HCl, reflux; 26, 
NaOAc, EtOH, rt, 18 h; (d) Ba(OH)2⋅8H2O, 1,4-dioxane/H2O (1:1), 60 ºC, 30 min then 26, 
18 h, 30%. 
                                                
‡‡ This was inconsequential since hydrolysis of the acetyl group would occur in the next step. 
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2.2.2.4 Synthesis of (5)-Bromoverongamine Analogues 
The histamine side chain of (5)-bromoverongamine (14) was appended to the 
collection of collection of five α-oximino acid derivatives (69 to 73) to give the 
corresponding products 74 to 78 in good yields (Scheme 24). For the substrates, 74 to 
77, removal of the PMB group was achieved with aluminium trichloride and anisole 
in dichloromethane, giving 79 to 82 in moderate to low yields. Under these conditions 
it was not possible to deprotect 78 as it was not soluble in dichloromethane.§§ 
However, minimal conversion was observed (by LCMS) when the reaction was 
performed in neat anisole and at extended reaction times (24 hours), but it was not 
possible to isolate sufficient quantities of 83 for the purposes of characterisation or 
biological screening. 
a, b or c
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Scheme 24 (5)-Bromoverongamine analogue synthesis. 
Reagents and conditions: (a) Histamine dihydrochloride, DCC, HOBt, iPr2EtN, CH2Cl2, rt, 
(for 69, 71, and 72); (b) ®T3P, histamine dihydrochloride iPr2EtN, CH2Cl2, 0 ºC to rt (for 70); 
CDI, THF, 0 ºC, 1 h then histamine, CH2Cl2, (for 73); (d) AlCl3, anisole, CH2Cl2, rt, 5 min. 
In addition to investigating aryl ring analogues of 14, we also wanted to explore the 
biological effects of modifying other potentially relevant functionality within the 
natural product. As a starting point, we planned to synthesise 85 and 87 which would 
allow us to explore whether the oxime and/or amide hydrogens are involved in 
hydrogen bonding to a potential biological target.***  
                                                
§§ This may be due to the presence of the phenolic functionality. 
*** It was reported in the first part of this chapter that the PMB protected congener (29) of (5)-
bromoverongamine was more active than the natural product with this being attributed to an increase in 
lipophilicity. Therefore, masking the oxime with a methyl group should give further insight into 
whether the difference in activity was a result of increasing lipophilicity or as a result of nullifying the 
H-bond donating ability of the free oxime. 
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The α-oximino acid 17 was reacted with CDI and the resulting activated ester was 
treated with methylhistamine to give the tertiary amide 84 in 35% yield (Scheme 25). 
The previously mentioned Lewis acidic conditions cleaved the PMB group to furnish 
the N-methylated product 85 in a yield of 79%. It would not have been possible to 
access the O-methyl oxime 87 directly from the natural product because of the 
susceptibility of imidazole ring nitrogens towards methlyation. Therefore a two-step 
procedure from 38 was required to circumvent this issue (Scheme 25). Accordingly, 
the phenylpyruvic acid derivative 38 was converted to the O-methyl oximino acid 86 
with O-methylhydroxylamine hydrochloride in the presence of sodium acetate. Then, 
86 was coupled with histamine dihydrochloride using DCC and HOBt to furnish O-
methyl-(5)-bromoverongamine (87) in a yield of 60% over the two steps.  
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Scheme 25 Synthesis of 85 and 87. 
Reagents and conditions: (a) CDI, THF, rt, 1 h then 0 ºC, methylhistamine, rt, 18 h, 35%; (b) 
AlCl3, anisole, CH2Cl2, rt, 5 min, 79%; (c) O-methylhydroxylamine hydrochloride, NaOAc, 
EtOH, rt, 2 h, 97%; (d) histamine dihydrochloride, DCC, HOBt, iPr2EtN, CH2Cl2, rt, 18 h, 
62%. 
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2.2.2.5 Synthesis of JBIR-44 Analogues 
To access the JBIR-44 analogues, the α-oximino acids 69 to 73 were coupled to 3,5-
dibromotyramine hydrobromide using ®T3P as the coupling agent (Scheme 26).††† 
This gave the coupled products 89 to 92 in moderate yields (30-46%). These were 
consistent with the yield (42%) of the corresponding reaction that was used to access 
the natural product (Scheme 17). We hypothesised that a trans-esterification reaction 
between the phenolic functionality in the amine coupling partner and the activated 
ester of the α-oximino acid was responsible for these diminished yields although no 
evidence for the presence of this ester by-product was observed. Finally, removal of 
the PMB group gave the JBIR-44 analogues 7 and 93 to 96. 
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Scheme 26 JBIR-44 analogue synthesis. 
Reagents and conditions: (a) ®T3P, 3,5-dibromotyramine hydrobromide, iPr2EtN, CH2Cl2, 0 
ºC to rt; (b) AlCl3, anisole, CH2Cl2, rt, 5 min. 
With an established route towards JBIR-44 analogues, we also sought to synthesise a 
small number of analogues that would enable us to probe the effect of masking the 
hydrogen bond donating abilities of both the oxime and the phenolic functionality in 
the tyramine side chain. These compounds would also complement those produced 
within the (5)-bromoverongamine series. 
                                                
††† When these coupling reactions were performed with DCC/HOBt, purification of the products from 
the crude reaction mixture was labourious. 
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Scheme 27 Synthesis of analogues 98, 99, and 100.  
Reagents and conditions: (a) ®T3P, 3,5-dibromotyramine hydrobromide, iPr2EtN, 
CH2Cl2/DMF (1:1), 0 ºC to rt, 18 h, 36%; (b) MeI, K2CO3, acetone, reflux, 5 h, 93%; (c) MeI, 
K2CO3, acetone, reflux, 3 h, 89%; (d) AlCl3, anisole, CH2Cl2, rt, 5 min, 94%. 
Using the conditions mentioned previously, O-methyl oximino acid 86 was coupled to 
3,5-dibromotyramine hydrobromide in 36% yield to give O-methyl oxime JBIR-44 
(97) (Scheme 27). The phenolic oxygen in 97 was subsequently methylated with 
methyl iodide to furnish analogue 98. In order to obtain the O-methylated phenol 
analogue 100, O-PMB JBIR-44 (36) was treated with methyl iodide to give 99. The 
PMB group could then be removed to access the desired analogue 100 in 84% over 
the two steps.  
2.2.2.6 Biological Activity 
Members of the two compound libraries pertaining to the (5)-bromoverongamine and 
JBIR-44 analogue series were screened against the ovarian cancer SK-OV-3 cell line. 
The primary aim of this initial screen was to identify whether any of the structural 
modifications incorporated into these analogues resulted in a significant decrease in 
cytotoxicity. Because the majority of these analogues differ from the parent 
compounds by a single modification, this would enable delineation of the key 
pharmacophoric elements of these molecules. On the other hand, the insight gained 
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from analogues with improved potency, along with those which retained the activity 
of the parent compound, would also prove valuable. Therefore, it was hoped that data 
from this initial assay could be used to design a second generation of superior 
analogues.  
2.2.2.6.1 (5)-Bromoverongamine Series 
The MTS results for the 12 analogues from the (5)-bromoverongamine series are 
shown in Table 6. To recap, in terms of cytotoxicity towards SK-OV-3 cells, the 
natural product 14 was less active (EC50 >50 µM) than the PMB protected derivative 
29 (EC50 ~40µM). This trend was mirrored for the dichloro and diiodo analogues with 
the PMB derivatives 74 and 75 being more active than the free oximes 79 and 80, 
respectively. The cytotoxic activity of the PMB derivatives was independent of the 
halogen substituent as 74 (EC50 ~35 µM) and 75 (EC50 ~40 µM) possessed a similar 
activity to the dibromo compound 29 (EC50 ~40 µM). In exploring the effect of the 
oxime protection further, the activity of the O-methyl oxime 87 (EC50 >50 µM) was 
greater than that of the natural product (14) but lower than that of the PMB derivative 
(29). This observation supports the conclusion from the first part of this chapter, 
which stated that an increase in lipophilicity was the cause of the increase in 
cytotoxicity. 
The trend in cytotoxicity of the corresponding free oximes appeared to follow the Van 
der Waal’s radii and the halogen bonding capabilities of the halogen substituents; 74 
was inactive with 75 (EC50 ~50 µM) more active than (5)-bromoverongamine (14). 
Interestingly, either replacing the halogens with methoxy substituents (77 and 82) or 
removing them altogether (76 and 81) resulted in a complete loss of activity. 
Furthermore, the drop in activity was also observed for compounds incorporating 
either an N-methyl group (84 and 85), or a phenolic functionality (78) indicated that 
these modifications were also unfavourable.  
To summarise, none of the modifications in this series yielded analogues with 
superior activity to compounds 14 and 29. However, we have found that the presence 
of halogen substitients at C-3 and C-5 is essential for conferring the observed 
cytotoxicity whereas all other modifications gave compounds with either reduced or 
no activity. In light of their moderate activity and the relationship between 
lipophilicity and cytotoxicity, it was decided that further investigations into the 
anticancer properties of this class of compounds were not warranted.  
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2.2.2.6.1 JBIR-44 Series 
The MTS results for the 14 analogues from the JBIR-44 series are shown in Table 7. 
To recap, the natural product 16 displayed moderate activity (EC50 22 µM) against 
SK-OV-3 cells. On the other hand, the PMB derivative 36 was inactive.  
Both the dichloro (93) and diiodo (94) analogues of JBIR-44 were significantly less 
active than the natural product with EC50 values of ~60 µM and ~55 µM, respectively. 
Furthermore, the trimethoxy analogue 96 only caused a significant loss in cell 
viability at high concentrations (>60 µM) and the dihydro analogue 95 was 
completely inactive. These results suggest that, whilst halogen substitution at C-2 and 
C-4 is superior to either methoxy or hydrogen, dibromo substitution is essential for 
optimal activity. 
As expected, the PMB derivatives 88, 89, and 99 were completely inactive up to 100 
µM. Compounds 90 and 91 also showed poor activity causing only a 30% loss of cell 
viability at concentrations greater than 60 µM. The only exception to this was the 
diphenol 92 which had an EC50 value of ~50 µM. Following on from this, compounds 
97 and 98, possessing the O-methyl oximes, were also inactive. 
Whereas methylation at the C-15 phenol of JBIR-44 caused no significant loss in 
activity (100 EC50 32 µM), loss of the C-18 methyl group (7) had a detrimental 
impact on the cytotoxicity (EC50 ~50 µM). 
To summarise, we have shown that the oxime functionality in JBIR-44 is essential for 
eliciting a cytotoxic response since masking it with either a PMB or methyl group 
results in a significant loss in activity. In addition, out of the substituents examined, 
the presence of bromine at C-2 and C-4 is optimal. Furthermore, since methylation of 
the C-15 phenol was well tolerated, it would appear that there is scope for installing 
additional functionality at this position to give subsequent analogues with more 
favourable physicochemical properties. 
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Table 6 MTS assay results for the (5)-bromoverongamine series of analogues screened 
against SK-OV-3 cells. Drug incubations were for 48 h. 
OMe
Br Br
N
HO
O
N
H
N
H
N
(5)-Bromoverongamine (14)  
EC50 >50 µM 
OMe
Br Br
N
PMBO
O
N
H
N
H
N
O-PMB-(5)-Bromoverongamine (29)  
EC50 40 µMa 
OMe
H H
N
PMBO
O
N
H
N
H
N
76  
N/A 
OMe
Cl Cl
N
PMBO
O
N
H
N
H
N
74  
EC50 ~35 µM 
OH
Br Br
N
PMBO
O
N
H
N
H
N
78  
EC50 >50 µM 
OMe
MeO OMe
N
PMBO
O
N
H
N
H
N
77  
N/Ab  
OMe
I I
N
PMBO
O
N
H
N
H
N
75  
EC50 ~40 µM 
OMe
Br Br
N
PMBO
O
N N
H
N
84
Me
 
EC50 >50 µM 
OMe
H H
N
HO
O
N
H
N
H
N
81  
N/A 
OMe
Cl Cl
N
HO
O
N
H
N
H
N
79  
N/A 
OMe
I I
N
HO
O
N
H
N
H
N
80  
EC50 ~50 µM 
OMe
MeO OMe
N
HO
O
N
H
N
H
N
82  
N/A 
OMe
Br Br
N
MeO
O
N
H
N
H
N
87  
EC50 >50 µM 
OMe
Br Br
N
HO
O
N N
H
N
85
Me
 
N/A 
a Calculated from three independent experiments. b ~20% Decrease in cell viability observed 
at 100 µM.  
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Table 7 MTS assay results for the JBIR-44 series of analogues screened against SK-OV-3 
cells. Drug incubations were for 48 h.  
JBIR-44 (16)
OMe
Br Br
N
HO
O
N
H
Br
Br
OH
 
EC50 22 µMa 
O-PMB-JBIR-44 (36)
OMe
Br Br
N
PMBO
O
N
H
Br
Br
OH
 
N/A 
OMe
H H
N
PMBO
O
N
H
Br
Br
OH
90  
EC50 >50 µM 
OMe
MeO OMe
N
PMBO
O
N
H
Br
Br
OH
91  
EC50 >50 µM 
OMe
Cl Cl
N
PMBO
O
N
H
Br
Br
OH
88  
N/A 
OH
Br Br
N
PMBO
O
N
H
Br
Br
OH
92  
EC50 ~50 µM 
OMe
I I
N
PMBO
O
N
H
Br
Br
OH
89  
N/A 
OMe
H H
N
HO
O
N
H
Br
Br
OH
95  
N/A 
OMe
MeO OMe
N
HO
O
N
H
Br
Br
OH
96  
EC50 >50 µM 
OMe
Cl Cl
N
HO
O
N
H
Br
Br
OH
93  
EC50 ~60 µM 
OH
Br Br
N
HO
O
N
H
Br
Br
OH
7  
EC50 ~50 µM 
OMe
I I
N
HO
O
N
H
Br
Br
OH
94  
EC50 ~55 µM 
OMe
Br Br
N
PMBO
O
N
H
Br
Br
OMe
99  
N/A 
OMe
Br Br
N
HO
O
N
H
Br
Br
OMe
100  
EC50 32 µMa 
OMe
Br Br
N
MeO
O
N
H
Br
Br
OH
97  
N/A 
OMe
Br Br
N
MeO
O
N
H
Br
Br
OMe
98  
                     N/A 
a Calculated from three independent experiments. 
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2.2.3 Conclusion and Future Work 
We have developed an efficient route towards analogues of oxime-histamine and 
oxime-tyramine bromotyrosine-derived natural products that incorporate 
modifications on the aryl ring, the oxime, and the side chain. This has enabled us to 
conduct SAR analysis on both (5)-bromoverongamine (14) and JBIR-44 (16) 
analogues.  
From these data, we can conclude that these two natural products display different 
anticancer profiles. In light of this, the preliminary SAR studies performed on the 
JBIR-44 analogues could be expanded upon in the future to probe this activity further. 
In addition, despite analogues of 14 not showing promise as an anticancer agent, 
based on its known activity, we hope to screen these compounds in antibacterial and 
antifungal assays in the future. Following on from this and, given the importance of 
the dibromomethoxyaryl moiety and the free oxime on the activity of these molecules, 
we also plan on synthesising a library of compounds derived from the coupling of 
non-naturally occurring amines to the α-oximino acid 17 with the hope that this 
would produce novel hits with more favourable physicochemical properties.  
To conclude, this research further ignited our interest into these natural products and 
led us to explore the chemistry and biology of another class of bromotyrosine 
products: the spirocyclohexadienylisoxazoline derivatives. 
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2.2.4 Chemistry: Experimental 
General Experimental Details 
Refer to Section 2.1.6 for general experimental details. 
3,5-Dichloro-4-hydroxybenzaldehyde (54) 
OH
Cl Cl
O
4
7
1
 
Procedure 1  
To a solution of 4-hydroxybenzaldehyde (53) (122 mg, 1.00 mmol) in CH2Cl2 (3 mL) 
in a 2-5 mL vial was added sulfuryl chloride (0.810 mL, 10.0 mmol). The vial was 
sealed and heated under microwave irradiation at 80 ºC for 10 h. The reaction vessel 
was vented, after which a white precipitate formed. The mixture was evaporated to 
dryness in vacuo to furnish 54 and 55 (in a 7:1 ratio by 1H NMR) as a white solid 
(187 mg). This was used without further purification.  
Procedure 2 
To a solution of 4-hydroxybenzaldehyde (53) (500 mg, 4.09 mmol) in CH2Cl2 (6 mL) 
in a 20 mL vial was added sulfuryl chloride (3.32 mL, 41.0 mmol). The vial was 
sealed and heated at 65 ºC for 2 h. The reaction vessel was vented and the mixture 
washed with H2O (20 mL), dried and evaporated to dryness in vacuo to furnish 54 as 
a white solid (523 mg) which was used without further purification.  
For characterisation purposes, a sample was purified by flash column chromatography 
(30% EtOAc/Hexane) to furnish 54 as a white solid. 
Rf 0.40 (30% Et2O/Petrol); νmax (thin film)/cm-1 3343br, 1690s, 1486s, 1200s, 1144s; 
δH (400 MHz, CDCl3) 9.81 (1H, s, H-7), 7.82 (2H, s, H-2/6), 6.41 (1H, br s, OH); δC 
(100 MHz, CDCl3); 188.4 (C-7), 152.8 (C-4), 130.2 (C-1), 129.8 (C-2/6), 122.2 (C-
3/5); m/z (ESI+) found 212.9484, [M+Na]+ C7H4Cl2O2Na requires 212.9481; elem. 
anal. C7H4Cl2O2 requires C 44.02%, H 2.11%, found C 43.69%, H 2.02%. 
Consistent with literature data.21 
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3,5-Dichloro-4-methoxybenzaldehyde (51) 
OMe
Cl Cl
O
15
4
7  
A: To a stirred solution of a 7:1 mixture of 54 and 55 (187 mg, procedure 1) in 
acetone (5 mL) was added anhydrous K2CO3 (193 mg, 1.40 mmol). After 30 min, 
iodomethane (117 µL, 1.88 mmol) was added and the reaction mixture was heated 
under reflux for 2.5 h. Upon cooling to room temperature, the solvent was removed in 
vacuo, the residue was partitioned between water (20 mL) and EtOAc (20 mL) and 
the organic layer separated. The aqueous phase was extracted with EtOAc (20 mL × 
3), the combined organic layers were dried and concentrated in vacuo. The residue 
was purified by flash column chromatography (5% Et2O/Petrol) to furnish 51 (141 
mg, 0.688 mmol, 69% over 2 steps from 53) as a white solid. 
B: To a stirred solution of 54 (523 mg, procedure 2) in acetone (15 mL) was added 
anhydrous K2CO3 (568 mg, 4.11 mmol). After 30 min, iodomethane (682 µL, 11.0 
mmol) was added and the reaction mixture was heated under reflux for 3 h. Upon 
cooling to room temperature, the solvent was removed in vacuo, the residue was 
partitioned between water (30 mL) and EtOAc (30 mL) and the organic layer 
separated. The aqueous phase was extracted with EtOAc (30 mL × 3), the combined 
organic layers were dried and concentrated in vacuo. The residue was purified by 
flash column chromatography (5% Et2O/Petrol) to furnish 51 (336 mg, 1.64 mmol, 
40% over 2 steps from 53) as a white solid. 
Rf 0.45 (10% Et2O/Petrol); νmax (thin film)/cm-1 2856w, 1691s, 1586s, 1556s, 1266s; 
δH (400 MHz, CDCl3) 9.86 (1H, s, H-7), 7.82 (2H, s, H-2/6), 3.97 (3H, s, H-15); δC 
(100 MHz, CDCl3); 188.6 (C-7), 157.3 (C-4), 133.1 (C-1), 130.6 (C-3/5), 130.0 (C-
2/6), 61.0 (C-15); m.p. 63-65 ºC (lit.,22 60 ºC). elem. anal. C8H6Cl2O2 requires C 
46.86%, H 2.95%, found C, 46.78%, H, 2.93%. 
Consistent with literature data.22 
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4-Hydroxy-3,5-diiodobenzaldehyde (57) 
OH
I I
O
4
7
1
 
Procedure 1 
To a stirred solution of 4-hydroxybenzaldehyde (53) (3.51 g, 28.7 mmol), sodium 
periodate (6.16 g, 28.8 mmol), and sodium chloride (3.36 g, 57.5 mmol) in 
AcOH/H2O (9:1, 100 mL) was added potassium iodide (9.55 g, 57.5 g) portionwise. 
After 96 h, EtOAc (500 mL) and 10% sodium thiosulfate solution (500 mL) were 
added. The organic layer was separated and the aqueous phase was extracted with 
EtOAc (500 mL). The combined organic layers were washed with 10% sodium 
thiosulfate solution (500 mL), brine (500 mL), dried and evaporated to dryness in 
vacuo to furnish 57 (10.5 g, 28.1 mmol, 98%) as a white solid. 
Procedure 2 
To a stirred solution of 4-hydroxybenzaldehyde (53) (78.0 mg, 0.639 mmol) in 
CH2Cl2 (5 mL) at 0 ºC was added bis(pyridine)iodonium tetrafluoroborate (500 mg, 
1.34 mmol). After 1 h, H2O (20 mL) was added and the aqueous phase was extracted 
with CH2Cl2 (20 mL × 3) and the combined organic layers were dried and 
concentrated in vacuo. The residue was purified by flash column chromatography 
(20-100% EtOAc/Petrol) to furnish 57 (228 mg, 0.610 mmol, 95%) as a white solid. 
Rf 0.34 (30% EtOAc/Petrol); νmax (thin film)/cm-1 3181br, 1665s, 1563m, 1456m, 
1095s; δH (400 MHz, CDCl3) 9.74 (1H, s, H-7), 8.20 (2H, s, H-2/6), 6.28 (1H, br s, 
OH); δC (100 MHz, d6-DMSO) 189.1 (C-7), 160.6 (C-4), 140.6 (C-1), 132.1 (C-2/6), 
86.4 (C-3/5); elem. anal. C7H4I2O2 requires C 22.49%, H 1.08 %, found C 22.20 %, H 
1.10 %. 
Consistent with literature data.23 
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3,5-Diiodo-4-methoxybenzaldehyde (52) 
OMe
I I
O
15
4
7
1
 
To a stirred solution of 57 (4.00 g, 10.7 mmol) in acetone (60 mL) at room 
temperature was added anhydrous K2CO3 (2.21 g, 16.0 mmol). After 30 min, 
iodomethane (1.33 mL, 21.4 mmol) was added and the reaction mixture was heated at 
reflux for 3.5 h, after which a further portion of iodomethane (1.33 mL, 21.4 mmol) 
was added. After 1.5 h, the mixture was cooled to room temperature, concentrated in 
vacuo, the residue was partitioned between water (250 mL) and EtOAc (150 mL) and 
the organic layer separated. The aqueous phase was extracted with EtOAc (150 mL × 
3) and the combined organic layers were dried and concentrated in vacuo. The residue 
was purified by flash column chromatography (5-10% EtOAc/Petrol) to furnish 52 
(3.75 g, 9.67 mmol, 90%) as a white solid. 
Rf 0.69 (10% EtOAc/Petrol); νmax (thin film)/cm-1 2938w, 2859w, 1689s, 1673s, 
1536s, 1184s; δH (400 MHz, CDCl3) 9.77 (1H, s, H-7), 8.22 (2H, s, H-2/6), 3.88 (3H, 
s, H-15); δC (100 MHz, CDCl3) 187.8 (C-7), 163.5 (C-4), 141.0 (C-1), 135.2 (C-2/6), 
91.2 (C-3/5), 60.8 (C-15); m/z (ESI+) found 410.8343, [M+Na]+ C8H6I2O2Na requires 
410.8349; m.p. 126-128 ºC (lit.,24 124 ºC); elem. anal. C8H6I2O2 requires C 24.77 %, 
H 1.56 %, found C 24.44%, H 1.53%. 
(±)-4-(3,5-Diiodo-4-methoxyphenyl)-4-hydroxybutan-2-one (58) 
OMe
I I
OH
O
15
4
7
1
9  
Rf 0.14 (20% EtOAc/Petrol); νmax (thin film)/cm-1 3600-3300br, 2936w, 1706s, 
1535w, 1461s, 1249s, 992s; δH (400 MHz, CDCl3) 7.70 (2H, s, H-2/6), 5.00-4.96 (1H, 
m, H-7), 3.78 (3H, s, H-15), 3.61 (1H, d, J 3.3 Hz, OH), 2.82-2.68 (2H, m, H-8) 2.15 
(3H, s, H-10); δC (100 MHz, CDCl3) 208.1 (C-9), 157.7 (C-4), 142.6 (C-1), 137.0 (C-
2/6), 90.4 (C-3/5), 67.5 (C-7), 60.5 (C-15), 51.6 (C-8), 30.6 (C-10). 
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General Procedure 1: Erlenmeyer Azlactone Synthesis 
A stirred mixture of aldehyde (1 eq.), N-acetylglycine (1.3 eq.), sodium acetate (1.3 
eq.) and acetic anhydride (5 eq.) were heated under reflux until the starting aldehyde 
was fully consumed (TLC). Upon cooling to room temperature, the mixture was 
partitioned between H2O and CH2Cl2, the organic layer was separated, washed with 
H2O and brine, dried and concentrated in vacuo. The residue was purified by flash 
column chromatography to furnish the desired azlactone product. 
(Z)-4-(4-Methoxybenzylidene)-2-methyloxazol-5(4H)-one (61) 
OMe
15
4
8
1
O
N
O
1' 2'
 
Following general procedure 1 using aldehyde 49: Purified by flash column 
chromatography (50% CH2Cl2/Petrol) to furnish 61 (478 mg, 2.20 mmol, 88%) as a 
yellow solid. 
Rf 0.32 (70% CH2Cl2/Petrol); νmax (thin film)/cm-1 1796m, 1769s, 1748m, 1658s, 
1590s, 1159s; δH (400 MHz, CDCl3) 8.03 (2H, d, J 8.9 Hz, H-2/6), 7.07 (1H, s, H-7), 
6.93 (2H, d, J 8.9 Hz, H-3/5), 3.84 (3H, s, H-15), 2.36 (3H, s, H-2'); δC (100 MHz, 
CDCl3) 168.0 (C-1'), 164.8 (C-9), 161.9 (C-4), 134.1 (C-2/6), 131.3 (C-7), 130.3 (C-
8), 126.0 (C-1), 114.3 (C-3/5), 55.3 (C-15), 15.5 (C-2'); m/z (ESI+) found 218.0822, 
[M+H]+ C12H11NO3 requires 218.0817; m.p. 110-112 ºC (lit.,25 109.5-110 ºC); elem. 
anal. C12H11NO3 requires C 66.35 %, H 5.10 %, N 6.45 %, found C 66.22 %, H 5.09 
%, N 6.46 %. 
Consistent with literature data.26 
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(Z)-2-Methyl-4-(3,4,5-trimethoxybenzylidene)oxazol-5(4H)-one (62) 
OMe
MeO OMe
15
4
8
1
O
N
O
1' 2'
16
 
Following general procedure 1 using aldehyde 50: Purified by flash column 
chromatography (70-100% CH2Cl2/Petrol) to furnish 62 (514 mg, 1.85 mmol, 70%) 
as a pale yellow solid. 
Rf 0.54 (30% EtOAc/Petrol); νmax (thin film)/cm-1 3005w, 1794m, 1763s, 1654m, 
1424s, 1251s; δH (400 MHz, CDCl3) 7.36 (2H, s, H-2/6), 6.99 (1H, s, H-7), 3.89 (3H, 
s, H-15), 3.88 (6H, s, H-16), 2.36 (3H, s, H-2'); δC (100 MHz, CDCl3) 167.7 (C-1'), 
165.5 (C-9), 153.0 (C-3/5), 140.8 (C-4), 131.5 (C-8), 131.2 (C-7), 128.4 (C-1), 109.4 
(C-2/6), 60.9 (C-15), 56.0 (C-16) 15.6 (C-2'); m/z (ESI+) found 278.1035, [M+H]+ 
C14H16NO5 requires 278.1028; m.p. 154-156 ºC (lit.,20 157-158.5 ºC); elem. anal. 
C14H15NO5 requires C 60.64%, H 5.45%, N 5.05%, found C 60.55%, H 5.47%, N 
5.11%. 
Consistent with literature data.20 
(Z)-4-(3,5-Dichloro-4-methoxybenzylidene)-2-methyloxazol-5(4H)-one (59) 
OMe
Cl Cl
15
4
8
1
O
N
O
1' 2'
 
Following general procedure 1 using aldehyde 51: Purified by flash column 
chromatography (50% CH2Cl2/Petrol) to furnish 59 (355 mg, 1.24 mmol, 71%) as a 
pale yellow solid. 
Rf 0.37 (10% EtOAc/Petrol); νmax (thin film)/cm-1 2940w, 1803m, 1791s, 1763s, 
1656s, 1601s, 1257s; δH (400 MHz, CDCl3) 8.04 (2H, s, H-2/6), 6.91 (1H, s, H-7), 
3.95 (3H, s, H-15), 2.42 (3H, s, H-2'); δC (100 MHz, CDCl3); 167.2 (C-1'), 167.0 (C-
9), 154.1 (C-4), 133.7 (C-8), 132.1 (C-2/6), 130.5 (C-1), 129.8 (C-3/5), 127.4 (C-7), 
60.9 (C-15), 15.7 (C-2'); m/z (ESI+) found 286.0044, [M+H]+ C12H10Cl2NO3 (35Cl) 
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requires 286.0038; m.p. 186-188 ºC; elem. anal. C12H9Cl2NO3 requires C 50.38%, H 
3.17%, N 4.90% found C 50.14%, H 3.08%, N 4.60%. 
Crystals of 59 were obtained by slow evaporation of CDCl3. The structure was 
confirmed by X-ray crystallographic analysis and given the unique identifier sl1029. 
(Z)-2,6-Dibromo-4-((2-methyl-5-oxooxazol-4(5H)-ylidene)methyl)phenyl acetate 
(63) 
O
Br Br
4
8
1
O
N
O
1' 2'
O
4'3'
 
Following general procedure 1 using aldehyde 23: Purified by flash column 
chromatography (50% CH2Cl2/Petrol) to furnish 63 (650 mg, 1.61 mmol, 85%) as a 
pale yellow solid. 
Rf 0.50 (100% CH2Cl2); νmax (thin film)/cm-1 3070w, 1804m, 1759s, 1662m, 1168s, 
892s; δH (400 MHz CDCl3) 8.27 (2H, s, H-2/6), 6.90 (1H, s, H-7), 2.42 (3H, s, H-2'), 
2.40 (3H, s, H-4'); (100 MHz, CDCl3) 167.7 (C-1'), 166.79 (C-3'), 166.77 (C-9), 147.6 
(C-4), 135.2 (C-2/6), 134.4 (C-1), 133.5 (C-8), 126.5 (C-7), 118.1 (C-3/5), 20.4 (C-
4'), 15.7 (C-2'); m.p. 188-190 ºC (lit.,27 187-189 ºC); elem. anal. C13H9Br2NO4 
requires C 38.74%, H 2.25%, N 3.48% found C 38.69%, H 2.19%, N 3.34%. 
Consistent with literature data.27 
Chapter 2 Part II: (5)-Bromoverongamine and JBIR-44: Structure-Activity Relationship Analysis 
 108 
(Z)-4-(3,5-Diiodo-4-methoxybenzylidene)-2-methyloxazol-5(4H)-one (60) 
OMe
I I
15
4
8
1
O
N
O
1' 2'
 
Following general procedure 1 using aldehyde 52: Purified by flash column 
chromatography (50% CH2Cl2/Petrol) to furnish 60 (1.10 g, 2.35 mmol, 92%) as a 
pale yellow solid. 
Rf 0.40 (10% EtOAc/Petrol); νmax (thin film)/cm-1 1808m, 1764s, 1663s, 1456m, 
1254s; δH (400 MHz, CDCl3) 8.48 (2H, s, H-2/6), 6.88 (1H, s, H-7), 3.90 (3H, s, H-
15), 2.43 (3H, s, H-2'); δC (100 MHz, CDCl3) 167.1 (C-1'), 167.0 (C-9), 160.7 (C-4), 
143.0 (C-2/6), 133.5 (C-8), 132.9 (C-1), 126.7 (C-7), 90.7 (C-3/5), 60.8 (C-15), 15.7 
(C-2'); m/z (ESI+) found 469.8755, [M+H]+ C12H10I2NO3 requires 469.8750; m.p. 
161-163 ºC (lit.,28 169.5-171 ºC); elem. anal. C12H9I2NO3 requires C 30.73%, H 
1.93%, N 2.99%, found C 30.71%, H 1.91%, N 2.83%. 
Consistent with literature data.28 
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General Procedure 2: Azlactone Hydrolysis 
A stirred suspension of azlactone in aqueous HCl (3 N, 10 mL per mmol of substrate) 
was heated under reflux and the reaction progress monitored by 1H NMR analysis. 
Upon completion, the mixture was cooled to room temperature and the precipitate 
was isolated by filtration, washed with H2O and dried in vacuo to furnish the desired 
phenylpyruvic acid. 
(Z)-2-Hydroxy-3-(4-methoxyphenyl)acrylic acid (66) 
15
1
9
OH
OHO
OMe
 
Following general procedure 2 using azlactone 61: furnished 66 (755 mg, 3.89 mmol, 
94%) as a brown solid which was used without further purification. 
νmax (thin film)/cm-1 3457m, 3000-2500br, 1658s, 1238s; δH (600 MHz, CD3OD) 7.71 
(2H, d, J 8.7 Hz, H-2/6), 6.88 (2H, d, J 8.7 Hz, H-3/5), 6.46 (1H, s, H-7), 3.79 (3H, s, 
H-15); δC (125 MHz, CD3OD) 168.6 (C-9), 160.5 (C-4), 140.5 (C-8), 132.2 (C-2/6), 
129.0 (C-1), 114.7 (C-3/5), 111.8 (C-7), 55.6 (C-15); elem. anal. C10H10O4 requires C 
61.85 %, H 5.19 %, found C 61.95 %, H 5.18 %. 
Consistent with literature data.26 
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(Z)-3-(3,5-Dichloro-4-methoxyphenyl)-2-hydroxyacrylic acid (64) 
OMe
Cl Cl
OH
HO O
15
4
9
7
1
 
Following general procedure 2 using azlactone 59: furnished 64 (308 mg, 1.17 mmol, 
97%) as a pale yellow solid which was used without further purification. 
νmax (thin film)/cm-1 3475w, 3091w, 2944w, 2580w, 1682s, 1646s, 1423s, 1145s; δH 
(400 MHz, CD3OD) 7.75 (2H, s, H-2/6), 6.33 (1H, s, H-7), 3.86 (3H, s, H-15); δC 
(100 MHz, CD3OD) 167.5 (C-9), 152.0 (C-4), 143.8 (C-8), 134.4 (C-1), 130.7 (C-
2/6), 130.0 (C-3/5), 108.1 (C-7), 61.2 (C-15); m.p. 191-193 ºC (lit.,29 190 ºC); elem. 
anal. C10H8Cl2O4 requires C 45.66%, H 3.07%, found C, 45.43%, H, 3.03%. 
Consistent with literature data.29 
(Z)-3-(3,5-Dibromo-4-hydroxyphenyl)-2-hydroxyacrylic acid (68) 
OH
Br Br
OH
HO O
4
9
7
1
 
Following general procedure 2 using azlactone 63: furnished 68 (396 mg, 1.17 mmol, 
94%) as a white solid which was used without further purification. 
νmax (thin film)/cm-1 3465m, 3100-2800br, 1678s, 1648s, 1584m, 1475s; δH (400 MHz 
CD3OD) 7.92 (2H, s, H-2/6), 6.32 (1H, s, H-7); (100 MHz, CD3OD) 167.8 (C-9), 
151.3 (C-4), 142.4 (C-8), 134.2 (C-2/6), 131.1 (C-1), 111.9 (C-3/5), 108.7 (C-7); 
elem. anal. C9H6Br2O4 requires C 31.99%, H 1.79%, found C 32.29%, H 1.84%. 
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(Z)-3-(3,5-Diiodo-4-methoxyphenyl)-2-hydroxyacrylic acid (65) 
OMe
I I
OH
HO O
15
4
9
7
1
 
Following general procedure 2 using azlactone 60: furnished 65 (2.24 g, 5.02 mmol, 
88%) as a beige solid which was used without further purification. 
νmax (thin film)/cm-1 3509w, 3200-2500br, 1683s, 1650s, 1242s; δH (600 MHz, 
CD3OD) 8.23 (2H, s, H-2/6), 6.30 (1H, s, H-7), 3.82 (3H, s, H-15); δC (125 MHz, 
CD3OD) 167.5 (C-9), 159.0 (C-4), 143.6 (C-8), 141.8 (C-2/6), 136.6 (C-1), 107.4 (C-
7), 90.7 (C-3/5), 61.2 (C-15); elem. anal. C10H8I2O4 requires C 26.93%, H 1.81%, 
found C 27.19%, H 1.76%. 
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General Procedure 3: α-Oximino acid synthesis 
To a stirred solution of the phenylpyruvic acid (1 eq.) and O-para-methoxybenzyl 
hydroxylamine hydrochloride (1 eq.) in EtOH (10 mL per mmol of substrate) was 
added sodium acetate (3 eq.). After 18 h, H2O was added, the mixture was acidified 
(pH 0) by the addition of aqueous HCl (3 N) and extracted with EtOAc (3 × 100 mL). 
The combined organic extracts were dried and evaporated to dryness in vacuo to 
furnish the desired α-oximino acid. 
(E)-2-(((4-Methoxybenzyl)oxy)imino)-3-(4-methoxyphenyl)propanoic acid (71) 
OMe
15
8
1
N
O
OH
O
MeO
9
1'
8'
5'
2'
 
Following general procedure 3 using phenylpyruvic acid 66: furnished 71 (593 mg, 
1.80 mmol, 98%) as a white solid which was used without further purification. 
Rf 0.46 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 2939w, 1706s, 1614m, 1514s, 
1240s; δH (500 MHz, CDCl3) 7.27 (2H, d, J 8.3 Hz, H-3'/7'), 7.17 (2H, d, J 8.6 Hz, H- 
H-2/6), 6.91 (2H, d, J 8.7 Hz, H-4'/6'), 6.78 (2H, d, J 8.7 Hz, H-3/5), 5.22 (2H, s, H-
1'), 3.834 (2H, s, H-7), 3.830 (3H, s, H-8'), 3.77 (3H, s, H-15); δC (125 MHz, CDCl3) 
162.5 br (C-9), 159.9 (C-5'), 158.4 (C-4), 150.1 (C-8), 130.3 (C-2/6), 130.2 (C-3'/7'), 
127.8 (C-2'), 127.0 (C-1), 114.0 (C-4'/6'), 113.9 (C-3/5), 78.1 (C-1'), 55.3 (C-8'), 55.2 
(C-15), 29.4 (C-7); m/z (ESI+) found 352.1174, [M+Na]+ C18H19NO5Na requires 
352.1161.  
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(E)-3-(3,5-Dichloro-4-methoxyphenyl)-2-(((4-methoxybenzyl)oxy)imino) 
propanoic acid (69) 
OMe
Cl Cl
15
8
1
N
O
OH
O
MeO
9
1'
8'
5'
2'
 
Following general procedure 3 using phenylpyruvic acid 64: furnished 69 (298 mg, 
0.748 mmol, 99%) as a white solid which was used without further purification. 
Rf 0.42 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 3670w, 2988m, 2902m, 1698m, 
1513m, 1478m, 1257s, 983s; δH (400 MHz, CDCl3) 7.28 (2H, d, J 8.7 Hz, H-3'/7'), 
7.16 (2H, s, H-2/6), 6.92 (2H, d, J 8.7 Hz, H-4'/6'), 5.25 (2H, s, H-1'), 3.86 (3H, s, H-
15), 3.83 (3H, s, H-8'), 3.79 (2H, s, H-7); δC (100 MHz, CDCl3) 163.2 (C-9), 160.1 
(C-5'), 151.2 (C-4), 148.6 (C-8), 132.4 (C-1), 130.4 (C-3'/7'), 129.6 (C-2/6), 129.1 (C-
3/5), 127.4 (C-2'), 114.2 (C-4'/6'), 78.5 (C-1'), 60.6 (C-15), 55.3 (C-8'), 29.3 (C-7); 
m/z (ESI+) found 420.0398, [M+Na]+ C18H17Cl2NO5Na (35Cl) requires 420.0381. 
(E)-3-(3,5-Dibromo-4-hydroxyphenyl)-2-(((4-methoxybenzyl)oxy)imino) 
propanoic acid (72) 
OH
Br
8
1
N
O
OH
O
MeO
9
1'
5'
2'
Br
 
Following general procedure 3 using phenylpyruvic acid 68: furnished 72 (459 mg, 
0.97 mmol, 100%) as a white solid which was used without further purification. 
Rf 0.27 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 3492s, 3300-2900br, 1694s, 
1474s, 1239s, 1009s; δH (400 MHz, CDCl3) 7.34 (2H, s, H-2/6), 7.28 (2H, d, J 8.7 
Hz, H-3'/7'), 6.93 (2H, d, J 8.7 Hz, H-4'/6'), 5.78 (1H, s, OH), 5.24 (2H, s, H-1'), 3.83, 
(3H, s, H-8'), 3.77 (2H, s, H-7); δC (125 MHz, CDCl3); 161.8 (C-9), 160.1 (C-5'), 
148.9 (C-8), 148.3 (C-4), 132.8 (C-2/6), 130.4 (C-3'/7'), 129.4 (C-1), 127.3 (C-2'), 
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114.2 (C-4'/6'), 109.6 (C-3/5), 78.5 (C-1'), 55.3 (C-8'), 28.7 (C-7) m/z (ESI+) found 
471.9419, [M+H]+ C17H16Br2NO5 (79Br) requires 471.9395; m.p. 130-132 ºC. 
(E)-3-(3,5-Diiodo-4-methoxyphenyl)-2-(((4-methoxybenzyl)oxy)imino)propanoic 
acid (70) 
OMe
I I
15
8
1
N
O
OH
O
MeO
9
1'
8'
5'
2'
 
Following general procedure 3 using phenylpyruvic acid 65: furnished 70 (549 mg, 
0.945 mmol, 99%) as a white solid which was used without further purification. 
Rf 0.32 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 3600-3200br, 2946w, 2837w, 
1695s, 1513s, 1416s, 1246s; δH (400 MHz, CDCl3) 7.64 (2H, s, H-2/6), 7.29 (2H, d, J 
8.7 Hz, H-3'/7'), 6.94 (2H, d, J 8.7 Hz, H-4'/6'), 5.24 (2H, s, H-1'), 3.83, (3H, s, H-8'), 
3.82 (3H, s, H-15), 3.76 (2H, s, H-7); δC (100 MHz, CDCl3) 161.8 (C-9), 160.1 (C-5'), 
157.9 (C-4), 148.7 (C-8), 140.5 (C-2/6), 134.6 (C-1), 130.4 (C-3'/7'), 127.3 (C-2'), 
114.3 (C-4'/6'), 90.3 (C-3/5), 78.6 (C-1'), 60.7 (C-15), 55.3 (C-8'), 28.4 (C-7); m/z 
(ESI+) found 603.9091, [M+H]+ C18H17I2NO5Na requires 603.9094; m.p. 122-124 ºC. 
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(E)-2-(((4-Methoxybenzyl)oxy)imino)-3-(3,4,5-trimethoxyphenyl)propanoic acid 
(73) 
OMe
15
8
1
N
O
OH
O
MeO
9
1'
8'
5'
2'
OMeMeO
16
 
A mixture of azlactone 62 (278 mg, 1.00 mmol) and Ba(OH)2·8H2O (2.21 g, 7.00 
mmol) in dioxane/ H2O (1:1, 15 mL) was stirred at 60 ºC. After 1 h, O-para-
methoxybenzyl hydroxylamine hydrochloride (190 mg, 1.00 mmol) was added, and 
the mixture was stirred vigorously at the same temperature. After 18 h, the reaction 
mixture was cooled to 0 ºC and acidified (pH 0) with aqueous HCl (3 N). The mixture 
was extracted with EtOAc (3 × 50 mL) and the combined organic extracts were dried 
and concentrated in vacuo. The residue was purified by flash column chromatography 
(1-10% MeOH/CH2Cl2) to furnish 73 (125 mg, 0.32 mmol, 32%) as a white solid. 
Rf 0.31 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 3700-3200br, 2949s, 1714w, 
1611m, 1589s, 1121s; δH (400 MHz, CDCl3) 7.28 (2H, d, J 8.6 Hz, H-3'/7'), 6.84 (2H, 
d, J 8.7 Hz, H-4'/6'), 6.46 (2H, s, H-2/6), 5.24 (2H, s, H-1'), 3.83 (2H, s, H-7), 3.82 
(3H, s, H-8'), 3.80 (3H, s, H-15), 3.71 (6H, s, H-16); δC (125 MHz, CDCl3) 163.0 (C-
9), 160.0 (C-5'), 153.1 (C-3/5), 149.6 (C-8), 136.8 (C-4), 130.5 (C-1), 130.0 (C-3'/7'), 
127.6 (C-2'), 114.0 (C-4'/6'), 106.3 (C-2/6), 78.3 (C-1'), 60.8 (C-15), 55.9 (C-16), 55.3 
(C-8'), 30.5 (C-7); m/z (ESI+) found 412.1386, [M+Na]+ C20H23NO7Na requires 
412.1372. 
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(E)-3-(3,5-Dibromo-4-methoxyphenyl)-2-(methoxyimino)propanoic acid (86) 
OMe
Br
8
1
N
MeO
OH
O
9
1'
Br
15
 
To a stirred solution of 38 (109 mg, 0.310 mmol) and O-methyl hydroxylamine 
hydrochloride (25.9 mg, 0.310 mmol) in EtOH (3.10 mL) was added sodium acetate 
(76.3 mg, 0.930 mmol). After 2 h, the mixture was acidified (pH 0) with aqueous HCl 
(3 N). The mixture was extracted with EtOAc (3 × 30 mL) and the combined organic 
extracts were dried and evaporated to dryness in vacuo to furnish 86 (115 mg, 0.302 
mmol, 97%) as a white solid which was used without further purification. 
Rf 0.26 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 2942w, 1706s, 1472s, 1259s, 
1043s; δH (400 MHz, CDCl3) 7.38 (2H, s, H-2/6), 4.12 (3H, s, H-1'), 3.83 (3H, s, H-
15), 3.79 (2H, s, H-7); δC (100 MHz, CDCl3); 165.0 (C-9), 152.9 (C-4), 148.4 (C-8), 
133.7 (C-1), 133.1 (C-2/6), 117.9 (C-3/5), 64.0 (C-1'), 60.5 (C-15), 29.1 (C-7) m/z 
(ESI+) found 379.9146, [M+H]+ C11H12Br2NO4 (79Br) requires 379.9133. 
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(E)-N-(2-(1H-Imidazol-4-yl)ethyl)-2-(((4-methoxybenzyl)oxy)imino)-3-(4-
methoxyphenyl)propanamide (76) 
OMe
15
8
1
N
O
N
H
O
MeO
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2'
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H
N
12
14
 
To a stirred solution of acid 71 (126 mg, 0.383 mmol) in CH2Cl2 (6 mL) was added 
N,N’-dicyclohexylcarbodiimide (95.0 mg, 0.460 mmol) and N-hydroxybenzotriazole 
(62.0 mg, 0.459 mmol). After stirring for 5 min, histamine dihydrochloride (98.0 mg, 
0.532 mmol) and iPr2EtN (184 µL, 1.07 mmol) were added. After 24 h, the mixture 
was concentrated in vacuo and the residue partitioned between H2O (40 mL) and 
EtOAc (40 mL). The organic layer was separated and the aqueous layer was extracted 
with EtOAc (3 × 40 mL). The combined organic extracts were washed with brine 
(100 mL), dried and concentrated in vacuo. The residue was purified by flash column 
chromatography (1-2% MeOH/CH2Cl2) to furnish 76 (140 mg, 0.331 mmol, 86%) as 
a white foam. 
Rf 0.43 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 3324w, 2928m, 2850m, 1676m, 
1625m, 1575m, 1509s, 1243s, 1034s; δH (500 MHz, CDCl3) 7.53 (1H, s, H-14), 7.24 
(2H, d, J 8.6 Hz, H-3'/7'), 7.18 (2H, d, J 8.6 Hz, H-2/6), 6.88 (2H, d, J 8.7 Hz, H-
4'/6'), 6.76 (2H, d, J 8.6 Hz, H-3/5), 6.74 (1H, s, H-13), 5.11 (2H, s, H-1'), 3.85 (2H, 
s, H-7), 3.82 (3H, s, H-8'), 3.76 (3H, s, H-15), 3.57 (2H, apparent q, J 6.4 Hz, H-10), 
2.83 (2H, t, J 6.6 Hz, H-11); δC (125 MHz, CDCl3) 162.8 (C-9), 159.5 (C-5'), 158.1 
(C-4), 152.6 (C-8), 134.6 (C-14), 130.4 (C-2/6), 129.9 (C-3'/7'), 129.0 (C-2'), 128.3 
(C-1), 113.8 (C-4'/6'), 113.7 (C-3/5), 76.9 (C-1'), 55.3 (C-8'), 55.2 (C-15), 39.0 (C-
10), 29.1 (C-7), 27.1 (C-11); m/z (ESI+) found 423.2038, [M+H]+ C23H27N4O4 
requires 423.2032. 
Peaks corresponding to C-12 and C-13 were not visible. 
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(E)-N-(2-(1H-Imidazol-4-yl)ethyl)-2-(((4-methoxybenzyl)oxy)imino)-3-(3,4,5-
trimethoxyphenyl)propanamide (77) 
OMe
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To a stirred solution of 73 (300 mg, 0.770 mmol) in THF (10 mL) was added CDI 
(150 mg, 0.925 mmol). After 1 h the solution was cooled to 0 ºC and histamine (85.6 
mg, 0.770 mmol) and CH2Cl2 (10 mL) were added, after which the reaction was 
warmed to room temperature and stirred for 18 h. The mixture was concentrated in 
vacuo and the residue partitioned between H2O (20 mL) and CH2Cl2 (20 mL). The 
organic layer was separated and the aqueous layer was extracted with CH2Cl2 (3 × 20 
mL). The combined organic extracts were washed with brine (20 mL), dried and 
concentrated in vacuo. The residue was purified by flash column chromatography (5-
10 % MeOH/CH2Cl2) to furnish 77 (228 mg, 0.473 mmol, 61%) as a white foam. 
Rf 0.57 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 3343w, 3114w, 2939w, 2836w, 
1663s, 1513s, 1240s, 1119s; δH (400 MHz, CDCl3) 9.52 (1H, br s, NH), 7.56 (1H, s, 
H-14) 7.24 (2H, d, J 8.6 Hz, H-3'/7'), 6.89 (2H, d, J 8.7 Hz, H-4'/6'), 6.75 (1H, s, H-
13), 6.47 (2H, s, H-2/6), 5.11 (2H, s, H-1'), 3.83 (2H, s, H-7), 3.78 (3H, s, H-8'), 3.77 
(3H, s, H-15), 3.67 (6H, s, H-16), 3.58 (2H, apparent q, J 6.4 Hz, H-10), 2.82 (2H, t, J 
6.6 Hz, H-11); δC (125 MHz, CDCl3) 162.8 (C-9), 159.7 (C-5'), 152.9 (C-3/5), 152.0 
(C-8), 136.3 (C-4), 135.7 br (C-12), 134.7 (C-14), 131.8 (C-1), 130.1 (C-3'/7'), 128.7 
(C-2'), 116.0 br (C-13), 113.8 (C-4'/6') , 106.4 (C-2/6), 77.1 (C-1'), 60.8 (C-15), 55.9 
(C-16), 55.3 (C-8'), 39.1 (C-10), 30.2 (C-7), 27.0 (C-11); m/z (ESI+) found 483.2238, 
[M+H]+ C25H31N4O6 requires 483.2244. 
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(E)-N-(2-(1H-Imidazol-4-yl)ethyl)-3-(3,5-dichloro-4-methoxyphenyl)-2-(((4-
methoxybenzyl)oxy)imino)propanamide (74) 
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To a stirred solution of acid 69 (71.8 mg, 0.180 mmol) in CH2Cl2 (3 mL) was added 
N,N’-dicyclohexylcarbodiimide (44.7 mg, 0.217 mmol) and N-hydroxybenzotriazole 
(29.2 mg, 0.216 mmol). After stirring for 5 min, histamine dihydrochloride (36.5 mg, 
0.198 mmol) and iPr2EtN (77 µL, 0.436 mmol) were added. After 18 h, the mixture 
was concentrated in vacuo and the residue partitioned between H2O (30 mL) and 
EtOAc (30 mL). The organic layer was separated and the aqueous layer was extracted 
with EtOAc (3 × 30 mL). The combined organic extracts were washed with brine 
(100 mL), dried and concentrated in vacuo. The residue was purified by flash column 
chromatography (1-5% MeOH/CH2Cl2) to furnish 74 (64.1 mg, 0.130 mmol, 72%) as 
a white foam. 
Rf 0.52 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 3300-2800br, 2935w, 1662s, 
1612m, 1514s, 1478s, 1248s, 995s δH (400 MHz CDCl3) 8.54 (1H, br s, NH), 7.59 
(1H, s, H-14), 7.24 (2H, d, J 8.6 Hz, H-3'/7'), 7.16 (2H, s, H-2/6), 6.88 (2H, d, J 8.7 
Hz, H-4'/6'), 6.79 (1H, s, H-13), 5.11 (2H, s, H-1'), 3.83 (3H, s, H-15), 3.80 (3H, s, H-
8'), 3.78 (2H, s, H-7), 3.59 (2H, apparent q, J 6.4 Hz, H-10), 2.84 (2H, t, J 6.6 Hz, H-
11); δC (100 MHz, CDCl3) 162.3 (C-9), 159.7 (C-5'), 150.9 (C-8), 150.7 (C-4), 135.8 
br (C-12), 134.7 (C-14), 133.7 (C-1), 130.1 (C-3'/7'), 129.7 (C-2/6), 128.8 (C-3/5), 
128.4 (C-2'), 115.8 br (C-13), 114.0 (C-4'/6'), 77.3 (C-1'), 60.6 (C-15), 55.3 (C-8'), 
39.1 (C-10), 28.8 (C-7), 27.0 (C-11); m/z (ESI+) found 491.1270, [M+H]+ 
C23H25Cl2N4O4 (35Cl) requires 491.1253. 
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(E)-N-(2-(1H-Imidazol-4-yl)ethyl)-3-(3,5-dibromo-4-hydroxyphenyl)-2-(((4-
methoxybenzyl)oxy)imino)propanamide (78) 
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To a stirred solution of acid 72 (100 mg, 0.211 mmol) in CH2Cl2 (5 mL) were added 
N,N′-dicyclohexylcarbodiimide (52.3 mg, 0.253 mmol) and N-hydroxybenzotriazole 
(34.3 mg, 0.254 mmol). After stirring for 5 min, histamine dihydrochloride (46.8 mg, 
0.254 mmol) and iPr2EtN (99 µL, 0.575 mmol) were added. After 18 h, the solvent 
was removed in vacuo and the residue partitioned between H2O (30 mL) and EtOAc 
(30 mL). The organic layer was separated and the aqueous layer was extracted with 
EtOAc (3 × 30 mL). The combined organic extracts were washed with brine (100 
mL), dried and concentrated in vacuo. The residue was purified by flash column 
chromatography (1-10% MeOH/CH2Cl2) to furnish 78 (91.5 mg, 0.162 mmol, 77%) 
as a white foam. 
Rf 0.47 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 3137w, 2933w, 1660s, 1612m, 
1514s, 1247s, 1007s; δH (400 MHz, CD3OD) 7.62 (1H, s, H-14), 7.27 (2H, s, H-2/6), 
7.23 (2H, d, J 8.7 Hz, H-3'/7'), 6.88 (2H, d, J 8.7 Hz, H-4'/6'), 6.83 (1H, s, H-13), 5.12 
(2H, s, H-1'), 3.77 (3H, s, H-8'), 3.70 (2H, s, H-7), 3.49 (2H, t, J 7.1 Hz, H-10), 2.80 
(2H, t, J 7.1 Hz, H-11); δC (100 MHz, CD3OD) 164.6 (C-9), 161.2 (C-5'), 152.9 (C-
8), 151.1 (C-4), 136.0 (C-14), 135.7 br (C-12), 133.9 (C-2/6), 131.3 (C-1), 131.2 (C-
3'/7'), 130.0 (C-2'), 117.8 br (C-13), 115.0 (C-4'/6'), 112.1 (C-3/5), 78.3 (C-1'), 55.7 
(C-8'), 40.3 (C-10), 29.3 (C-7), 27.6 (C-11); m/z (ESI+) found 565.0097, [M+H]+ 
C22H23Br2N4O4 (79Br) requires 565.0086. 
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(E)-N-(2-(1H-Imidazol-4-yl)ethyl)-3-(3,5-diiodo-4-methoxyphenyl)-2-(((4-
methoxybenzyl)oxy)imino)propanamide (75) 
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To a stirred solution of 70 (226 mg, 0.389 mmol), histamine dihydrochloride (107 mg, 
0.583 mmol) and iPr2EtN (204 µL, 1.17 mmol) in CH2Cl2 (5 mL) at 0 ºC was added 
®T3P (347 µL of a 50% w/w solution in EtOAc, 0.584 mmol) dropwise. After 1 h the 
reaction mixture was warmed to room temperature and stirred for 18 h upon which 
H2O (20 mL) and CH2Cl2 (20 mL) were added and the organic phase removed. The 
aqueous layer was extracted with CH2Cl2 (20 mL × 2) and the combined organic 
layers were dried and concentrated in vacuo. The residue was purified by flash 
column chromatography (1-10% MeOH/CH2Cl2) to furnish 75 (137 mg, 0.203 mmol, 
52%). 
Rf 0.52 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 2934w, 2836w, 1660s, 1513s, 
1460s, 1246s; δH (500 MHz, CDCl3) 7.64 (2H, s, H-2/6), 7.59 (1H, s, H-14), 7.25 
(2H, d, J 8.4 Hz, H-3'/7'), 6.91 (2H, d, J 8.5 Hz, H-4'/6'), 6.79 (1H, s, H-13), 5.11 (2H, 
s, H-1'), 3.81 (3H, s, H-8'), 3.79 (3H, s, H-15), 3.75 (2H, s, H-7), 3.59 (2H, apparent 
q, J 6.4 Hz, H-10), 2.84 (2H, t, J 6.6 Hz, H-11); δC (125 MHz, CDCl3); 162.3 (C-9), 
159.6 (C-5'), 157.2 (C-4), 150.9 (C-8), 140.5 (C-2/6), 136.1 (C-1), 135.8 (br, C-12), 
134.7 (C-14), 130.2 (C-3'/7'), 128.4 (C-2'), 115.9 (br, C-13), 114.1 (C-4'/6'), 90.1 (C-
3/5), 76.7 (C-1'), 60.6 (C-15), 55.3 (C-8'), 39.1 (C-10), 28.1 (C-7), 27.1 (C-11); m/z 
(ESI+) found 674.9982, [M+H]+ C23H25I2N4O4 requires 674.9965. 
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(E)-N-(2-(1H-Imidazol-4-yl)ethyl)-3-(3,5-dibromo-4-methoxyphenyl)-2-
(methoxyimino)propanamide (87) 
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To a stirred solution of acid 86 (39.7 mg, 0.104 mmol) in CH2Cl2 (4 mL) were added 
N,N′-dicyclohexylcarbodiimide (25.8 mg, 0.125 mmol) and N-hydroxybenzotriazole 
(16.9 mg, 0.125 mmol). After stirring for 5 min, histamine dihydrochloride (23.0 mg, 
0.125 mmol) and iPr2EtN (49 µL, 0.285 mmol) were added. After 18 h, the solvent 
was removed in vacuo and the residue partitioned between H2O (20 mL) and EtOAc 
(20 mL). The organic layer was separated and the aqueous layer was extracted with 
EtOAc (3 × 20 mL). The combined organic extracts were washed with brine (50 mL), 
dried and concentrated in vacuo. The residue was purified by flash column 
chromatography (1-10% MeOH/CH2Cl2) to furnish 87 (30.6 mg, 64.5 µmol, 62%) as 
a white foam. 
Rf 0.45 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 2939w, 1660m, 1542w, 1472s; δH 
(400 MHz, CD3OD) 7.59 (1H, s, H-14), 7.43 (2H, s, H-2/6), 6.84 (1H, s, H-13), 4.02 
(3H, s, H-1'), 3.81 (3H, s, H-15), 3.80 (2H, s, H-7), 3.49 (2H, t, J 7.2 Hz, H-10), 2.80 
(2H, t, J 7.2 Hz, H-11); δC (100 MHz, CD3OD) 164.5 (C-9), 154.0 (C-4), 152.4 (C-8), 
136.8 (C-1), 136.1 (C-14), 135.9 (C-13), 134.4 (C-2/6), 118.7 (C-3/5), 117.8 br (C-
12), 63.6 (C-1'), 61.0 (C-15), 40.5 (C-10), 29.4 (C-7), 27.7 (C-11); m/z (ESI+) found 
472.9845, [M+H]+ C16H19Br2N4O3 (79Br) requires 472.9824. 
Chapter 2 Part II: (5)-Bromoverongamine and JBIR-44: Structure-Activity Relationship Analysis 
 123 
General Procedure 4: PMB removal 
To a stirred solution of PMB protected substrate (1 eq.) and anisole (10 eq.) in CH2Cl2 
(5 mL per 0.2 mmol substrate) was added aluminium trichloride (10 eq.). After 5 min, 
the mixture was basified by the addition of a saturated aqueous solution of NaHCO3 
followed by the addition of a saturated aqueous solution of Rochelle’s salt. After 
stirring for 10 min, the aqueous phase was extracted with CH2Cl2 and the combined 
organic layers were dried and concentrated in vacuo. The residue was purified by 
flash column chromatography.  
(E)-N-(2-(1H-Imidazol-4-yl)ethyl)-2-(hydroxyimino)-3-(4-methoxyphenyl) 
propanamide (81) 
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Following general procedure 4 using substrate 76: residue purified by flash column 
chromatography (10-20% MeOH/CH2Cl2) furnished 81 (3.00 mg, 9.92 µmol, 21%) as 
a white solid. 
Rf 0.12 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 3400-3100br, 2925w, 1652s, 
1509s, 1462s, 1245s; δH (400 MHz, CD3OD) 7.55 (1H, s, H-14), 7.16 (2H, d, J 8.8 
Hz, H-2/6), 6.79 (1H, s, H-13), 6.78 (2H, d, J 8.6 Hz, H-3/5), 3.82 (2H, s, H-7), 3.74 
(3H, s, H-15), 3.47 (2H, t, J 7.2 Hz, H-10), 2.77 (2H, t, J 7.2 Hz, H-11); δC (125 
MHz, CD3OD) 165.9 (C-9), 159.6 (C-4), 153.6 (C-8), 136.0 (C-14), 131.1 (C-2/6), 
130.1 (C-1), 114.7 (C-3/5), 55.6 (C-15), 40.2 (C-10), 29.0 (C-7), 27.0 (C-11); m/z 
(ESI+) found 303.1463, [M+H]+ C15H19N4O3 requires 303.1457. 
Peaks corresponding to C-12 and C-13 were not visible. 
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(E)-N-(2-(1H-Imidazol-4-yl)ethyl)-2-(hydroxyimino)-3-(3,4,5-
trimethoxyphenyl)propanamide (82) 
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Following general procedure 4 using substrate 77: residue purified by flash column 
chromatography (10-20% MeOH/CH2Cl2) furnished 82 (19.5 mg, 53.8 µmol, 58%) as 
a white foam. 
Rf 0.14 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 3300-3100br, 2925w, 2853w, 
1737w, 1655m, 1590s, 1421s, 1120s; δH (500 MHz, CD3OD) 7.57 (1H, s, H-14), 6.81 
(1H, s, H-13), 6.59 (2H, s, H-2/6), 3.85 (2H, s, H-7), 3.80 (6H, s, H-16), 3.72 (3H, H-
15), 3.48 (2H, t, J 7.2 Hz, H-10), 2.78 (2H, t, J 7.2 Hz, H-11); δC (125 MHz, CD3OD) 
165.9 (C-9), 154.3 (C-3/5), 153.2 (C-8), 137.5 (C-4), 136.1 (C-14), 136.1 br (C-12), 
134.2 (C-1), 117.8 (br, C-13), 107.5 (C-2/6), 61.1 (C-15), 56.5 (C-16), 40.3 (C-10), 
30.1 (C-11), 27.7 (C-7); m/z (ESI+) found 363.1678, [M+H]+ C17H23N4O5 requires 
363.1668. 
(E)-N-(2-(1H-Imidazol-4-yl)ethyl)-3-(3,5-dichloro-4-methoxyphenyl)-2-
(hydroxyimino)propanamide (79) 
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Following general procedure 4 using substrate 74: residue purified by flash column 
chromatography (5-10% MeOH/CH2Cl2) furnished 79 (9.50 mg, 25.6 µmol, 63%) as 
a white solid. 
Rf 0.20 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 3400-3200br, 2926w, 1659m, 
1529m, 1478s, 1265s, 994s; δH (400 MHz, CD3OD) 7.57 (1H, s, H-14), 7.27 (2H, s, 
H-2/6), 6.83 (1H, s, H-13), 3.82 (5H, s, H-15 and H-7), 3.49 (2H, t, J 7.2 Hz, H-10), 
2.79 (2H, t, J 7.2 Hz, H-11); δC (100 MHz, CD3OD) 165.3 (C-9), 152.1 (C-8), 151.9 
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(C-4), 136.3 (C-1), 136.1 (C-14), 136.0 br (C-12), 130.7 (C-2/6), 129 9 (C-3/5), 117.9 
br (C-13), 61.1 (C-15), 40.3 (C-10), 28.9 (C-7), 27.7 (C-11); m/z (ESI+) found 
371.0676, [M+H]+ C15H17Cl2N4O3 (35Cl) requires 371.0678. 
(E)-N-(2-(1H-Imidazol-4-yl)ethyl)-3-(3,5-diiodo-4-methoxyphenyl)-2-
(hydroxyimino)propanamide (80) 
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Following general procedure 4 using substrate 75: residue purified by flash column 
chromatography (2-10% MeOH/CH2Cl2) furnished 80 (12.7 mg, 22.9 µmol, 12%) as 
a white solid. 
Rf 0.38 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 3342w, 2930w, 1670s, 1642m, 
1460s; δH (500 MHz, CD3OD) 7.71 (2H, s, H-2/6), 7.57 (1H, s, H-14), 6.83 (1H, s, H-
13), 3.79 (2H, s, H-7), 3.78 (3H, s, H-15), 3.49 (2H, t, J 7.2 Hz, H-10), 2.79 (2H, t, J 
7.2 Hz, H-11); δC (125 MHz, CD3OD); 165.3 (C-9), 158.8 (C-4), 152.2 (C-8), 141.6 
(C-2/6), 138.2 (C-1), 136.1 (C-14) 136.1 (hidden, C-12) 117.8 (br, C-13), 90.7 (C-
3/5), 61.1 (C-15), 40.3 (C-10), 28.2 (C-7), 27.7 (C-11); m/z (ESI+) found 554.9412, 
[M+H]+ C15H17I2N4O3 requires 554.9390. 
In the HMBC spectrum, there is a coupling between H-10 (δH 3.49) and the signal δC 
136.1. As C-14 is 5 bonds away from H-10, this interaction is attributed to the 3 bond 
coupling with C-12. 
OMe
I I
N
HO
N
H
O
N
H
N
H H
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C-12 !C 136.1  
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(E)-N-(3,5-Dibromo-4-hydroxyphenethyl)-2-(((4-methoxybenzyl)oxy)imino)-3-(4-
methoxyphenyl)propanamide (90) 
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To a stirred solution of acid 71 (83.5 mg, 0.254 mmol), amine 20 (105 mg, 0.279 
mmol) and iPr2EtN (165 µL, 0.961 mmol) in CH2Cl2/DMF (1:1, 6 mL) at 0 ºC was 
added ®T3P (197 µL of a 50% w/w solution in EtOAc, 0.330 mmol) dropwise. After 
1 h the reaction mixture was warmed to room temperature and stirred for 18 h upon 
which H2O (20 mL) and CH2Cl2 (20 mL) were added and the organic phase removed. 
The aqueous layer was extracted with CH2Cl2 (20 mL × 2) and the combined organic 
layers were dried and concentrated in vacuo. The residue was purified by flash 
column chromatography (20-50% Et2O/Petrol) to furnish 90 (47.0 mg, 77.5 µmol, 
31%) as a colourless oil. 
Rf 0.39 (50% Et2O/Petrol); νmax (thin film)/cm-1 3400-3100w, 2933w, 1664m, 1611m, 
1509s, 1244s; δH (400 MHz, CDCl3) 7.27 (2H, s, H-13/17), 7.22 (2H, d, J 8.7 Hz, H-
3'/7'), 7.17 (2H, d, J 8.8 Hz, H-2/6), 6.88 (2H, d, J 8.7 Hz, H-4'/6'), 6.77 (2H, d, J 8.8 
Hz, H-3/5), 5.49 (1H, br s, OH), 5.11 (2H, s, H-1'), 3.85 (2H, s, H-7), 3.83 (3H, s, H-
8'), 3.77 (3H, s, H-18), 3.47 (2H, apparent q, J 6.7 Hz, H-10), 2.71 (2H, t, J 7.0 Hz, 
H-11); δC (100 MHz, CDCl3) 162.7 (C-9), 159.6 (C-5'), 158.1 (C-4), 152.5 (C-8), 
148.1 (C-15), 133.5 (C-12), 132.2 (C-13/17), 130.3 (C-2/6), 129.8 (C-3'/7'), 128.8 (C-
2'), 128.2 (C-1), 113.9 (C-4'/6'), 113.8 (C-3/5), 109.9 (C-14/16), 77.0 (C-1'), 55.3 (C-
8'), 55.2 (C-18), 40.4 (C-10), 34.3 (C-11), 29.0 (C-7); m/z (ESI+) found 605.0283, 
[M+H]+ C26H27Br2N2O5 (79Br) requires 605.0287. 
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(E)-N-(3,5-Dibromo-4-hydroxyphenethyl)-2-(((4-methoxybenzyl)oxy)imino)-3-
(3,4,5-trimethoxyphenyl)propanamide (91) 
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To a stirred solution of acid 73 (139 mg, 0.357 mmol), amine 20 (160 mg, 0.426 
mmol) and iPr2EtN (232 µL, 1.35 mmol) in CH2Cl2/DMF (1:1, 8 mL) at 0 ºC was 
added ®T3P (275 µL of a 50% w/w solution in EtOAc, 0.463 mmol) dropwise. After 
1 h the reaction mixture was warmed to room temperature and stirred for 18 h upon 
which H2O (30 mL) and CH2Cl2 (30 mL) were added and the organic phase removed. 
The aqueous layer was extracted with CH2Cl2 (30 mL × 2) and the combined organic 
layers were dried and concentrated in vacuo. The residue was purified by flash 
column chromatography (40-80% Et2O/Petrol) to furnish 91 (103 mg, 0.155 mmol, 
43%) as a white foam. 
Rf 0.28 (70% Et2O/Petrol); νmax (thin film)/cm-1 3348br, 2936w, 1663s, 1611w, 
1590s, 1513s, 1242s, 1124s; δH (400 MHz, CDCl3) 7.28 (2H, s, H-13/17), 7.23 (2H, 
d, J 8.7 Hz, H-3'/7') 6.87 (2H, d, J 8.7 Hz, H-4'/6'), 6.76 (1H, t, J 6.1 Hz, NH), 6.49 
(2H, s, H-2/6), 5.95 (1H, s, OH), 5.13 (2H, s, H-1'), 3.84 (2H, s, H-7), 3.81 (3H, s, H-
8'), 3.79 (3H, s, H-18), 3.70 (6H, s, H-19), 3.49 (2H, apparent q, J 7.0 Hz, H-10), 2.73 
(2H, t, J 7.0 Hz, H-11); δC (100 MHz, CDCl3) 162.6 (C-9), 159.7 (C-5'), 152.9 (C-
3/5), 151.9 (C-8), 148.1 (C-15), 136.5 (C-4), 133.4 (C-12), 132.2 (C-13/17), 131.6 (C-
1), 130.0 (C-3'/7'), 128.6 (C-2'), 113.9 (C-4'/6'), 109.9 (C-14/16), 106.5 (C-2/6), 77.2 
(C-1'), 60.7 (C-18), 55.9 (C-19), 55.3 (C-8'), 40.5 (C-10), 34.3 (C-11), 30.1 (C-7); m/z 
(ESI+) found 665.0491, [M+H]+ C28H31Br2N2O7 (79Br) requires 665.0498. 
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(E)-N-(3,5-Dibromo-4-hydroxyphenethyl)-3-(3,5-dichloro-4-methoxyphenyl)-2-
(((4-methoxybenzyl)oxy)imino)propanamide (88) 
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To a stirred solution of acid 69 (100 mg, 0.251 mmol), amine 20 (94.3 mg, 0.251 
mmol) and iPr2EtN (172 µL, 1 mmol) in CH2Cl2/DMF (1:1, 5 mL) at 0 ºC was added 
®T3P (194 µL of a 50% w/w solution in EtOAc, 0.326 mmol) dropwise. After 1 h the 
reaction mixture was warmed to room temperature and stirred for 20 h upon which 
H2O (30 mL) and EtOAc (30 mL) were added and the organic phase removed. The 
aqueous layer was extracted with EtOAc (30 mL × 2) and the combined organic 
layers were washed with brine, dried and concentrated in vacuo. The residue was 
purified by flash column chromatography (20-60% Et2O/Petrol) to furnish 88 (50.5 
mg, 74.8 µmol, 30%) as a white foam. 
Rf 0.48 (50% Et2O/Petrol); νmax (thin film)/cm-1 3399br, 2934m, 1665s, 1611m, 
1513s, 1476s, 1246s, 996s; δH (400 MHz CDCl3) 7.29 (2H, s, H-13/17), 7.22 (2H, d, J 
8.7 Hz, H-3'/7'), 7.19 (2H, s, H-2/6), 6.89 (2H, d, J 8.7 Hz, H-4'/6'), 6.73 (1H, t, J 6.0, 
NH), 5.86 (1H, br s, OH), 5.12 (2H, s, H-1'), 3.85 (3H, s, H-18), 3.82 (3H, s, H-8'), 
3.80 (2H, s, H-7) 3.50 (2H, apparent q, J 6.7 Hz, H-10), 2.74 (2H, t, J 7.0 Hz, H-11); 
δC (100 MHz, CDCl3) 162.2 (C-9), 159.8 (C-5'), 150.9 (C-8), 150.8 (C-4), 148.1 (C-
15), 133.5 (C-1), 133.3 (C-12), 132.2 (C-13/17), 130.1 (C-3'/7'), 129.7 (C-2/6), 128.9 
(C-3/5), 128.3 (C-2'), 114.0 (C-4'/6'), 109.9 (C-14/16), 77.5 (C-1'), 60.6 (C-18), 55.3 
(C-8'), 40.5 (C-10), 34.3 (C-11), 28.8 (C-7); m/z (ESI+) found 672.9539, [M+H]+ 
C26H25Br2Cl2N2O5 (79Br, 35Cl) requires 672.9507. 
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(E)-N-(3,5-Dibromo-4-hydroxyphenethyl)-3-(3,5-dibromo-4-hydroxyphenyl)-2-
(((4-methoxybenzyl)oxy)imino)propanamide (92) 
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To a stirred solution of acid 72 (123 mg, 0.260 mmol), amine 20 (117 mg, 0.311 
mmol) and iPr2EtN (176 µL, 1.02 mmol) in CH2Cl2/DMF (1:1, 8 mL) at 0 ºC was 
added ®T3P (201 µL of a 50% w/w solution in EtOAc, 0.338 mmol) dropwise. After 
1 h the reaction mixture was warmed to room temperature and stirred for 16 h upon 
which H2O (30 mL) and EtOAc (30 mL) were added and the organic phase removed. 
The aqueous layer was extracted with EtOAc (30 mL × 2) and the combined organic 
layers were washed with brine, dried and concentrated in vacuo. The residue was 
purified by flash column chromatography (20-50% Et2O/Petrol) to furnish 92 (69.4 
mg, 92.5 µmol, 36%) as a white foam. 
Rf 0.33 (50% Et2O/Petrol); νmax (thin film)/cm-1 3489w, 3401w, 2936w, 1663s, 
1611m, 1514s, 1474s, 1242s; δH (400 MHz, CDCl3) 7.36 (2H, s, H-13/17), 7.28 (2H, 
s, H-2/6), 7.23 (2H, d, J 8.7 Hz, H-3'/7'), 6.90 (2H, d, J 8.7 Hz, H-4'/6'), 6.74 (1H, t, J 
6.0 Hz, NH), 5.89 (1H, s, OH), 5.83 (1H, s, OH), 5.12 (2H, s, H-1'), 3.82 (3H, s, H-
8'), 3.77 (2H, s, H-7), 3.50 (2H, q, J 6.7 Hz, H-10), 2.74 (2H, t, J 7.0 Hz, H-11); δC 
(100 MHz, CDCl3) 162.2 (C-9), 159.7 (C-5'), 151.2 (C-8), 148.1 (C-4), 147.9 (C-15), 
133.3 (C-12), 132.8 (C-13/17), 132.2 (C-2/6), 130.7 (C-1), 130.1 (C-3'/7'), 128.3 (C-
2'), 114.1 (C-4'/6'), 109.9 (C-3/5), 109.5 (C-14/16), 77.4 (C-1'), 55.3 (C-8'), 40.5 (C-
10), 34.2 (C-11), 28.4 (C-7); m/z (ESI+) found 746.8324, [M+H]+ C25H23Br4N2O5 
(79Br) requires 746.8340. 
Chapter 2 Part II: (5)-Bromoverongamine and JBIR-44: Structure-Activity Relationship Analysis 
 130 
(E)-N-(3,5-Dibromo-4-methoxyphenethyl)-3-(3,5-dibromo-4-methoxyphenyl)-2-
(((4-methoxybenzyl)oxy)imino)propanamide (99) 
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To a stirred solution of 36 (91.0 mg, 0.119 mmol) in acetone (4 mL) at room 
temperature was added anhydrous K2CO3 (24.5 mg, 0.177 mmol). The resulting 
mixture was stirred for 20 min, then treated with iodomethane (14.8 µL, 0.238 mmol) 
and stirred at reflux for a further 3 h. After this time, acetone and excess iodomethane 
were removed in vacuo and the resulting residue was partitioned between EtOAc (20 
mL) and H2O (20 mL). The organic layer was separated and the aqueous layer was 
extracted with EtOAc (3 x 20 mL). The combined organic extracts were washed with 
brine, dried and concentrated in vacuo. The residue was purified by flash column 
chromatography (30-50% Et2O/Petrol) to furnish 99 (82.5 mg, 0.106 mmol, 89%) as a 
colourless oil. 
Rf 0.50 (50% Et2O/Petrol); νmax (thin film)/cm-1 2929w, 1670m, 1513s, 1470s, 1250s; 
δH (400 MHz CDCl3) 7.41 (2H, s, H-1/5), 7.35 (2H, s, H-13/17), 7.23 (2H, d, J 8.7 
Hz, H-3'/7'), 6.90 (2H, d, J 8.7 Hz, H-4'/6'), 6.74 (1H, t, J 6.0, NH), 5.13 (2H, s, H-1'), 
3.88 (3H, s, H-19), 3.84 (3H, s, H-18), 3.82 (3H, s, H-8'), 3.80 (2H, s, H-7), 3.51 (2H, 
apparent q, J 6.9 Hz, H-10), 2.76 (2H, t, J 7.1 Hz, H-11); δC (100 MHz, CDCl3) 162.2 
(C-9), 159.8 (C-5'), 152.9 (C-15), 152.7 (C-3), 150.9 (C-8), 137.5 (C-12), 134.7 (C-
6), 133.5 (C-1/5), 132.9 (C-13/17), 130.1 (C-3'/7'), 128.3 (C-2'), 118.2 (C-14/16), 
117.7 (C-2/4), 114.1 (C-4'/6'), 77.5 (C-1'), 60.6 (C-19), 60.5 (C-18), 55.3 (C-8'), 40.4 
(C-10), 34.5 (C-11), 28.6 (C-7); m/z (ESI+) found 774.8666, [M+H]+ C27H27Br4N2O5 
(79Br) requires 774.8653. 
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(E)-N-(3,5-Dibromo-4-hydroxyphenethyl)-3-(3,5-diiodo-4-methoxyphenyl)-2-(((4-
methoxybenzyl)oxy)imino)propanamide (89) 
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To a stirred solution of acid 70 (50.7 mg, 87.3 µmol), amine 20 (32.8 mg, 87.3 µmol) 
and iPr2EtN (60.6 µL, 0.349 mmol) in CH2Cl2/DMF (1:1, 3 mL) at 0 ºC was added 
®T3P (67.5 µL of a 50% w/w solution in EtOAc, 0.113 mmol) dropwise. After 1 h the 
reaction mixture was warmed to room temperature and stirred for 20 h upon which 
H2O (30 mL) and EtOAc (30 mL) were added and the organic phase removed. The 
aqueous layer was extracted with EtOAc (30 mL × 2) and the combined organic 
layers were washed with brine, dried and concentrated in vacuo. The residue was 
purified by flash column chromatography (20-60% Et2O/Petrol) to furnish 89 (34.4 
mg, 40.1 µmol, 46%) as a colourless oil. 
Rf 0.45 (50% Et2O/PE 40-60); νmax (thin film)/cm-1 3396br, 2928m, 1663s, 1611m, 
1513s, 1460s, 1245s; δH (400 MHz CDCl3) 7.66 (2H, s, H-2/6), 7.29 (2H, H-13/17), 
7.24 (2H, d, J 8.7 Hz, H-3'/7'), 6.92 (2H, d, J 8.7 Hz, H-4'/6'), 6.72 (1H, t, J 6.0, NH), 
5.87 (1H, br s, OH), 5.12 (2H, s, H-1'), 3.83 (3H, s, H-8'), 3.81 (3H, s, H-18), 3.77 
(2H, s, H-7), 3.50 (2H, apparent q, J 6.7 Hz, H-10), 2.74 (2H, t, J 7.0 Hz, H-11); δC 
(100 MHz, CDCl3) 162.2 (C-9), 159.7 (C-5'), 157.4 (C-4), 150.9 (C-8), 148.1 (C-15), 
140.5 (C-2/6), 135.9 (C-1), 133.4 (C-12), 132.2 (C-13/17), 130.1 (C-3'/7'), 128.3 (C-
2'), 114.1 (C-4'/6'), 109.9 (C-14/16), 90.1 (C-3/5), 77.4 (C-1'), 60.6 (C-18), 55.3 (C-
8'), 40.5 (C-10), 34.3 (C-11), 28.1 (C-7); m/z (ESI+) found 856.8209, [M+H]+ 
C26H25Br2I2N2O5 (79Br) requires 856.8220. 
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(E)-N-(3,5-Dibromo-4-hydroxyphenethyl)-2-(hydroxyimino)-3-(4-
methoxyphenyl)propanamide (95) 
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Following general procedure 4 using substrate 90: residue purified by flash column 
chromatography (20-50% Et2O/Petrol) furnished 95 (23.0 mg, 47.3 µmol, 93%) as a 
white solid. 
Rf 0.20 (50% Et2O/Petrol); νmax (thin film)/cm-1 3400-3200br, 2973w, 2932w, 1655s, 
1627m, 1509s, 1242s, 1036s; δH (400 MHz, CD3OD) 7.31 (2H, s, H-13/17), 7.13 (2H, 
d, J 8.8 Hz, H-2/6), 6.77 (2H, d, J 8.8 Hz, H-3/5), 3.82 (2H, s, H-7), 3.74 (3H, s, H-
18), 3.40 (2H, t, J 7.2 Hz, H-10), 2.67 (2H, t, J 7.2 Hz, H-11); δC (100 MHz, CD3OD) 
166.0 (C-9), 159.6 (C-4), 153.6 (C-8), 150.7 (C-15), 134.6 (C-12), 133.6 (C-13/17), 
131.0 (C-2/6), 130.0 (C-1), 114.8 (C-3/5), 112.1 (C-14/16), 55.6 (C-18), 41.5 (C-10), 
34.9 (C-11), 29.0 (C-7); m/z (ESI+) found 484.9720, [M+H]+ C18H19Br2N2O4 (79Br) 
requires 484.9712. 
(E)-N-(3,5-Dibromo-4-hydroxyphenethyl)-2-(hydroxyimino)-3-(3,4,5-
trimethoxyphenyl)propanamide (96) 
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Following general procedure 4 using substrate 91: residue purified by flash column 
chromatography (40-100% Et2O/Petrol) furnished 96 (19.2 mg, 35.2 µmol, 30%) as a 
white solid. 
Rf 0.24 (70% Et2O/Petrol); νmax (thin film)/cm-1 3400-3100br, 2934w, 2838w, 1658s, 
1626m, 1591s, 1421s, 1122s; δH (400 MHz, CDCl3) 7.53 (1H, br s, NOH), 7.27 (2H, 
s, H-13/17), 6.71 (1H, t, J 6.1 Hz, NH), 6.59 (2H, s, H-2/6), 5.79 (1H, br s, OH), 3.91 
(2H, s, H-7), 3.83 (6H, s, H-19), 3.81 (3H, s, H-18), 3.51 (2H, apparent q, J 6.7 Hz, 
H-10), 2.73 (2H, t, J 7.1 Hz, H-11); δC (100 MHz, CDCl3) 162.7 (C-9), 153.7 (C-8), 
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153.1 (C-3/5), 148.1 (C-15), 136.7 (C-4), 133.3 (C-12), 132.2 (C-13/17), 131.5 (C-1), 
109.9 (C-14/16), 106.5 (C-2/6), 60.8 (C-18), 56.1 (C-19), 40.5 (C-10), 34.3 (C-11), 
29.4 (C-7); m/z (ESI+) found 544.9938, [M+H]+ C20H23Br2N2O6 (79Br) requires 
544.9923.  
(E)-N-(3,5-Dibromo-4-hydroxyphenethyl)-3-(3,5-dichloro-4-methoxyphenyl)-2-
(hydroxyimino)propanamide (93) 
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Following general procedure 4 using substrate 88: residue purified by flash column 
chromatography (20-50% Et2O/Petrol) furnished 93 (18.8 mg, 33.9 µmol, 85%) as a 
colourless oil. 
Rf 0.28 (50% Et2O/Petrol); νmax (thin film)/cm-1 3399w, 3218br, 2934w, 1659m, 
1625m, 1530m, 1476s, 1265s, 994s; δH (400 MHz CD3OD) 7.32 (2H, s, H-2/6), 7.27 
(2H, s, H-13/17), 3.83 (5H, s, H-7 and H-18), 3.41 (2H, t, J 7.2 Hz, H-10), 2.70 (2H, 
t, J 7.2 Hz, H-11); δC (100 MHz, CD3OD) 165.4 (C-9), 152.1 (C-8), 151.9 (C-4), 
150.7 (C-15), 136.2 (C-1), 134.6 (C-12), 133.6 (C-13/17), 130.7 (C-2/6), 129.9 (C-
3/5), 112.1 (C-14/16), 61.1 (C-18), 41.7 (C-10), 34.9 (C-11), 28.9 (C-7); m/z (ESI+) 
found 552.8926, [M+H]+ C18H17Br2Cl2N2O4 (79Br, 35Cl) requires 552.8932. 
(E)-N-(3,5-Dibromo-4-hydroxyphenethyl)-3-(3,5-dibromo-4-hydroxyphenyl)-2-
(hydroxyimino)propanamide (7) 
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Following general procedure 4 using substrate 92: residue purified by flash column 
chromatography (20-50% Et2O/Petrol) furnished 7 (17.0 mg, 27.0 µmol, 84%) as a 
white solid.  
Rf 0.21 (50% Et2O/Petrol); νmax (thin film)/cm-1 3500-3000br, 2929w, 1659m, 1536m, 
1474s, 1408m, 1241s; δH (400 MHz, CD3OD) 7.39 (2H, s, H-2/6), 7.31 (2H, s, H-
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13/17), 3.78 (2H, s, H-7), 3.40 (2H, q, J 7.3 Hz, H-10), 2.69 (2H, t, J 7.3 Hz, H-11); 
δC (100 MHz, CD3OD) 165.5 (C-9), 152.6 (C-8), 150.8 (C-15), 150.7 (C-4), 134.6 (C-
12), 133.9 (C-2/6), 133.6 (C-13/17), 132.2 (C-1), 112.1 (C-3/5), 112.0 (C-14/16), 41.8 
(C-10), 34.9 (C-11), 28.4 (C-7); m/z (ESI+) found 626.7786, [M+H]+ C17H15Br4N2O4  
(79Br) requires 626.7765. 
Consistent with literature data.30 
(E)-N-(3,5-Dibromo-4-methoxyphenethyl)-3-(3,5-dibromo-4-methoxyphenyl)-2-
(hydroxyimino)propanamide (100) 
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Following general procedure 4 using substrate 99: residue purified by flash column 
chromatography (20-30% Et2O/Petrol) furnished 100 (55.5 mg, 84.3 µmol, 94%) as a 
white solid. 
Rf 0.40 (50% Et2O/Petrol); νmax (thin film)/cm-1 3206br, 2928w, 1657m, 1532m, 
1471s, 1420s, 1258s; δH (400 MHz CDCl3) 8.38 (1H, s, OH) 7.49 (2H, s, H-1/5), 7.32 
(2H, s, H-13/17), 6.77 (1H, t, J 6.1, NH), 3.89 (2H, s, H-7), 3.87 (3H, s, H-19), 3.85 
(3H, s, H-18), 3.50 (2H, apparent q, J 6.8 Hz, H-10), 2.75 (2H, t, J 7.1 Hz, H-11); δC 
(100 MHz, CDCl3) 162.8 (C-9), 152.8 (C-15), 152.7 (C-3), 152.1 (C-8), 137.3 (C-12), 
134.7 (C-6), 133.5 (C-1/5), 132.8 (C-13/17), 118.1 (C-14/16), 117.8 (C-2/4), 60.62 
(C-19), 60.55 (C-18), 40.4 (C-10), 34.4 (C-11), 27.9 (C-7); m/z (ESI+) found 
654.8087, [M+H]+ C19H19Br4N2O4 (79Br) requires 654.8078. 
Crystals of 100 were obtained by slow evaporation of a solution of Et2O/Hexane. The 
structure was confirmed by X-ray crystallographic analysis and given the unique 
identifier sl1005.  
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(E)-N-(3,5-Dibromo-4-hydroxyphenethyl)-3-(3,5-diiodo-4-methoxyphenyl)-2-
(hydroxyimino)propanamide (94) 
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Following general procedure 4 using substrate 89: residue purified by flash column 
chromatography (20-50% Et2O/Petrol) furnished 94 (14.8 mg, 20.1 µmol 73%) as a 
white solid. 
Rf 0.29 (50% Et2O/Petrol); νmax (thin film)/cm-1 3400-3200br, 2933w, 1655s, 1623m, 
1532s, 1460s, 1241s, 990s; δH (400 MHz CD3OD) 7.73 (2H, s, H-2/6), 7.32 (2H, H-
13/17), 3.79 (2H, s, H-7), 3.78 (3H, s, H-18), 3.41 (2H, t, J 7.3 Hz, H-10), 2.70 (2H, t, 
J 7.3 Hz, H-11); δC (100 MHz, CD3OD) 165.4 (C-9), 158.8 (C-4), 152.2 (C-8), 150.8 
(C-15), 141.6 (C-2/6), 138.2 (C-1), 134.6 (C-12), 133.6 (C-13/17), 112.2 (C-14/16), 
90.7 (C-3/5), 61.1 (C-18), 41.8 (C-10), 34.9 (C-11), 28.2 (C-7); m/z (ESI+) found 
736.7612, [M+H]+ C18H17Br2I2N2O4 (79Br) requires 736.7644. 
Chapter 2 Part II: (5)-Bromoverongamine and JBIR-44: Structure-Activity Relationship Analysis 
 136 
(E)-N-(3,5-Dibromo-4-hydroxyphenethyl)-3-(3,5-dibromo-4-methoxyphenyl)-2-
(methoxyimino)propanamide (97) 
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To a stirred solution of acid 86 (55.7 mg, 0.146 mmol), amine 20 (65.8 mg, 0.175 
mmol) and iPr2EtN (99.0 µL, 0.575 mmol) in CH2Cl2/DMF (1:1, 3 mL) at 0 ºC was 
added ®T3P (113 µL of a 50% w/w solution in EtOAc, 0.19 mmol) dropwise. After 
18 h, H2O (10 mL) and CH2Cl2 (10 mL) were added and the organic phase removed. 
The aqueous layer was extracted with CH2Cl2 (10 mL × 2) and the combined organic 
layers were dried and concentrated in vacuo. The residue was purified by flash 
column chromatography (10-30% Et2O/Petrol) to furnish 97 (34.2 mg, 52.0 µmol, 
36%). 
Rf 0.13 (20% Et2O/Petrol); νmax (thin film)/cm-1 3676m, 2988s, 2901s, 1666m, 
1525m, 1407m; δH (400 MHz, CDCl3) 7.43 (2H, s, H-2/6), 7.29 (2H, s, H-13/17), 
6.77 (1H, t, J 5.9 Hz, NH), 5.80 (1H, s, OH), 4.02 (3H, s, H-19), 3.85 (3H, s, H-18), 
3.82 (2H, s, H-7), 3.51 (2H, apparent q, J 6.0 Hz, H-10), 2.75 (2H, t, J 7.1 Hz, H-11); 
δC (100 MHz, CDCl3) 162.2 (C-9), 152.7 (C-4), 150.7 (C-8), 148.2 (C-15), 134.8 (C-
1), 133.41 (C-12), 133.37 (C-2/6), 132.3 (C-13/17), 117.9 (C-3/5), 109.9 (C-14/16), 
63.4 (C-19), 60.6 (C-18), 40.6 (C-10), 34.4 (C-11), 28.5 (C-7); m/z (ESI+) found 
654.8085, [M+H]+ C19H19Br4N2O4 (79Br) requires 654.8078. 
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(E)-N-(3,5-Dibromo-4-methoxyphenethyl)-3-(3,5-dibromo-4-methoxyphenyl)-2-
(methoxyimino)propanamide (98) 
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To a stirred solution of 97 (18.0 mg, 27.4 µmol) in acetone (2 mL) at room 
temperature was added anhydrous K2CO3 (5.7 mg, 41.2 µmol). The resulting mixture 
was stirred for 20 min, then treated with iodomethane (17.1 µL, 0.274 mmol) and 
stirred at reflux 5 h. After this time, acetone and excess iodomethane were removed in 
vacuo and the resulting residue was partitioned between EtOAc (20 mL) and H2O (20 
mL). The organic layer was separated and the aqueous layer was extracted with 
EtOAc (3 x 20 mL). The combined organic extracts were washed with brine, dried 
and concentrated in vacuo. The residue was purified by flash column chromatography 
(30-50% Et2O/Petrol) to furnish 98 (17.2 mg, 25.6 µmol, 93%) as a colourless oil. 
Rf 0.58 (50% Et2O/Petrol); νmax (thin film)/cm-1 3404w, 2931w, 1668m, 1520m, 
1471s, 1420s, 1258s; δH (400 MHz CDCl3) 7.43 (2H, s, H-1/5), 7.34 (2H, s, H-13/17), 
6.77 (1H, br s, NH), 4.01 (3H, s, C-20), 3.87 (3H, s, H-19), 3.85 (3H, s, H-18), 3.81 
(2H, s, H-7) 3.51 (2H, apparent q, J 6.8 Hz, H-10), 2.76 (2H, t, J 7.1 Hz, H-11); δC 
(125 MHz, CDCl3) 162.2 (C-9), 152.8 (C-15), 152.7 (C-3), 150.6 (C-8), 137.4 (C-12), 
134.7 (C-6), 133.3 (C-1/5), 132.9 (C-13/17), 118.1 (C-14/16), 117.8 (C-2/4), 63.3 (C-
20), 60.61 (C-19), 60.55 (C-18), 40.4 (C-10), 34.4 (C-11), 28.4 (C-7); m/z (ESI+) 
found 668.8251, [M+H]+ C20H21Br4N2O4 (79Br) requires 668.8235.  
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(E)-N-(2-(1H-Imidazol-5-yl)ethyl)-3-(3,5-dibromo-4-methoxyphenyl)-2-(((4-
methoxybenzyl)oxy)imino)-N-methylpropanamide (84) 
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To a solution of acid 17 (283 mg, 0.581 mmol) in THF (3 mL) at room temperature 
was added CDI (104 mg, 0.641 mmol). After 1 h the solution was cooled to 0 ºC and 
a solution of methylhistamine31 (73.0 mg, 0.583 mmol) in THF (2 mL) was added 
dropwise. The reaction was warmed to rt and stirred for 18 h after which the solvent 
was removed in vacuo and the residue partitioned between H2O (20 mL) and EtOAc 
(20 mL). The organic layer was separated and the aqueous layer was extracted with 
EtOAc (3 × 20 mL). The combined organic extracts were washed with brine (20 mL), 
dried and concentrated in vacuo. The residue was purified by flash column 
chromatography (3-10% MeOH/CH2Cl2) to furnish 84 (122 mg, 0.205 mmol, 35%) as 
a yellow oil.  
Rf 0.78 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 3207br, 2968w, 2931w, 1627s, 
1613s, 1513s, 1471s, 1248s; The product exists as a rotameric mixture (ratio of 
1.15:1) at room temperature in CDCl3. Major Rotamer: δH (400 MHz CDCl3) 9.96 
(1H, br s, NH), 7.51 (1H, s, H-14), 7.32 (2H, s, H-2/6), 7.22 (2H, d, J 8.6 Hz, H-3'/7'), 
6.86 (2H, d, J 8.6 Hz, H-4'/6'), 6.74 (1H, s, H-13), 5.07 (2H, s, H-1'), 3.81 (3H, s, H-
15), 3.78 (3H, s, H-8'), 3.76 (2H, s, H-7), 3.62 (2H, t, J 7.3 Hz, H-10), 2.80 (2H, t, J 
7.3 Hz, H-11), 2.76 (3H, s, H-16). Minor Rotamer: δH (400 MHz CDCl3) 9.96 (1H, br 
s, NH), 7.51 (1H, s, H-14), 7.38 (2H, s, H-2/6), 7.18 (2H, d, J 8.6 Hz, H-3'/7'), 6.82 
(2H, d, J 8.6 Hz, H-4'/6'), 6.60 (1H, s, H-13), 5.07 (2H, s, H-1'), 3.79 (3H, s, H-8'), 
3.75 (3H, s, H-15), 3.68 (2H, s, H-7), 3.56 (2H, t, J 7.3 Hz, H-10), 2.88 (3H, s, H-16) 
2.68 (2H, t, J 7.3 Hz, H-11); m/z (ESI+) found 593.0396, [M+H]+ C24H26Br2N4O4 
(79Br) requires 593.0399. 
Using VT 1H NMR, the peaks coalesced at 120 ºC although the peak corresponding to 
H-14 was lost. Multiple peaks were lost in the VT 13C NMR at 120 ºC. At 25 ºC the 
13C NMR was too complex to accurately interpret (see Section 2.2.6.1).  
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(E)-N-(2-(1H-Imidazol-5-yl)ethyl)-3-(3,5-dibromo-4-methoxyphenyl)-2-
(hydroxyimino)-N-methylpropanamide (85) 
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Following general procedure 4 using substrate 84: Residue purified by flash column 
chromatography (10-20% MeOH/CH2Cl2) to furnish 85 (12.6 mg, 26.6 µmol, 79%) as 
a pale yellow oil. 
Rf 0.16 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 3400-3100br, 2971w, 1611s, 
1543m, 1471s, 1259s, 987s; The product exists as a rotameric mixture (ratio of 
1.15:1) at room temperature in CD3OD. Major Rotamer δH (400 MHz CD3OD) 7.59 
(1H, s, H-14), 7.50 (2H, s, H-2/6), 6.81 (1H, s, H-13), 3.79 (3H, s, H-15), 3.73 (2H, s, 
H-7), 3.59 (2H, t, J 7.5 Hz, H-10), 2.93 (3H, s, H-16), 2.77-2.72 (2H, m, H-11). 
Minor Rotamer δH (400 MHz CD3OD) 7.58 (1H, s, H-14), 7.49 (2H, s, H-2/6), 6.80 
(1H, s, H-13), 3.82 (3H, s, H-15), 3.83 (2H, s, H-7), 3.59 (2H, t, J 7.5 Hz, H-10), 2.89 
(3H, s, H-16), 2.77-2.72 (2H, m, H-11); m/z (ESI+) found 472.9818, [M+H]+ 
C16H19Br2N4O3 (79Br) requires 478.9824. 
Due to the rotameric nature of 85 and the limited amount of material obtained, the 13C 
NMR spectrum was too complex to accurately interpret. The 1H NMR spectrum is 
provided in Section 2.2.6.1. 
2.2.5 Biology: Experimental 
Refer to Section 2.1.7 for experimental details. 
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2.2.6 Appendix 
2.2.6.1 NMR Spectra 
1H NMR (d6-DMSO 500 MHz) VT spectrum of 84 at 25 ºC (blue) and 120 ºC (red). 
 
 
Chapter 2 Part II: (5)-Bromoverongamine and JBIR-44: Structure-Activity Relationship Analysis 
 141 
13C NMR (d6-DMSO 125 MHz) VT spectrum of 84 at 25 ºC (blue) and 120 ºC (red). 
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1H NMR (CD3OD 400 MHz) spectrum of 85 
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2.2.6.2 Crystal Structure Data 
(Z)-4-(3,5-Dichloro-4-methoxybenzylidene)-2-methyloxazol-5(4H)-one (59) 
 
Crystal data and structure refinement for sl1029 
  
Identification code    sl1029 
Empirical formula    C12H9Cl2NO3 
Formula weight    286.10 
Temperature     180(2) K 
Wavelength     0.71073 Å 
Crystal system    Triclinic 
Space group     P-1 
Unit cell dimensions    a = 7.2007(1) Å α = 102.473(1)º
      b = 7.6943(2) Å β = 98.169(1)º 
      c  = 11.6371(2) Å γ = 104.107(1)º 
Volume     597.49(2) Å3 
Z      2 
Density (calculated)    1.590 Mg/m3 
Absorption coefficient   0.541 mm–1 
F(000)      292 
Crystal size     0.35 × 0.28 × 0.21 mm3 
Theta range for data collection  3.75 to 33.13º 
Index ranges     -11<=h<=11, -11<=k<=11, -16<=1<=17 
Reflections collected    11625 
Independent reflections   4517 [R(int) = 0.0220] 
Completeness to theta = 33.13º  99.3% 
Absorption correction    Semi-empirical from equivalents 
Max. and min. transmission   0.898 and 0.860 
Refinement method    Full-matrix least-squares on F2 
Data / restraints / parameters   4517 / 0 / 165 
Goodness-of-fit on F2    1.055 
Final R indices [I>2sigma (I)]  R1 = 0.0314, wR2 = 0.0805 
R indices (all data)    R1 = 0.0378, wR2 = 0.0844  
Largest diff. peak and hole   0.396 and –0.336 e. Å–3 
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(E)-N-(3,5-Dibromo-4-methoxyphenethyl)-3-(3,5-dibromo-4-methoxyphenyl)-2-
(hydroxyimino)propanamide (100) 
 
Crystal data and structure refinement for sl1005 
  
Identification code    sl1005 
Empirical formula    C19H18Br4N2O4 
Formula weight    657.99 
Temperature     180(2) K 
Wavelength     0.71073 Å 
Crystal system    Orthorhombic 
Space group     P2bca 
Unit cell dimensions    a = 14.775(3) Å α = 90º 
      b = 13.554(3) Å β = 90º 
      c  = 22.852(5) Å γ = 90º 
Volume     4576.7(16) Å3 
Z      8 
Density (calculated)    1.910 Mg/m3 
Absorption coefficient   7.062 mm–1 
F(000)      2544 
Crystal size     0.30 × 0.10 × 0.02 mm3 
Theta range for data collection  3.61 to 25.00º 
Index ranges     -16<=h<=17, -13<=k<=13, -27<=1<=26 
Reflections collected    20333 
Independent reflections   3820 [R(int) = 0.0554] 
Completeness to theta = 25.00º  94.7% 
Absorption correction    Semi-empirical from equivalents 
Max. and min. transmission   0.853 and 0.581 
Refinement method    Full-matrix least-squares on F2 
Data / restraints / parameters   3820 / 0 / 264 
Goodness-of-fit on F2    1.052 
Final R indices [I>2sigma (I)]  R1 = 0.0991, wR2 = 0.2477 
R indices (all data)    R1 = 0.1280, wR2 = 0.2690  
Largest diff. peak and hole   2.219 and –2.715 e. Å–3 
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Compound Numbering 
In this chapter, the numbering of the carbon atoms in subereamolline A and B is 
based on the convention outlined by Abou-Shoer and co-workers (Figure 27).1 
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Figure 27 Atom labeling of subereamolline A and B. 
Stereochemistry 
Throughout this chapter, absolute stereochemistry is represented by bold and hashed 
wedged bonds; bold and hashed bar bonds represent relative stereochemistry; wavy 
bonds are used for cases where the relative stereochemistry is unknown.  
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3.1 Spirocyclohexadienylisoxazoline Bromotyrosine 
Derivatives 
3.1.1 Structure 
Bromotyrosine derivatives in this class are characterised by their signature 
asymmetric spirocyclohexadienylisoxazoline (SHI) motif. Aerothionin (1), the first 
member of this class to be discovered, was optically active ([α]D +252º) and 
contained two SHI units connected by a four-carbon chain linker (Figure 28).2 The 
relative stereochemistry between the C-1 hydroxyl group and the oxygen in the 
isoxazoline ring of the SHI moiety was assumed to be trans by analogy with (+)-
aeroplysinin-1 (2).3 However, it took another ten years to unravel the absolute 
configuration since crystals of 1 were unstable to X-rays. Using circular dichroism* to 
verify the crystallographic analysis solved this problem.4  
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Figure 28 Structure of (+)-aerothionin (1) and (+)-aeroplysinin-1 (2). The SHI motif is 
highlighted in red. 
As alluded to in Section 1.3.2, the relative stereochemistry between C-1 and C-6 
(trans) is conserved amongst all compounds in this class as a consequence of their 
biosynthesis. The arene oxide 4, derived from dibromotyrosine (3), undergoes 
intramolecular nucleophilic attack from the hydroxyl group of the oxime to construct 
the SHI motif in 5 (Scheme 28).5 The stereospecific nature of this epoxide opening 
leads to the observed trans relative configuration.  
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4 5  
Scheme 28 Proposed biosynthesis of the SHI motif. 
                                                
* The SHI motif has a distinctive CD spectra resulting from the helicity imparted by skewed diene and 
the trans relationship of the oxygens.  
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In a peculiarity that is not frequently observed in nature, this arene oxide biosynthetic 
pathway can produce both enantioforms of the SHI motif, depending on the genera of 
sponge. For example, purealidin J (6) and pseudoceratinine A (7) are enantiomers of 
one another and were isolated from Psammaplysilla purpurea6 and Pseudoceratina 
verrucosa,7 respectively (Figure 29). The reason why both enantiomers are 
biosynthesised is not known, however, derivatives possessing the same SHI motif as 6 
appear to be much more abundant in nature.8 Since these isoxazoline derivatives are 
believed to be precursors for aeroplysinin-1 (2) (Section 1.3.3) one could hypothesise 
that enzymatic degradation of the more common enantioform, would lead to the more 
biologically relevant enantiomer of 2. Indeed, under the proposed degradative 
pathway (Scheme 4) derivatives containing the same SHI motif as 6 would give (+)-2.  
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Figure 29 Structures of purealidin J (6) and pseudoceratinine A (7). 
The structural similarities shared between bromotyrosine isoxazolines means that 
comparison of NMR spectra, optical rotations and CD spectra is often used to aid the 
structural elucidation of new derivatives. Despite this, mistakes can still be made and 
this is typified by the case of zamamistatin (Figure 30). Isolated by Uemura and co-
workers, zamamistatin was optically active ([α]D +248º) and its ESIMS exhibited 
1:4:6:4:1 quintet ion peak at m/z 697, 699, 701, 703 and 705, indicating the presence 
of four bromine atoms. In combination with NMR data, the natural product was 
determined to be a symmetrical dimer with the unprecedented structure 8. 9  
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Figure 30 Proposed structures of zamamistatin (8 and 9) along with the actual structure (2). 
In 2006, Kigoshi and co-workers re-isolated zamamistatin and revised the structure to 
9, based on the NMR spectra of synthetic models.10 Later, they discovered the IR 
spectra indicated the presence of a nitrile (2258 cm–1) and closer inspection of the 
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ESIMS revealed the presence of a triplet ion peak at m/z 361.9 (initially thought to be 
[M/2+Na]+) along with the quintet peak (at a concentration of 15 µM).11 However, 
running the same sample at a lower concentration (0.15 µM) caused the larger, quintet 
ion peak to disappear. Based on these observations, zamamistatin was actually 
determined to be (+)-aeroplysinin-1 (2). Once again, this example emphasises the 
value of total synthesis in being able to confirm or invalidate the proposed structures 
of new natural products.  
3.1.2 Biological Activity 
The bioactivity profile exhibited by this class of products is less diverse than their 
oxime counterparts. To account for this observation, it is theorised that these 
isoxazoline metabolites serve as pro-toxins that are enzymatically degraded to give 
more active compounds; the evidence for this theory was reviewed in Section 1.3.3. 
However, the metabolic expenditure required to biosynthesise these parent 
compounds–over 60 have been isolated to date–would suggest they also have a 
protective role. In fact, some of these derivatives have been shown to exhibit 
cytotoxic activities in cancer cell lines. 
11-Oxoaerothionin (10) (Figure 31) showed selective cytotoxicity against HCT 116 
(colon cancer) cells over a range of 120 nM to 1.2 µM.12 Fistularin-3 (13), whose 
stereochemistry at C-10 and C-18 has not been established, inhibited cell growth in 
epidermoid, prostate and leukaemia cell lines (IC50 3.6, 3.8 and 1.2 µM, 
respectively).13 Araplysillin-1 (11), araplysillin-2 (not shown), purealidin S (15) and 
purealidin Q (14) were cytotoxic against ovarian tumour A2780 (EC50 18.6, 14.8, 7.4 
and 2.5 µM, respectively) and leukaemia K562 cell lines (EC50 28, 43, 6.0 and 1.5 
µM, respectively).14 In a separate study, 14 along with purealidin P (12) proved to be 
cytotoxic against murine lymphoma K1210 (EC50 1.3 and 3.9 µM, respectively) and 
human epidermal carcinoma KB (nasopharynx) (EC50 1.6 and 10.6 µM, respectively) 
cell lines.6 
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Figure 31 Structures of cytotoxic bromotyrosine-derived isoxazolines. 
3.2 Subereamollines A and B 
3.2.1 Isolation and Biological Activity 
The isolation of subereamollines A (16) and B (17) (Figure 32) was reported by 
Abou-Shoer and co-workers in 2008 following the reinvestigation of the crude extract 
from the Red Sea sponge Suberea mollis.1 Owing to the small quantities isolated (4.9 
mg of 16 and 2.0 mg of 17), investigation into their biological properties was limited. 
Neither 16 nor 17 exhibited antioxidant activity, however, 16 was found to possess 
modest antimicrobial activity against Staphylococcus aureus (3 mm inhibition zone at 
a concentration of 3 mg/mL). Furthermore, it was not reported if their cytotoxic 
activities had been investigated and as a result, the subereamollines were attractive 
synthetic targets since they are structurally related to the cytotoxic isoxazoline natural 
products shown in Figure 31. 
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Figure 32 Subereamollines A (16) and (17). 
In terms of structure, both 16 and 17 contain a 2,4-dibromo-1-hydroxy-3-
methoxyspirocyclohexadienylisoxazole moiety attached to a linear carbamate 
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containing side chain via an amide linkage. Although not explicitly stated in the 
isolation paper, the absolute stereochemistries at C-1 and C-6 were determined to be 
(R) and (S) based on the optical rotations of 16 {[α]D +156.5 (c 0.55, MeOH)} and 17 
{[α]D +22.9 (c 6.25, CH2Cl2)}. These optical rotations correlated with (+)-aerothionin 
(1) {[α]D +210 (c 1.7, MeOH)} (Figure 28).4  
In addition to achieving the total syntheses of 16 and 17, it was also our aim to 
develop a strategy that incorporated a method for obtaining both enantiomers of the 
natural products in excellent enantiopurity. This was desirable for two reasons: firstly, 
it would be possible to investigate whether any observed bioactivity was dependent 
on the stereochemistry of the SHI motif; secondly, it is more than likely that the 
“unnatural” enantiomer is also produced in nature given the occurrence of 6 and 7 
(Figure 29).  
3.2.2 Synthetic Strategy 
The total syntheses of natural products from the same SHI class of bromotyrosine- 
derivatives as 16 and 17 have previously been reported in the literature.15 The 
universal strategy in synthesising these molecules has involved coupling the SHI 
motif to the appropriate side chain to form the key amide bond. Therefore, in a similar 
strategy, it was envisaged that 16 and 17 could be accessed from coupling the 
spiroisoxazoline acid (±)-18 with amine 19 or 20, respectively (Scheme 29).  
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Scheme 29 Retrosynthetic analysis of 16 and 17. 
Interestingly, (–)-18 has been isolated from the marine sponge Pseudoceratina sp. as 
an optically pure isomer with its absolute configuration defined as 1S,6R by CD 
analysis.16 To date, only Day and co-workers have reported the synthesis of (±)-18, 
and, while it was successfully employed as an intermediate in their synthesis of 
purealin, the DCC/HOBt mediated amidation only proceeded in 54%.17 Nevertheless, 
this was a significant improvement on the prior art since amidation reactions had 
previously been performed directly on the methyl ester 21 (Figure 33).15 
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Figure 33 Structure of methyl ester 21. 
Hoshino and co-workers achieved the first synthesis of optically active 21 by 
developing an asymmetric oxidative spirocyclisation which employed a chiral 
auxiliary (24) derived from a phenyl decalol (Scheme 30).18 Spirocyclisation of oxime 
ester 22 upon treatment with PhIO and CSA furnished 23 in a yield of 83% and a 
diastereomeric excess of between 70–80% as determined by 1H NMR analysis. 
Following removal of the chiral auxiliary with TFA and conversion of the resulting 
acid to the methyl ester, diastereoselective reduction of the ketone using Zn(BH4)2 
furnished the desired, optically enriched, methyl ester 21. Whilst this represented the 
first asymmetric synthesis of this SHI structural motif, the method required a multi-
step synthesis of the chiral auxiliary and only delivered the final product in moderate 
enantiopurity (84% ee). 
In an alternative approach developed by Nishiyama and co-workers, a racemic 
mixture of 21 was resolved by derivatisation with (–)-camphanic chloride to give the 
corresponding diastereomeric camphanate esters 25a and 25b, which could then be 
separated by silica gel chromatography. Subsequent methanolysis provided 
enantiopure (+)- and (–)-21, which were used to achieve the first syntheses of 
optically pure (+)- and (–)-aerothionin (1).19  
After assessing the merits of these two methods it was clear that the stereoselective 
spirocyclisation was not viable for our purpose. Despite the fact that resolution can 
deliver enantiopure material, we also wanted to investigate an alternative method for 
separation of the racemic products which would avoid the need for additional 
synthetic manipulations. Therefore, it was decided to investigate the possibility of 
separating the natural product racemates themselves either by resolution or 
preparative chiral HPLC. Furthermore, we envisaged that a combination of these 
methods would enable the absolute configuration at C-1 and C-6 to be unambiguously 
assigned.  
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Scheme 30 Hoshino synthesis of optically active 21. 
Reagents and conditions: (a) p-nitrophenol, DCC, CH2Cl2, 91%; (b) 24, MeLi, HMPA, PhMe, 
0 ºC, 85%; (c) H2, Pd-black, AcOH/1,4-dioxane (1:1), 90%; (d) PhIO, CSA, CH2Cl2, –78 ºC, 
83%, (70-80% de); (e) TFA, CH2Cl2, 0 ºC; (f) DCC, DMAP, MeOH, CH2Cl2, 71% over 
2 steps, 84% ee after recrystallisation; (g) Zn(BH4)2, CH2Cl2/Et2O (3:2). 
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Scheme 31 Nishiyama synthesis of optically pure 21. 
Reagents and conditions: (a) (–)-camphanic chloride, py, CH2Cl2, 25a, 46%; 25b, 47%; 
(b) K2CO3, MeOH, (+)-21 quant, (–)-21 quant. 
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3.3 Results and Discussion 
3.3.1 Synthesis of Spiroisoxazoline Acid 18 
Beginning with the commercially available 2-hydroxy-4-methoxybenzaldehyde (26), 
bromination with N-bromosuccinimide afforded 27. Subsequent benzyl protection of 
the phenol furnished aldehyde 28 in 92% yield over 2 steps (Scheme 32). This was 
then converted into the corresponding azlactone 29 by heating with N-acetylglycine 
and sodium acetate in the presence of acetic anhydride (Erlenmeyer conditions).20 
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Scheme 32 Synthesis of azlactone 29. 
Reagents and conditions: (a) NBS, DMF, 0 ºC, 50 min, 93%; (b) BnCl, NaI, K2CO3, DMF, rt, 
13 h, 99%; (c) N-acetylglycine, NaOAc, Ac2O, 120 ºC, 6 h, 90%. 
Saponification of the crude azlactone (29) with barium hydroxide and subsequent 
condensation with O-benzylhydroxylamine furnished the carboxylic acid 30 which 
could be isolated by trituration from hexane and diethyl ether. As mentioned in 
Section 2.1.4.1, the modest yield of 49% is common for transformations of this nature 
and likewise, could not be improved upon even when 29 had been either recrystallised 
or purified by flash chromatography. Furthermore, following trituration TLC analysis 
showed numerous by-products in the mother liquor. The major by-product was 
isolated by chromatography and discovered to be oxime 31 (22%). It is postulated that 
this may have arisen from the hydrolysis of 29 back to its parent aldehyde (28), under 
the basic conditions, and subsequent condensation with the O-benzylhydroxylamine. 
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Scheme 33 Saponification of 29. 
Reagents and conditions: (a) Ba(OH)2·8H2O, 1,4-dioxane/H2O (1:1), 60 ºC, 1 h then            
O-benzylhydroxylamine, 16 h, 30, 49%; 31, 22% 
As mentioned in Chapter 2, azlactones are known to hydrolyse efficiently under 
acidic conditions21 to give phenylpyruvic acid derivatives which can then be 
converted to their corresponding oxime acids.22 When azlactone 29 was subjected to 
the hydrolysis conditions (3 N HCl, reflux), 1H and 13C NMR analysis of the product 
showed that in addition to the hydrolysis of the azlactone, debenzylation of the 
phenolic oxygen had also occurred. This led us to suspect the product was the 
phenylpyruvic acid 33 (Scheme 34). 
Fortunately, it was possible to crystallise the product from diethyl ether and X-ray 
crystallographic analysis revealed the structure to be the known enol coumarin 32 
(Figure 34).† Therefore, it is believed that under the reaction conditions 33 undergoes 
acid catalysed lactonisation to produce 32. Since sufficient quantities of 30 were 
obtained from the method described in Scheme 33, the use of an alternative phenolic 
protecting group was not investigated.  
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Scheme 34 Formation of coumarin 32. 
 Reagents and conditions: (a) 3 N HCl, reflux, 24 h, 68%.  
 
                                                
† This coumarin had previously been synthesised by Spilling and co-workers and used as an 
intermediate in the synthesis of purealidin N (J. Org. Chem. 2005, 70, 6398).  
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Figure 34 X-ray crystal structure of coumarin 32. 
The oxidative cyclisation precursor, oxime methyl ester 35, could be obtained in two 
steps from 30. Firstly, treatment of 30 with trimethylsilyldiazomethane gave the 
corresponding methyl ester 34 (Scheme 35). Subsequently, the benzyl groups were 
removed via hydrogenolysis over palladium black to furnish the cyclisation precursor 
35. 
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Scheme 35 Synthesis of cyclisation precursor 35. 
Reagents and conditions: (a) TMSCHN2, PhMe/MeOH (3:1), 0 ºC to rt, 1 h, 95%;              (b) 
Pd-black, H2, 1,4-dioxane/AcOH (1:1), rt, 3 h, 92% 
Several conditions known to affect the oxidative cyclisation of oxime 35 to the 
spiroisoxazoline (±)-36 have been reported in the literature. Nishiyama and co-
workers found that treatment of 35 with thallium(III) trifluoroacetate furnished 36 in 
27% yield whilst other oxidizing agents including bromine and 2,4,4,6-tetrabromo-
2,5-cyclohexadien-1-one were ineffective.23 To circumvent the toxicity issues 
associated with thallium salts, they subsequently developed an electroorganic 
oxidation whereby subjecting 35 to constant potential electrolysis‡ in the presence of 
tetrabutylammonium perchlorate furnished 36 in 68% yield.24 For this transformation, 
N-bromosuccinimide25 and iodobenzene diacetate26 mediated cyclisations have also 
                                                
‡ Electrolysis in which a constant voltage is applied. 
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been reported and, from a synthesis perspective, were the most appealing due to their 
practicality, low toxicity and good yields. Furthermore, since 36 is unstable to silica 
gel chromatography,25 a procedure that gave the crude material in good purity 
following a standard aqueous work-up was desirable. In our hands, iodobenzene 
diacetate proved to be the reagent of choice (Scheme 36).§ Spilling and co-workers 
reported the use of PS-iodobenzene diacetate to affect the same transformation in 
quantitative yield.27 Unfortunately, this reagent was not readily accessible and the use 
of a commercially available PS-4-hydroxyiodobenzene diacetate gave no conversion. 
Following work-up the crude mixture was taken on directly to the next step where 
diastereoselective reduction of (±)-36 with Zn(BH4)228 furnished the desired trans-
isomer (±)-21 and the undesired cis-isomer (±)-21a in diastereomeric ratio of 2.03:1 
(by 1H NMR). Purification of the crude mixture gave (±)-21 and (±)-21a in a yield of 
32% and 16%, respectively, over 2 steps from oxime 35.  
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Scheme 36 Oxidative cyclisation of 35 and subsequent reduction. 
Reagents and conditions: (a) PhI(OAc)2, MeCN, 0 ºC, 1 h; (b) Zn(BH4)2, CH2Cl2, rt, 10 min, 
(±)-21, 32% from 35; (±)-21a, 16% from 35. 
At this point, we were able to obtain X-ray quality crystals of (±)-21 and (±)-21a by 
slow evaporation from diethyl ether to confirm the relative stereochemistry of each 
isomer (Figure 35). It is worth mentioning that previously the relative 
stereochemistries of (±)-21 and (±)-21a had originally been established by 
comparison of their 1H NMR spectra with those of aerothionin (1) and cis,cis-
aerothionin.29 
 
 
 
                                                
§ Removal of the succinimide by-product from the NBS-mediated cyclisation proved to be laborious.  
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(±)-21 (±)-21a 
  
Figure 35 X-ray crystal structures of (±)-21 and (±)-21a. 
The methyl ester of (±)-21 was then saponified with lithium hydroxide to furnish 
spiroisoxazoline acid (±)-18 in an overall yield of 11% in 9 steps from the 
commercially available aldehyde 26 (Scheme 37). 
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Scheme 37 Saponification of methyl ester (±)-21. 
Reagents and conditions: (a) LiOH·H2O, MeOH/H2O (3:1), rt, 1 h, 99%. 
3.3.2 Synthesis of Amines 19 and 20 
The amine coupling partners could be synthesised in one step from the commercially 
available diamines putrescine (37) and cadaverine (38). Addition of the carbamylating 
agent ethyl phenyl carbonate (39)30 in EtOH to 37 and 38 minimised bis-
carbamylation and furnished the amine coupling partners 19 and 20 in 80% and 82% 
yield, respectively (Scheme 38).  
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n
H2N NH2
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Scheme 38 Synthesis of amine coupling partners. 
Reagents and conditions: (a) 39, EtOH, rt, 12 h, 19, 80%; 20, 82%. 
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3.3.3 Synthesis of Subereamollines A and B 
With both the acid and amine coupling partners in hand, the syntheses of (±)-16 and 
(±)-17 could be realised. The spiroisoxazoline (±)-18 was coupled to amines 19 and 
20 in the presence of DCC and HOBt to afford the natural products (±)-
subereamolline A (16) and B (17), respectively, in 91% and 75% yield (Scheme 39). 
Despite giving the natural products in good yield the use of DCC as coupling agent 
was far from ideal since careful chromatography was required to remove the 
dicyclohexylurea (DCU) by-product. 
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Scheme 39 Synthesis of (±)-16 and (±)-17. 
Reagents and conditions: (a) DCC, HOBt, amine 19 or 20, iPr2EtN, CH2Cl2, rt, 18h, (±)-16, 
91%; (±)-17, 75%; (b) ®T3P, amine 19 or 20, iPr2EtN, CH2Cl2, 0 ºC, 2 h, (±)-16, 96%; (±)-17, 
97%.  
Upon reinvestigation of this coupling step, it was found that the coupling agent ®T3P 
furnished 16 and 17 in 96% and 97% yields, respectively. In addition, purification 
was simplified by the fact that the polyphosphate by-product could be extracted from 
the product during an aqueous work-up.  
The 1H and 13C NMR spectra of synthetic 16 and 17 matched those of the natural 
materials (see Appendix).1 We have also established that the originally reported 13C 
chemical shift assignments of C-2 (δC 122.9 ppm) and C-4 (δC 114.3 ppm) should be 
switched on the basis of COLOC NMR experiments reported for related spirocyclised 
products.31 This is also supported by the HMBC correlations in the natural products 
(Figure 36).  
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Figure 36 1H 13C HMBC correlations for subereamolline B (17). 
In the HMBC spectra of the natural and synthetic samples of 16 and 17, the 
quaternary carbon (δC 114.3 ppm) couples strongly to the protons H-1 (δH 4.07 and 
4.06 ppm, respectively) and H-5 (δH 6.42 and 6.40 ppm, respectively). However, the 
quaternary carbon (δC 122.9 ppm) only couples to H-5. Therefore the original 
assignments for C-2 (δC 122.9 ppm) and C-4 (δC 114.3 ppm) proposed by Abou-Shoer 
and co-workers should be reversed. 
3.3.4 Side Chain Variations 
In a continuation of our studies on the oxime-type bromotyrosine derivatives, we 
sought to append the (5)-bromoverongamine and JBIR-44 side chains to the spiro acid 
(±)-18. These spirocyclised analogues (40 and 41) would provide additional insight 
into the biological importance of the oxime functionality in these compounds.** 
Accordingly, (±)-18 was coupled to histamine dihydrochloride and 3,5-
dibromotyramine hydrobromide with ®T3P to give (±)-aerophobin-1 (40) and (±)-
41,†† respectively (Scheme 40). Multiple attempts to improve the low yields were 
unsuccessful but sufficient quantities for screening could still be obtained by this 
method. 
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Scheme 40 Synthesis of (±)-aerophobin-1 (40) and (±)-41. 
Reagents and conditions: (a) ®T3P, amine, iPr2EtN, CH2Cl2, 0 ºC, 2 h, (±)-40, 20%; (±)-41, 
11%. 
                                                
** The presence of the C-1 hydroxyl means that 40 and 41 are not direct spirocyclised analogues of                     
(5)-bromoverongamine and JBIR-44. 
†† Although this compound has not yet been isolated from a natural source, we hypothesise that 41 is a 
naturally occurring bromotyrosine-derivative given its structural similarity to 11, 12, 14, and 15.  
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3.3.5 Separation of Racemic Subereamollines A and B 
With the natural products in hand, we then wanted to investigate how best to separate 
the racemates. In our first attempt, (±)-17 could be derivatised with (–)-camphanic 
chloride;‡‡ however, all efforts to separate the respective diastereoisomers 42a and 
42b by normal-phase chromatography were in vain (Scheme 41). The use of other 
chiral derivatising agents was not explored since this had been previously investigated 
for the separation of (±)-21 by Nishiyama and co-workers 19  
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Scheme 41 Derivatisation of (±)-17 with (–)-camphanic chloride. 
Reagents and conditions: (a) (–)-camphanic chloride, DMAP, CH2Cl2, 0 ºC to rt, 6 h. 
Pleasingly, the enantiomeric forms of (±)-16 and (±)-17 were separated using 
preparative chiral HPLC (CHIRALPAK AD-H column and 10% iPrOH in hexane at a 
flow rate of 5 mL/min) (Scheme 42). In both cases, the first compound to elute was 
the naturally occurring enantiomer. The optical rotations of (+)-16 (Rt = 40.3 min) 
and (+)-17 (Rt = 48.3 min) agreed with those observed for natural 16 and 17.§§ To our 
knowledge this is the first reported use of chiral HPLC to separate compounds in this 
class of natural products. Furthermore, this method could deliver the quantities of 
enantiopure material required for the cytotoxicity testing. 
                                                
‡‡ Due to the complex nature of the 1H and 13C NMR spectra, this was confirmed by HRMS. 
§§ The optical rotation for (+)-17 reported by Abou-Shoer and co-workers was [α]D +22.9 (c 6.25, 
CH2Cl2). Due to the fact that only 2.0 mg were isolated, we believe there was a typographical error in 
the reported concentration. 
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Scheme 42 Preparative chiral HPLC separations of (±)-16 and (±)-17. 
3.3.6 Confirmation of the Absolute Stereochemistries at C-1 and C-6 
In order to confirm the absolute stereochemistries at C-1 and C-6 it was necessary to 
synthesise the natural products from an optically pure intermediate whose absolute 
configuration was known. As discussed in Section 3.2.2, Nishiyama reported the 
synthesis of the enantiomeric forms of methyl ester 21 by resolution with (–)-
camphanic chloride (Scheme 31). Furthermore, in this research the absolute 
stereostructures of the spiroisoxazolines (+)- and (–)-21 were unambiguously 
assigned.*** Therefore, we initially adopted this method to access (+)- and (–)-21. 
Racemic methyl ester 21 could be coupled to (–)-camphanic chloride in the presence 
of DMAP to give, as expected, a 1:1 diastereomeric mixture of 25a and 25b by 1H 
NMR (Scheme 43). 
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Scheme 43 Derivatisation of  (±)-21. 
Reagents and conditions: (a) (–)-camphanic chloride, DMAP, CH2Cl2, 0 ºC to rt, 6 h. 
                                                
*** This was achieved by using both enantiomers to synthesise (+)- and (–)-aeroplysinin-1 (2), the 
absolute configurations of which had previously been determined by X-ray crystallography. 
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The diastereoisomers 25a and 25b were reported to be “easily separable” by silica gel 
chromatography although the eluting conditions were not described. A screen of 
solvent systems found that, by analytical TLC, two elutions with CH2Cl2/EtOAc 
(99:1) gave visible separation of 25a (Rf 0.50) and 25b (Rf 0.45). However, attempts 
to separate these compounds on a synthetically useful scale were unsuccessful as it 
was not possible to prevent co-elution of the two diastereoisomers. 
This problem was circumvented since it was possible to obtain (+)-21 (Rt = 30.9 min) 
and (–)-21 (Rt = 32.9 min) by chiral HPLC separation of (±)-21 (CHIRALPAK AD-H 
column and 4% iPrOH in hexane at a flow rate of 5 mL/min). A sample of both (+)-
21 and (–)-21 was converted to the corresponding camphanate esters (25a and 25b) 
using the conditions described in Scheme 43. As expected, the 1H NMR spectra of 
these derivatives matched those reported in the literature thus confirming the absolute 
structure of the HPLC material.19  
Saponification of (+)-21 and (–)-21 under the conditions described in Scheme 37 
furnished the corresponding carboxylic acids (+)-18 and (–)-18 (Scheme 44). These 
were then coupled with amines 19 and 20 and expected to give (+)-16 and (–)-17, 
respectively. This was confirmed by analytical HPLC (CHIRALPAK AD-H column 
and 10% iPrOH in hexane at a flow rate of 1 mL/min) thus proving the original 
stereochemical assignments at C-1 and C-6 (see appendix for HPLC traces). 
Furthermore, this analysis also showed that, saponification of the methyl ester with 
lithium hydroxide did not erode the stereochemistry. 
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Scheme 44 Synthesis of (+)-16 and (–)-17 from enantiopure methyl ester. 
Reagents and conditions: (a) DCC, HOBt, iPr2EtN, CH2Cl2, rt, 18 h; (b) LiOH·H2O, 
MeOH/H2O (3:1), rt, 1 h. 
3.3.7 Biological Screening 
The racemic and enantiomeric forms of the subereamollines were screened against 
ovarian (SK-OV-3) and cervical (HeLa) cell lines (Table 8). However, following 48 h 
treatment, none of the compounds were active up to a concentration of 100 µM. 
Coumarin 32, oxime 35, (±)-aerophobin-1 (40) and (±)-41 were also inactive against 
SK-OV-3 cells. 
Table 8 MTS assay results for compounds screened against SK-OV-3 and HeLa cells. Drug 
incubations were for 48 h. 
Compound 
Cell Line (±)-16 (±)-17 (+)-16 (–)-16 (+)-17 (–)-17 32 35 (±)-40 (±)-41 
SK-OV-3 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
HeLa N/A N/A N/A N/A N/A N/A – – – – 
N/A (not active); – (not tested) 
Aerophobin-1 (40) has been isolated as a major component from a number of 
Verongida sponges. 32 Interestingly, it was shown to have moderate cytotoxic activity 
against ovarian A2780 (ID50 45 µM) and leukaemia K562 (ID50 51 µM) cells14 but 
was inactive against murine lymphoma L1210 and human epidermoid carcinoma KB 
cells.6 
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It is perhaps surprising that (±)-41 showed no activity since other SHI products with 
modified dibromotyramine appendages have exhibited cytotoxicity across a range of 
cell lines (Section 3.1.2). However, it is apparent that loss of the oxime functionality 
and aromaticity/planarity in the phenyl ring is unfavourable (cf. activity of JBIR-44 in 
Section 2.1.4.6). 
3.4 Conclusion and Future Work 
In conclusion, the first total syntheses of the bromotyrosine-derived natural products 
subereamolline A and B have been achieved and, in addition, the enantiomeric forms 
of 16 and 17 were obtained by chiral HPLC. This approach not only delivered 
enantiopure material but also removed the need to for additional synthetic operations 
and represents a significant improvement upon previous syntheses of products from 
this class of bromotyrosine derivatives. Furthermore, the absolute stereochemistries at 
C-1 and C-6 in the naturally occurring enantiomers (+)-16 and (+)-17 were confirmed 
to be R and S, respectively. Disappointingly, none of the compounds tested were 
cytotoxic and this may reflect the theory that the SHI class of derivatives serve to act 
as pro-toxins to more biologically active agents.  
A significant challenge which still needs to be addressed in the syntheses of these 
molecules is the development of a catalytic enantioselective oxidative spirocyclisation 
of the oxime 35 to the spiroisoxazoline 36. In the age of organocatalysis, the use of a 
chiral auxiliary (Scheme 30) is dated and leaves much to be desired. A truly 
asymmetric cyclisation would not only be more elegant but it would also increase 
atom efficiency and have the potential to impart greater asymmetric induction. 
Ideally, the catalyst should be based on a reagent with precedent in being able to 
efficiently affect the spirocyclisation in a racemic fashion. Of direct relevance to this, 
the last few years has seen the emergence of catalytic chiral hypervalent iodine 
precatalysts that rely on co-oxidants for their activation in situ.33 In pioneering work 
by Kita and co-workers, precatalyst 45 in the presence of mCPBA and acetic acid 
could dearomatise 1-napthol derivatives (43) to their corresponding spirolactones (44) 
in up to 69% ee††† (Scheme 45).34 In a continuation of this work, Ishihara and co-
workers developed a C2-symmetric chiral iodoarene catalyst (46) capable of 
performing the same transformation in up to 94% yield and 92% ee.35 
                                                
††† When a stoichiometric amount of the corresponding iodine(III) reagent of 46 was used, higher 
enantioselectivities (up to 86% ee) were observed. 
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Scheme 45 Enantioselective oxidative spirolactonisation. 
Reagents and conditions: (a) 45 (15 mol%), mCPBA, AcOH, up to 70% yield and 69% ee; (b) 
46 (10–15 mol%), mCPBA, up to 94% and 92% ee.  
In these examples, the catalyst optimisation was carried out on 1-napthyl derivatives 
and attempts to perform the spirolactonisation of simple phenol derivatives with the 
optimised precatalyst 46 proved unsuccessful.35 Furthermore, to our knowledge, the 
use of chiral hypervalent iodine catalysts to affect the oxidative spirocyclisation of 
oximes to spiroisoxazolines had not been investigated. Both of these issues need to be 
addressed and therefore, further investigations exploring the feasibility of this strategy 
for constructing chiral spiroisoxazolines would be of great value.  
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3.5 Chemistry: Experimental 
General Experimental Details  
Refer to Section 2.1.6 for general experimental details. In addition, specific optical 
rotations were recorded on a Perkin-Elmer 343 digital polarimeter using a sodium 
lamp (589 nm) as the light source. Concentrations (c) are quoted in g per 100 ml. 
Chiral HPLC was performed on an HP Agilent 1100. 
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3,5-Dibromo-2-hydroxy-4-methoxybenzaldehyde (27) 
O
OMe
OH
BrBr
1
7
5
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To a stirred solution of 2-hydroxy-4-methoxybenzaldehyde (26) (8.10 g, 53.2 mmol) 
in DMF (20 mL) at 0 ºC was added N-bromosuccinimide (19.0 g, 107 mmol) in DMF 
(40 mL) dropwise over 30 min. After stirring at 0 ºC for a further 20 min Et2O (600 
mL) was added and the mixture was washed with H2O (500 mL × 2), 10% aqueous 
Na2S2O3 (400 mL × 3), brine (500 mL), dried, and evaporated to dryness in vacuo to 
furnish 27 (15.3 g, 49.4 mmol, 93%) as a white solid. 
Rf 0.32 (10% Et2O/Petrol); νmax (thin film)/cm-1 3052w, 1651s, 1417m, 1289s, 1193s; 
δH (400 MHz, CDCl3) 11.72 (1H, s, OH), 9.79 (1H, s, H-7), 7.73 (1H, s, H-5), 3.97 
(3H, s, H-8); δC (100 MHz, CDCl3) 194.1 (C-7), 161.2 (C-3), 159.5 (C-1), 136.3 (C-
5), 118.7 (C-6), 107.9 (C-4), 107.8 (C-2), 61.0 (C-8). 
Consistent with literature data.25 
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2-(Benzyloxy)-3,5-dibromo-4-methoxybenzaldehyde (28) 
O
OMe
O
BrBr
1
7
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To a stirred solution of 27 (11.2 g, 36.1 mmol), sodium iodide (5.41 g, 36.1 mmol), 
anhydrous K2CO3 (12.0 g, 86.8 mmol) in DMF (58 mL) was added benzyl chloride 
(4.18 mL, 36.3 mmol). The mixture was stirred for 13 h before partitioning between 
H2O (500 mL) and Et2O (500 mL). The aqueous phase was extracted with Et2O (500 
mL × 2) and the combined organic layers were washed with 5% LiCl solution (300 
mL × 2), H2O (500 mL × 2), brine (500 mL), dried, and evaporated to dryness in 
vacuo to furnish 27 (14.3 g, 35.7 mmol, 99%) as a white solid. 
Rf 0.49 (10% Et2O/Petrol); νmax (thin film)/cm-11689s, 1577m, 1366s, 1161s; δH (400 
MHz, CDCl3) 9.94 (1H, s, H-7), 7.99 (1H, s, H-5), 7.40 (5H, m, H-3'/7', H-4'/6' and 
H-7'), 5.13 (2H, s, H-1'), 3.98 (3H, s, H-8); δC (100 MHz, CDCl3) 187.1 (C-7), 160.4 
(C-3), 159.3 (C-1), 134.9 (C-2'), 131.6 (C-5), 129.2 (C-4'/6'), 128.91 (C-5'), 128.87 
(C-3'/7'), 128.4 (C-6), 115.4 (C-4), 114.5 (C-2), 78.1 (C-1'), 61.0 (C-8); m/z (ESI+) 
found 420.9044, [M+Na]+ C15H12Br2O3Na (79Br) requires 420.9045; m.p. 85-87 ºC 
(lit.,36 91-93 ºC). 
Consistent with literature data.36 
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(Z)-4-(2-(Benzyloxy)-3,5-dibromo-4-methoxybenzylidene)-2-methyloxazol-5(4H)-
one (29) 
OMe
O
BrBr
1
7
5
12
1'
O
N
O 9
11
 
A stirred slurry of 28 (6.40 g, 16.0 mmol), sodium acetate (1.31 g, 16.0 mmol) and N-
acetylglycine (1.87 g, 16.0 mmol) in acetic anhydride (30 mL, 317 mmol) was heated 
to 120 ºC for 6 h. The reaction mixture was allowed to cool to room temperature and 
the resulting precipitate isolated by filtration. The filtrand was dissolved in CH2Cl2 
(200 mL), washed with H2O (200 mL), dried, and evaporated to dryness in vacuo to 
furnish 29 (6.93 g, 14.4 mmol, 90%) as an orange solid which was used without 
further purification. 
For characterisation purposes, a sample was purified by flash column chromatography 
(50% CH2Cl2/Petrol) to furnish 29 as a bright yellow solid. 
Rf 0.65 (20% EtOAc/Petrol); νmax (thin film)/cm-1 2944w, 1802s, 1655s, 1599s, 
1192s; δH (400 MHz, CDCl3) 8.87 (1H, s, H-5), 7.44-7.36 (5H, m, H-3'/7', H-4'/6' and 
H-7'), 7.23 (1H, s, H-7), 4.99 (2H, s, H-1'), 3.95 (3H, s, H-12), 2.39 (3H, s, H-11); δC 
(100 MHz, CDCl3) 167.0 (C-10), 166.8 (C-9), 157.1 (C-3), 156.4 (C-1), 135.2 (C-2'), 
134.7 (C-5), 133.3 (C-8), 128.9 (C-4'/6'), 128.71 (C-5'), 128.69 (C-3'/7'), 126.3 (C-6), 
122.7 (C-7), 114.7 (C-4), 113.8 (C-2), 77.3 (C-1'), 60.8 (C-12), 15.6 (C-11); m/z 
(ESI+) found 479.9464, [M+H]+ C19H16Br2NO4 (79Br) requires 479.9446; m.p. 128-
131 ºC (lit.,26 174-176 ºC); elem. anal. C19H15Br2NO4 requires C 47.43%, H 3.14%, N 
2.91% found C 47.06%, H 3.10%, N 2.80%. 
Consistent with literature data.26 
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(E)-3-(2-(Benzyloxy)-3,5-dibromo-4-methoxyphenyl)-2-
((benzyloxy)imino)propanoic acid (30) 
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A solution of 29 (4.00 g, 8.31 mmol) and Ba(OH)2·8H2O (18.3 g, 58.0 mmol) in 1,4-
dioxane (60 mL) and H2O (60 mL) was heated to 60 ºC. After 1 h O-
benzylhydroxylamine (3.07 g, 24.9 mmol) was added and the mixture was stirred for 
a further 16 h. The reaction mixture was cooled to 0 ºC, acidified to pH 0 with 3 N 
HCl and extracted with CH2Cl2 (250 mL × 3). The combined organic layers were 
dried, evaporated to dryness in vacuo and the resulting residue triturated with 
petroleum ether to furnish 30 (2.31 g, 4.10 mmol, 49%) as an off white solid. The 
mother liquor was concentrated in vacuo and the resulting residue was purified by 
flash column chromatography (10% Et2O/Petrol) to furnish 31 (924 mg, 1.83 mmol, 
22%) as a white solid. 
30: Rf 0.59 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 2991br, 1701s, 1455s, 1427s, 
1216s, 993s; δH (400 MHz, CDCl3) 7.50-7.48 (2H, m, H-10'/14'), 7.39-7.33 (6H, m, 
Ph-H), 7.21-7.19 (2H, m, Ph-H), 7.16 (1H, s, H-5), 5.22 (2H, s, H-1'), 5.01 (2H, s, H-
8'), 3.89 (2H, s, H-7), 3.88 (3H, s, H-10); δC (100 MHz, CDCl3) 163.4 (C-9), 154.3 
(C-1), 154.1 (C-3), 149.3 (C-8), 136.4 (C-9'), 135.6 (C-2'), 131.9 (C-5), 128.7 (C-6), 
128.6 (Ph-C), 128.4 (Ph-C), 128.3 (C-5' or C-12'), 128.2 (Ph-C), 128.03 (C-5' or C-
12'), 127.96 (Ph-C), 114.6 (C-4), 112.8 (C-2), 78.4 (C-1'), 74.7 (C-8'), 60.6 (C-10), 
25.3 (C-7); m/z (ESI+) found 583.9688, [M+Na]+ C24H21Br2NO5Na (79Br) requires 
583.9679 m.p. 159-161 ºC. 
Consistent with literature data.26  
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2-(Benzyloxy)-3,5-dibromo-4-methoxybenzaldehyde O-benzyl oxime (31)  
Rf 0.84 (30% Et2O/Petrol); νmax (thin film)/cm-1 2945w, 1599w, 1580w, 1457m, 
1365s, 1155s, 943s; δH (400 MHz, CDCl3) 8.40 (1H, s, H-7), 8.20 (1H, s, H-5), 7.59-
7.43 (10H, s, Ph-H), 5.36 (2H, s, H-1'), 5.05 (2H, s, H-1''), 4.04 (3H, s, H-8); δC (100 
MHz, CDCl3) 156.0 (C-3), 154.4 (C-1), 142.8 (C-7), 137.0 (C-2'), 135.4 (C-2''), 128.9 
(Ph-C), 128.28 (Ph-C), 128.25 (Ph-C), 128.14 (Ph-C), 128.06 (Ph-C), 128.02 (Ph-C), 
127.7 (Ph-C), 124.7 (C-6), 114.6 (C-4), 113.6 (C-2), 76.4 (C-1'), 76.2 (C-1''), 60.4 (C-
8); m.p. 69-71 ºC; elem. anal. C22H19Br2NO3 requires C 52.30%, H 3.79%, N 2.77%, 
found C 51.85%, H 3.79%, N 2.76%. 
Chapter 3: Total Syntheses of Subereamollines A and B 
 175 
6,8-Dibromo-3-hydroxy-7-methoxy-2H-chromen-2-one (32) 
1
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A suspension of azlactone 29 (428 mg, 0.890 mmol) and 3 N HCl (20 mL) were 
heated to reflux for 20 h. The mixture was cooled to room temperature and the white 
precipitate was isolated by filtration, washed with H2O (20 mL) and dried in vacuo to 
furnish 32 (211 mg, 0.603 mmol, 68%) as an off-white solid. 
νmax (thin film)/cm-1 3358m, 1699s, 1471m, 1251s, 1148s; δH (400 MHz, d6-DMSO) 
10.70 (1H, s, OH), 7.92 (1H, s, H-5), 7.07 (1H, s, H-7), 3.83 (3H, s, H-10); δC (100 
MHz, d6-DMSO) 157.2 (C-9), 152.5 (C-3), 146.0 (C-1), 141.7 (C-8), 128.5 (C-5), 
119.7 (C-2), 113.3 (C-7), 112.2 (C-4), 105.3 (C-6), 60.7 (C-10). 
Consistent with literature data.27 
Crystals of 32 were obtained by slow evaporation of Et2O. The structure was 
confirmed by X-ray crystallographic analysis and given the unique identifier sl1037.  
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(E)-Methyl-3-(2-(benzyloxy)-3,5-dibromo-4-methoxyphenyl)-2-
((benzyloxy)imino)propanoate (34) 
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To a stirred solution of 30 (307 mg, 0.545 mmol) in toluene/MeOH (3:1, 8 mL) at 0 
ºC was added trimethylsilyldiazomethane (2.0 M in hexane, 409 µL, 0.818 mmol) 
dropwise. The mixture was stirred for 1 h at room temperature and quenched by the 
addition of 3 N HCl (100 µL). The solvent was removed in vacuo and the residue 
partitioned between H2O (30 mL) and EtOAc (30 mL). The aqueous phase was 
extracted with EtOAc (30 mL × 2) and the combined organic layers were dried and 
evaporated to dryness in vacuo to furnish 34 (300 mg, 0.520 mmol, 95%) as an off 
white solid. 
Rf 0.31 (20% Et2O/Petrol); νmax (thin film)/cm-1 1724s, 1421m, 1207s, 998s; δH (400 
MHz, CDCl3) 7.52-7.49 (2H, m, H-10'/14'), 7.41-7.31 (6H, m, Ph-H), 7.23-7.21 (2H, 
m, Ph-H), 7.20 (1H, s, H-5), 5.26 (2H, s, H-1'), 4.97 (2H, s, H-8'), 3.92 (2H, s, H-7), 
3.89 (3H, s, H-11), 3.72 (3H, s, H-10); δC (100 MHz, CDCl3) 163.6 (C-9), 154.2 (C-
1), 153.8 (C-3), 149.9 (C-8), 136.5 (C-9'), 135.9 (C-2'), 132.0 (C-5), 128.6 (C-6), 
128.5 (Ph-C), 128.33 (Ph-C), 128.27 (C-5' or C-12'), 128.2 (Ph-C), 128.1 (C-5' or C-
12'), 127.8 (Ph-C), 114.4 (C-4), 112.7 (C-2), 78.0 (C-1'), 74.4 (C-8'), 60.5 (C-11), 
52.8 (C-10), 26.4 (C-7); m/z (ESI+) found 576.0048, [M+H]+ C25H24Br2NO5 (79Br) 
requires 576.0021; m.p. 97-99 ºC (lit.,26 97-99 ºC). 
Consistent with literature data.17 
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(E)-Methyl-3-(3,5-dibromo-2-hydroxy-4-methoxyphenyl)-2-
(hydroxyimino)propanoate (35) 
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A mixture of 34 (100 mg, 0.173 mmol) and palladium black (18 mg, 0.169 mmol) in 
dioxane/AcOH (1:1, 2.46 mL) was stirred under an H2 atmosphere for 3 h. The 
mixture was filtered through a pad of celite and the solvent removed in vacuo. The 
residue was taken up in EtOAc (15 mL), washed with water (15 mL) dried, and 
concentrated in vacuo. The residue was purified by flash column chromatography 
(25% EtOAc/Hexanes) to furnish 35 (63 mg, 0.159 mmol, 93%) as a white solid. 
Rf 0.37 (30% EtOAc/Hexanes); νmax (thin film)/cm-1 3267br, 1730s, 1593w, 1015s; δH 
(400 MHz, CDCl3) 7.40 (1H, s, H-5), 3.92 (2H, s, H-7), 3.90 (3H, s, H-11), 3.85 (3H, 
s, H-10); δC (100 MHz, CDCl3) 164.4 (C-9), 153.8 (C-3), 151.5 (C-1), 149.9 (C-8), 
133.4 (C-5), 119.4 (C-4), 107.6 (C-2), 60.5 (C-11), 53.4 (C-10), 25.5 (C-7); m/z 
(ESI+) found 395.9100, [M+H]+ C11H12Br2NO5 (79Br) requires 395.9082; m.p. 148-
150 ºC (lit.,26 150-152 ºC). 
The 13C chemical shift for C-6 is not visible, however, this is consistent with literature 
data.25  
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Methyl 7,9-dibromo-8-methoxy-10-oxo-1-oxa-2-azaspiro[4.5]deca-2,6,8-triene-3-
carboxylate (36) 
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To a stirred solution of 35 (397 mg, 1.00 mmol) in MeCN (45 mL) at 0 ºC was added 
iodobenzene diacetate (354 mg, 1.10 mmol). After 2 h, H2O (50 mL) was added and 
the mixture stirred for a further 10 min at room temperature. The mixture was 
extracted with CH2Cl2 (200 mL × 2) and the combined organic extracts were dried 
and evaporated to dryness in vacuo to furnish (±)-36 as an orange oil (523 mg) which 
was used without further purification. 
For characterisation purposes, a sample was purified by flash column chromatography 
(10-40% EtOAc/Hexane) to furnish (±)-36 as a white solid. 
Rf 0.62 (40% EtOAc/Hexanes); νmax (thin film)/cm-1 1725s, 1679m, 1239s, 732s; δH 
(400 MHz, CDCl3) 6.77 (1H, s, H-5), 4.18 (3H, s, H-10), 3.91 (3H, s, H-11), 3.62 
(1H, d, J 17.8 Hz, H-7a), 3.29 (1H, d, J 17.8 Hz, H-7b); δC (100 MHz, CDCl3) 188.6 
(C-1), 163.2 (C-9), 159.6 (C-3), 149.9 (C-8), 135.9 (C-5), 120.9 (C-4), 106.7 (C-2), 
86.8 (C-6), 62.1 (C-11), 53.1 (C-10), 44.4 (C-7). 
Consistent with literature data.18 
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Methyl 7,9-dibromo-10-hydroxy-8-methoxy-1-oxa-2-azaspiro[4.5]deca-2,6,8-
triene-3-carboxylate (21) 
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To a stirred solution of crude (±)-36 (523 mg) in CH2Cl2 (5 mL) at room temperature 
was added a freshly prepared solution of Zn(BH4)228 (0.21 M in Et2O, 1.73 mL, 0.363 
mmol). After 10 min, H2O (0.4 mL) was added and the mixture stirred for a further 20 
min. Following the addition of anhydrous MgSO4, the mixture was filtered and 
concentrated in vacuo. The residue was purified by careful flash column 
chromatography (10-20% EtOAc/Petrol) to furnish (±)-21 (127 mg, 0.320 mmol, 32% 
over 2 steps) and (±)-21a (64 mg, 0.161 mmol, 16% over 2 steps from 35) as pale 
yellow oils.  
(5S*,10R*)-Methyl 7,9-dibromo-10-hydroxy-8-methoxy-1-oxa-2- 
azaspiro[4.5]deca-2,6,8-triene-3-carboxylate (21) 
Rf 0.53 (40% EtOAc/Petrol); νmax (thin film)/cm-1 3370br, 2958w, 1732s, 1604m, 
1578m, 1431m, 1268s; δH (400 MHz, (CD3)2CO) 6.51 (1H, s, H-5), 5.38 (1H, d, J 8.1 
Hz, OH), 4.22 (1H, d, J 8.1 Hz, H-1), 3.84 (1H, d, J 18.2 Hz, H-7a), 3.83 (3H, s, H-
11), 3.73 (3H, s, H-10), 3.21 (1H, d, J 18.2 Hz, H-7b); δC (100 MHz, (CD3)2CO) 
161.1 (C-9), 152.4 (C-8), 148.7 (C-3), 132.0 (C-5), 122.1 (C-4), 113.7 (C-2), 92.4 (C-
6), 75.1 (C-1), 60.2 (C-11), 52.8 (C-10), 39.9 (C-7); m.p. 134-136 ºC; m/z (ESI+) 
found 395.9099, [M+H]+ C11H12Br2NO5 (79Br) requires 395.9082. 
Consistent with literature data.23 
Crystals of (±)-21 were obtained by slow evaporation of Et2O. The structure was 
confirmed by X-ray crystallographic analysis and given the unique identifier sl1040. 
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The enantiomers were separated using preparative chiral HPLC (CHIRALPAK 
AD-H column and 4% iPrOH in hexane at a flow rate of 5 mL/min). Retention 
times: (+)-21 = 30.9 min; (–)-21 = 32.9 min. 
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(+)-21 [α]D27.9 +165.5 (c 0.325, C6H6)             (–)-21   [α]D27.9 –150.9 (c 0.43, C6H6) 
     {lit. [α]D26 +217.1 (c 1.0, C6H6)}                      {lit. [α]D26 –210.3 (c 1.0, C6H6)} 
(5S*,10S*)-Methyl 7,9-dibromo-10-hydroxy-8-methoxy-1-oxa-2-
azaspiro[4.5]deca-2,6,8-triene-3-carboxylate (21a)  
Rf 0.47 (40% EtOAc/Petrol); νmax (thin film)/cm-1 3433br, 2938w, 1725s, 1597m, 
1575m, 1441s, 1248s; δH (400 MHz, (CD3)2CO) 6.61 (1H, s, H-5), 5.00 (1H, d, J 8.5 
Hz, OH), 4.56 (1H, d, J 8.4 Hz, H-1), 3.82 (3H, s, H-11), 3.71 (3H, s, H-10), 3.48 
(1H, d, J 17.9 Hz, H-7a), 3.40 (1H, d, J 17.9 Hz, H-7b); δC (100 MHz, (CD3)2CO) 
161.2 (C-9), 152.3 (C-8), 148.4 (C-3), 132.8 (C-5), 121.1 (C-4), 115.5 (C-2), 91.4 (C-
6), 75.2 (C-1), 60.1 (C-11), 52.8 (C-10), 43.3 (C-7); m.p. 125-127 ºC; m/z (ESI+) 
found 395.9073, [M+H]+ C11H12Br2NO5 (79Br) requires 395.9082. 
Consistent with literature data.23 
Crystals of (±)-21a were obtained by slow evaporation of Et2O. The structure was 
confirmed by X-ray crystallographic analysis and given the unique identifier sl1041. 
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(5S,10R)-Methyl 7,9-dibromo-8-methoxy-10-(((1R,4R)-4,7,7-trimethyl-3-oxo-2-
oxabicyclo[2.2.1]heptane-1-carbonyl)oxy)-1-oxa-2-azaspiro[4.5]deca-2,6,8-triene-
3-carboxylate (25a) 
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To a stirred solution of (+)-21 (9.20 mg, 23.2 µmol) in CH2Cl2 (2 mL) and DMAP 
(8.50 mg, 69.6 µmol) at 0 ºC was added a solution of (–)-camphanic chloride (10.1 
mg, 46.6 µmol) in CH2Cl2 (2 mL) dropwise. Upon warming to room temperature the 
mixture was stirred for 18 h after which H2O (15 mL) was added. The organic layer 
was separated and the aqueous phase was extracted with CH2Cl2 (20 mL × 2) The 
combined organic layers were dried and concentrated in vacuo. The residue was 
purified by flash column chromatography (25% EtOAc/Petrol) to furnish 25a (5.1 mg, 
8.84 µmol, 38%) as a colourless oil. 
Rf 0.50 (1% EtOAc/CH2Cl2, 2 elutions); νmax (thin film)/cm-1 2967w, 2936w, 1789s, 
1746s, 1728s, 1443m, 1259s, 1050s; δH (400 MHz, CDCl3) 6.40 (1H, s, H-5), 6.07 
(1H, s, H-1), 3.90 (3H, s, H-11), 3.77 (H-10), 3.60 (1H, d, J 18.2 Hz, H-7a), 3.05 (1H, 
d, J 18.2 Hz, H-7b), 2.48-2.41 (1H, m, camph CH2), 2.09-2.02 (1H, m, camph CH2), 
1.96-1.89 (1H, m, camph CH2), 1.70-1.64 (1H, m, camph CH2), 1.11 (3H, s, camph 
CH3), 1.04 (3H, s, camph CH3), 1.02 (3H, s, camph CH3); δc (100 MHz, CDCl3) 
177.7, 166.5, 159.9, 151.6, 150.1, 130.6, 121.2, 106.8, 90.8, 74.8, 60.3, 60.3, 55.0, 
54.6, 53.1, 39.5, 31.0, 28.8, 16.9, 16.6, 9.7; m/z (ESI+) found 575.9890, [M+H]+ 
C21H24Br2NO8 (79Br) requires 575.9869. 
Consistent with literature data.19 
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(5R,10S)-Methyl 7,9-dibromo-8-methoxy-10-(((1R,4R)-4,7,7-trimethyl-3-oxo-2-
oxabicyclo[2.2.1]heptane-1-carbonyl)oxy)-1-oxa-2-azaspiro[4.5]deca-2,6,8-triene-
3-carboxylate (25b) 
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To a stirred solution of (–)-21 (6.00 mg, 15.1 µmol) in CH2Cl2 (2 mL) and DMAP 
(5.50 mg, 45.0 µmol) at 0 ºC was added a solution of (–)-camphanic chloride 
(6.50 mg, 30.0 µmol) in CH2Cl2 (2 mL) dropwise. Upon warming to room 
temperature the mixture was stirred for 18 h after which H2O (15 mL) was added. The 
organic layer was separated and the aqueous phase was extracted with CH2Cl2 (20 mL 
× 2) The combined organic layers were dried and concentrated in vacuo. The residue 
was purified by flash column chromatography (25% EtOAc/Petrol) to furnish 25b 
(4.00 mg, 6.93 µmol, 46%) as a colourless oil. 
Rf 0.45 (1% EtOAc/CH2Cl2, 2 elutions); νmax (thin film)/cm-1 2966w, 2937w, 1790s, 
1748s, 1728s, 1443m, 1258s, 1051s; δH (400 MHz, CDCl3) 6.42 (1H, s, H-5), 6.12 
(1H, s, H-1), 3.90 (3H, s, H-11), 3.77 (H-10), 3.67 (1H, d, J 18.2 Hz, H-7a), 3.03 (1H, 
d, J 18.2 Hz, H-7b), 2.41-2.34 (1H, m, camph CH2), 2.15-2.08 (1H, m, camph CH2), 
1.97-1.90 (1H, m, camph CH2), 1.74-1.68 (1H, m, camph CH2), 1.11 (3H, s, camph 
CH3), 1.09 (3H, s, camph CH3), 0.97 (3H, s, camph CH3); δc (125 MHz, CDCl3) 
177.5, 166.3, 159.8, 151.5, 149.8, 130.8, 120.7, 107.2, 90.9, 74.3, 60.4, 60.3, 54.8, 
54.5, 53.2, 39.2, 31.3, 29.0, 16.7, 16.5, 9.6; m/z (ESI+) found 575.9879, [M+H]+ 
C21H24Br2NO8 (79Br) requires 575.9869. 
Consistent with literature data.19  
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(5S*,10R*)-7,9-Dibromo-10-hydroxy-8-methoxy-1-oxa-2-azaspiro[4.5]deca-2,6,8-
triene-3-carboxylic acid (18) 
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To a solution of (±)-21 (100 mg, 0.252 mmol) in H2O/MeOH (1:3, 15 ml) was added 
lithium hydroxide monohydrate (32.0 mg, 0.763 mmol). After 70 min 3 N HCl (1.5 
mL) was added followed by H2O (25 mL). The mixture was extracted with EtOAc (25 
mL × 2) and the combined organic extracts were dried and evaporated to dryness in 
vacuo to furnish (±)-18 (96 mg, 0.251 mmol, quant.) as a light brown foam which was 
used without further purification 
νmax (thin film)/cm-1 3402br, 2978w, 2935w, 1709s, 1598m, 1431m, 1255s; δH (600 
MHz, CD3OD) 6.43 (1H, s, H-5), 4.11 (1H, s, H-1) 3.75 (1H, d, J 18.3 Hz, H-7a), 
3.73 (3H, s, H-10) 3.10 (1H, d, J 18.3 Hz, H-7b); δC (150 MHz, CD3OD) 162.6 (C-9), 
153.8 (C-3), 149.3 (C-8), 132.2 (C-5), 122.8 (C-4), 114.1 (C-2), 93.1 (C-6), 75.5 (C-
1), 60.4 (C-10), 43.3 (C-7).  
Consistent with literature data.17 
The enantiopure esters (+)-21 and (–)-21 were converted to the corresponding 
enantiopure acids (+)-18 and (–)-18 by the procedure described above.  
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  (+)-18 [α]D27.5 +44.0 (c 0.42, CHCl3)               (–)-18 [α]D28.1 –31.3 (c 0.84, CHCl3) 
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Ethyl phenyl carbonate (39) 
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Phenol (94.0 mg, 1.00 mmol), diethylpyrocarbonate (174 µL, 1.18 mmol) and 
magnesium perchlorate (22.3 mg, 0.100 mmol) were heated at 40 ºC for 3 h. 
Following this, the mixture was partitioned between H2O (10 mL) and EtOAc (10 
mL). The organic layer was separated and the aqueous phase was extracted with 
EtOAc (3 × 10 mL). The combined organic layers were combined, dried and 
concentrated in vacuo. The residue was purified by flash column chromatography 
(5% Et2O/Petrol) to furnish 39 (163 mg, 0.981 mmol, 98%) as a colourless oil. 
Rf 0.35 (5% Et2O/Petrol); νmax (thin film)/cm-1 1756s, 1240s, 1203s, 1015s; δH (400 
MHz, CDCl3) δ 7.41-7.36 (2H, m, H-6/8), 7.26-7.17 (3H, m, H-5/9 and H-7), 4.32 
(2H, q, J 7.1 Hz, H-2), 1.39 (3H, t, J 7.1 Hz, H-1); δc (100 MHz, CDCl3) δ 153.6 (C-
3), 151.1 (C-4), 129.4 (C-6/8), 125.9 (C-7), 121.0 (C-5/9), 64.8 (C-2), 14.2 (C-1). 
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Ethyl (4-aminobutyl)carbamate (19) 
H2N
H
N O
O
1
7
 
To a stirred solution of butane-1,4-diamine (37) (943 mg, 10.7 mmol) in absolute 
EtOH (13 mL) at room temperature was added a solution of phenyl ethyl carbonate 
(39) (1.77 g, 10.7 mmol) in absolute EtOH (2 mL) dropwise. After 12 h, the mixture 
was concentrated in vacuo and the residue was taken up in H2O (25 mL) and acidified 
to pH 2-3 by the dropwise addition of 3 N HCl. The aqueous phase was washed with 
CH2Cl2 (50 mL × 3), basified by the addition of 10% aqueous sodium hydroxide 
solution and extracted with CH2Cl2 (50 mL × 3). The combined organic layers were 
dried and evaporated to dryness in vacuo to furnish 19 (1.36 g, 8.49 mmol, 79%) as a 
pale yellow oil. 
Rf 0.10 (12% MeOH/CH2Cl2); νmax (thin film)/cm-1 3328w, 2954w, 1683s, 1531s; δH 
(400 MHz, CDCl3) 4.96 (1H, br, NH), 4.09 (2H, q, J 6.8 Hz, H-2), 3.16 (2H, br, H-4), 
2.71 (2H, t, J 6.7 Hz, H-7), 1.57-1.43 (4H, m, H-5 and H-6), 1.22 (3H, t, J 7.0 Hz, H-
1), 1.03 (2H, br, NH2); δC (125 MHz, CDCl3) 156.6 (C-3), 60.4 (C-2), 41.7 (C-7), 
40.6 (C-4), 30.7 (C-6), 27.3 (C-5), 14.5 (C-1); m/z (ESI+) found 161.1287, [M+H]+ 
C7H17N2O2 requires 161.1285. 
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Ethyl (5-aminopentyl)carbamate (20) 
H
N O
O
1
8
H2N
 
To a stirred solution of pentane-1,5-diamine (38) (2.19 mL, 18.7 mmol) in absolute 
EtOH (70 mL) at room temperature was added phenyl ethyl carbonate (39) (3.10 g, 
18.7 mmol) in absolute EtOH (5 mL) dropwise. After 12 h the mixture was 
concentrated in vacuo and the residue was taken up in H2O (50 mL) and acidified to 
pH 2-3 by the dropwise addition of 3 N HCl. The aqueous phase was washed with 
CH2Cl2 (100 mL × 3), basified by the addition of 10% aqueous sodium hydroxide 
solution and extracted with CH2Cl2 (100 mL × 3). The combined organic layers were 
dried and evaporated to dryness in vacuo to furnish 20 (2.67 g, 15.3 mmol, 82%) as a 
pale yellow oil. 
Rf 0.11 (12% MeOH/CH2Cl2); νmax (thin film)/cm-1 3316w, 2932w, 1690s, 1540s, 
1255s; δH (400 MHz, CDCl3) 4.99 (1H, br, NH), 4.01 (2H, q, J 7.0 Hz, H-2), 3.07 
(2H, apparent q, J 6.5 Hz, H-4), 2.60 (2H, t, J 6.9 Hz, H-8), 1.46-1.34 (4H, m, H-5 
and H-7), 1.27-1.24 (2H, m, H-6), 1.22 (2H, br, NH2), 1.14 (3H, t, J 7.0 Hz, H-1); δC 
(100 MHz, CDCl3) 156.6 (C-3), 60.3 (C-2), 41.8 (C-8), 40.6 (C-4), 33.1 (C-7), 29.7 
(C-5), 23.8 (C-6), 14.5 (C-1); m/z (ESI+) found 175.1447, [M+H]+ C8H19N2O2, 
requires 175.1440. 
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General Procedures for coupling acid 18 to amines 19 and 20 
Procedure 1 
To a stirred solution of (±)-18 (1 eq.) and HOBt (1.3 eq.) in CH2Cl2 (10 mL per 0.1 
mmol substrate) at 0 ºC was added a solution of DCC (1.3 eq.) in CH2Cl2 (1 mL per 
0.1 mmol DCC). After 10 min, a solution of amine (1.3 eq.) in CH2Cl2 (2 mL per 0.1 
mmol amine) was added in one portion and the mixture was stirred at room 
temperature. After 18 h, H2O and CH2Cl2 were added and the organic phase 
separated. The aqueous layer was extracted with CH2Cl2 (× 2) and the combined 
organic layers were dried and concentrated in vacuo. The residue was purified by 
flash column chromatography.  
Procedure 2 
To a stirred solution of (±)-18 (1 eq.), amine (1 eq.) and iPr2EtN (2.5 eq.) in CH2Cl2 
(5 mL per 0.1 mmol substrate) at 0 ºC was added ®T3P (1.2 eq. of a 50% w/w 
solution in EtOAc) dropwise. After 2 h, H2O and CH2Cl2 were added and the organic 
phase separated. The aqueous layer was extracted with CH2Cl2 (× 2) and the 
combined organic layers were dried and concentrated in vacuo. The residue was 
purified by flash column chromatography. 
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Ethyl (4-((5S,10R)-7,9-dibromo-10-hydroxy-8-methoxy-1-oxa-2-
azaspiro[4.5]deca-2,6,8-triene-3-carboxamido)butyl)carbamate (16). 
Subereamolline A.  
OMe
OH
BrBr
1
5
10
O
N
7
H
N
O
N
H
O
O
9
16
17
 
Procedure 1: Purified by flash column chromatography (20-60% EtOAc/Petrol) to 
furnish (±)-subereamolline A (16) (31.3 mg, 59.6 µmol, 91%) as a colourless oil. 
Procedure 2: Purified by flash column chromatography (40-60% EtOAc/Petrol) to 
furnish (±)-subereamolline A (16) (58.0 mg, 0.110 mmol, 96%) as a colourless oil. 
Rf 0.42 (60% EtOAc/Petrol); νmax (thin film)/cm-1 3330br, 2936w, 1658s, 1536m, 
1438m, 1260m; δH (500 MHz, CD3OD) 6.42 (1H, s, H-5), 4.08 (1H, s, H-1), 4.05 
(2H, q, J 7.1 Hz, H-15), 3.77 (1H, d, J 18.3 Hz, H-7a), 3.73 (3H, s, H-17), 3.29 (2H, t, 
J 6.9 Hz, H-10), 3.11 (2H, t, J 6.7 Hz, H-13), 3.10 (1H, d, J 18.1 Hz, H-7b), 1.60-1.49 
(4H, m, H-11 and H-12), 1.22 (3H, t, J 7.1 Hz, H-16); δC (125 MHz, CD3OD) 161.5 
(C-9), 159.2 (C-14), 155.3 (C-8), 149.3 (C-3), 132.3 (C-5), 122.7 (C-4), 114.1 (C-2), 
92.3 (C-6), 75.5 (C-1), 61.6 (C-15), 60.4 (C-17), 41.2 (C-13), 40.2 (C-7), 40.1 (C-10), 
28.3 (C-12), 27.6 (C-11), 15.0 (C-16); m/z (ESI+) found 545.9872, [M+Na]+ 
C17H23Br2N3O6Na (79Br) requires 545.9851. 
The enantiomers were separated using preparative chiral HPLC (CHIRALPAK 
AD-H column and 10% iPrOH in hexane at a flow rate of 5 mL/min). Retention 
times: (+)-16 = 40.3 min; (–)-16 = 43.6 min 
 
OMe
OH
BrBr
O
N
H
N
O
N
H
O
O
                             
OMe
OH
BrBr
O
N
H
N
O
N
H
O
O
 
(+)-16 [α]D27.5 +83.9 (c 0.475, MeOH)               (–)-16 [α]D27.5 –94.3 (c 0.485, MeOH) 
  {lit. [α]D +156.5 (c 0.55, MeOH)}                          
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Ethyl (5-((5S,10R)-7,9-dibromo-10-hydroxy-8-methoxy-1-oxa-2-
azaspiro[4.5]deca-2,6,8-triene-3-carboxamido)pentyl)carbamate (17). 
Subereamolline B. 
OMe
OH
BrBr
O
N
H
N
O
H
N O
O
1
5
10
7
9
17
18
 
Procedure 1: Purified by flash column chromatography (20-60% EtOAc/Petrol) to 
furnish (±)-subereamolline B (17) (18.0 mg, 33.4 µmol, 75%) as a colourless oil. 
Procedure 2: Purified by flash column chromatography (40-60% EtOAc/Petrol) to 
furnish (±)-subereamolline B (17) (70.0 mg, 0.130 mmol, 97%) as a colourless oil. 
Rf 0.45 (60% EtOAc/Petrol); νmax (thin film)/cm-1 3349br, 2934w, 1663s, 1536s, 
1439m, 1260m; δH (500 MHz, CD3OD) 6.42 (1H, s, H-5), 4.08 (1H, s, H-1), 4.05 
(2H, q, J 7.1 Hz, H-16), 3.77 (1H, d, J 18.3 Hz, H-7a), 3.73 (3H, s, H-18), 3.28 (2H, t, 
J 7.1 Hz, H-10), 3.10-3.07 (2H, m, H-14), 3.09 (1H, hidden d, J 18.5 Hz, H-7b), 1.60-
1.54 (2H, m, H-11), 1.54-1.48 (2H, m, H-13), 1.39-1.33 (2H, m, H-12), 1.22 (3H, t, J 
7.1 Hz, H-17); δC (125 MHz, CD3OD) 161.5 (C-9), 159.2 (C-15), 155.3 (C-8), 149.3 
(C-3), 132.3 (C-5), 122.7 (C-4), 114.1 (C-2), 92.3 (C-6), 75.5 (C-1), 61.6 (C-16), 60.4 
(C-18), 41.5 (C-14), 40.3 (C-7), 40.2 (C-10), 30.6 (C-13), 30.0 (C-11), 25.1 (C-12), 
15.0 (C-17); m/z (ESI+) found 560.0029, [M+Na]+ C18H25Br2N3O6Na (79Br) requires 
560.0008. 
The enantiomers were separated using preparative chiral HPLC (CHIRALPAK 
AD-H column and 10% iPrOH in hexane at a flow rate of 5 mL/min). Retention 
times: (+)-17 = 48.3 min; (–)-17 = 52.9 min 
   
OMe
OH
BrBr
O
N
H
N
O
H
N O
O                      
OMe
OH
BrBr
O
N
H
N
O
H
N O
O  
(+)-17 [α]D27.7 +55.4 (c 0.33, CH2Cl2)             (–)-17 [α]D27.6 –50.0 (c 0.29, CH2Cl2) 
  {lit. [α]D +22.9 (c 6.25, CH2Cl2)} 
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(5S*,10R*)-N-(2-(1H-Imidazol-5-yl)ethyl)-7,9-dibromo-10-hydroxy-8-methoxy-1-
oxa-2-azaspiro[4.5]deca-2,6,8-triene-3-carboxamide (40).  
(±)-Aerophobin-1.  
OMe
OH
BrBr
1
5
10
O
N
7
H
N
O
9
15
HN
N
13
 
To a stirred solution of (±)-18 (49.0 mg, 0.128 mmol), histamine dihydrochloride 
(23.6 mg, 0.128 mmol), iPr2EtN (100 µL, 0.581 mmol) in CH2Cl2 (1.2 mL) at 0 ºC 
was added ®T3P (190 µL of a 50% w/w solution in EtOAc, 0.320 mmol). After 2 h, 
H2O (10 mL) and CH2Cl2 (10 mL) were added. The organic layer was separated, the 
aqueous layer extracted with CH2Cl2 (2 × 10 mL) and the combined organic extracts 
were dried and concentrated in vacuo. The residue was purified by flash column 
chromatography (5-10% MeOH/CH2Cl2) to furnish 40 (12.2 mg, 25.6 µmol, 20%) as 
a colourless oil.  
Rf 0.26 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 3244br, 2922w, 2851w, 1658s, 
1540s; δH (600 MHz, CD3OD) 7.67 (1H, s, H-14), 6.90 (1H, s, H-13), 6.43 (1H, s, H-
5), 4.06 (1H, s, H-1), 3.76 (1H, d, J 18.2 Hz, H-7a), 3.72 (3H, s, H-15), 3.52 (2H, t, J 
7.2 Hz, H-10), 3.09 (1H, d, J 18.2 Hz, H-7b), 2.83 (2H, t, J 7.2 Hz, H-11); δC (150 
MHz, CD3OD) 161.5 (C-9), 155.2 (C-8), 149.3 (C-3), 136.1 (C-14), 134.7 (C-12), 
132.2 (C-5), 122.8 (C-4), 117.6 (br, C-13), 114.2 (C-2), 92.3 (C-6), 75.5 (C-1), 60.4 
(C-15), 40.4 (C-10), 40.1 (C-7), 27.6 (C-11); m/z (ESI+) found 474.9625, [M+H]+ 
C15H17Br2N4O4 (79Br) requires 474.9617. 
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(5S*,10R*)-7,9-Dibromo-N-(3,5-dibromo-4-hydroxyphenethyl)-10-hydroxy-8-
methoxy-1-oxa-2-azaspiro[4.5]deca-2,6,8-triene-3-carboxamide (41) 
OMe
OH
BrBr
1
5
10
O
N
7
H
N
O
9
16
Br
Br
OH15
 
To a stirred solution of (±)-18 (52.0 mg, 0.136 mmol), 4-(2-aminoethyl)-2,6-
dibromophenol hydrobromide (61.3 mg, 0.163 mmol) and iPr2EtN (104 µL, 0.604 
mmol) in CH2Cl2 (4 mL) at 0 ºC was added ®T3P (105 µL of a 50% w/w solution in 
EtOAc, 0.177 mmol) dropwise. After 18 h H2O (10 mL) and EtOAc (10 mL) were 
added and the organic phase separated. The aqueous layer was extracted with EtOAc 
(10 mL × 2) and the combined organic layers were dried and concentrated in vacuo. 
The residue was purified by flash column chromatography (40-70% EtOAc/Petrol) to 
furnish 41 (9.7 mg, 14.7 µmol, 11 %) as a colourless oil 
Rf 0.23 (30% EtOAc/Petrol); νmax (thin film)/cm-1 3330br, 2927m, 2852w, 1655s, 
1595m, 1541s, 1475s, 735s; δH (500 MHz, CD3OD) 7.36 (2H, s, H-13/17), 6.41 (1H, 
s, H-5), 4.09 (1H, s, H-1), 3.76 (1H, d, J 18.3 Hz, H-7a), 3.73 (3H, s, H-16), 3.45 (2H, 
t, J 7.2 Hz, H-10), 3.06 (1H, d, J 18.3 Hz, H-7b), 2.74 (2H, t, J 7.2 Hz, H-11); δC (125 
MHz, CD3OD) 161.5 (C-9), 155.2 (C-8), 150.9 (C-15), 149.3 (C-3), 134.4 (C-12), 
133.7 (C-13/17), 132.2 (C-5), 122.8 (C-4), 114.2 (C-2), 112.2 (C-14/16), 92.4 (C-6), 
75.5 (C-1), 60.4 (C-16), 41.8 (C-10), 40.1 (C-7), 34.8 (C-11); m/z (ESI+) found 
656.7902, [M+H]+ C18H17Br4N2O5 (79Br) requires 656.7871. 
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3.6 Biology: Experimental 
Refer to Section 2.1.6 for experimental details. 
3.7 Appendix 
3.7.1 NMR Data of Natural Products 
18 
17 
16 
15 
14 
13 
12 
11 
10 
9 8 7 6 5 4 3 2 1 
A
tom
 
– 
60.4 
15.1 
61.7 
160.0 
41.3 
28.4 
27.7 
40.2 
161.1 
155.4 
40.3 
92.4 
132.4 
114.3 
149.4 
122.9 
75.6 
N
at. 16 
13C
 
75 M
H
z 
– 
60.4 
15.0 
61.6 
159.2 
41.2 
28.3 
27.6 
40.1 
161.5 
155.3 
40.2 
92.3 
132.3 
122.7 
149.3 
114.1 
75.5 
Syn. 16 
13C
 
125 M
H
z 
– 
3.72 s 
1.22 q 
4.04 q 
– 
3.11 m
 
1.54 m
 
1.54 m
 
3.30 m
 
– – 
3.77 d 
3.09 d 
– 
6.42 s 
– – – 
4.07 s 
N
at. 16 
1H
 
300 M
H
z 
– 
3.73 s 
1.22 t 
4.05 q 
– 
3.11 t 
1.60-1.49 m
 
1.60-1.49 m
 
3.29 t 
– – 
3.77 d 
3.10 d 
– 
6.42 s 
– – – 
4.08 s 
Syn. 16 
1H
 
500 M
H
z 
60.5 
15.1 
61.7 
159.0 
41.6 
30.7 
25.2 
30.1 
40.3 
161.6 
155.4 
40.4 
92.4 
132.4 
114.3 
149.4 
122.9 
75.6 
N
at. 17 
13C
 
75 M
H
z 
60.4 
15.0 
61.6 
159.2 
41.5 
30.6 
25.1 
30.0 
40.2 
161.5 
155.3 
40.3 
92.4 
132.3 
122.7 
149.3 
114.1 
75.5 
Syn. 17 
13C
 
125 M
H
z 
3.72 s 
1.22 t 
4.03 q 
– 
3.08 m
 
1.53 m
 
1.36 m
 
1.53 m
 
3.30 m
 
– – 
3.77 d 
3.09 d 
– 
6.40 s 
– – – 
4.06 s 
N
at. 17 
1H
 
300 M
H
z 
3.73 s 
1.22 t 
4.05 q 
– 
3.10-3.07 m
 
1.54-1.48 m
 
1.39-1.33 m
 
1.54 m
 
3.28 t 
– – 
3.77 d 
3.09 d 
– 
6.42 s 
– – – 
4.08 s 
Syn. 17 
1H
 
500 M
H
z 
Table 9 Comparison of the NMR data (CD3OD) of natural and synthetic subereamolline A 
(16) and (17).1 Discrepancies in the original assignment are highlighted in bold.  
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3.7.2 NMR Spectra of Natural Products 
1H NMR (CD3OD 300 MHz) spectrum of subereamolline A (natural material) 
 
 
 
1H NMR (CD3OD 500 MHz) spectrum of subereamolline A (synthetic material) 
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13C NMR (CD3OD 75 MHz) spectrum of subereamolline A (natural material) 
 
 
 
13C NMR (CD3OD 125 MHz) spectrum of subereamolline A (synthetic material) 
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1H NMR (CD3OD 300 MHz) spectrum of subereamolline B (natural material) 
 
 
 
1H NMR (CD3OD 500 MHz) spectrum of subereamolline A (synthetic material) 
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13C NMR (CD3OD 75 MHz) spectrum of subereamolline B (natural material) 
 
 
 
13C NMR (CD3OD 125 MHz) spectrum of subereamolline B (synthetic material) 
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1H NMR (CD3OD 500 MHz) spectrum of 41 
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13C NMR (CD3OD 125 MHz) spectrum of 41  
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1H NMR (CD3OD 600 MHz) spectrum of aerophobin-1 (synthetic material) 
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1H NMR (CD3OD 150 MHz) spectrum of aerophobin-1 (synthetic material) 
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3.7.3 Analytical Chiral HPLC Traces 
The following HPLC analyses were performed on an analytical CHIRALPAK AD-H 
column. Conditions: 10% iPrOH in hexane at a flow rate of 1 mL/min. 
 
Trace for (±)-16 
 
 
Trace for (+)-16 synthesised from (+)-18 
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Trace for (±)-17 
 
 
 
Trace for (–)-17 synthesised from (–)-18 
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3.7.4 Crystal Structure Data 
6,8-Dibromo-3-hydroxy-7-methoxy-2H-chromen-2-one (32) 
 
Crystal data and structure refinement for sl1037 
  
Identification code    sl1037 
Empirical formula    C10H6Br2O4 
Formula weight    349.97 
Temperature     250(2) K 
Wavelength     0.71073 Å 
Crystal system    Orthorhombic 
Space group     Pna2(1) 
Unit cell dimensions    a = 8.9710(2) Å α = 90º 
     b = 10.6189(2) Å β = 90º 
      c  = 22.6185(6) Å γ = 90º 
Volume     2154.69(8) Å3 
Z      8 
Density (calculated)    2.158 Mg/m3 
Absorption coefficient   7.518 mm–1 
F(000)      1344 
Crystal size     0.28 × 0.05 × 0.05 mm3 
Theta range for data collection  2.12 to 27.47º 
Index ranges     -11<=h<=11, -12<=k<=13, -18<=1<=28 
Reflections collected    11137 
Independent reflections   2504 [R(int) = 0.0477] 
Completeness to theta = 27.47º  98.9% 
Absorption correction    Semi-empirical from equivalents 
Max. and min. transmission   0.734 and 0.464 
Refinement method    Full-matrix least-squares on F2 
Data / restraints / parameters   2504 / 1 / 291 
Goodness-of-fit on F2    1.074 
Final R indices [I>2sigma (I)]  R1 = 0.0462, wR2 = 0.1169 
R indices (all data)    R1 = 0.0587, wR2 = 0.1354  
Largest diff. peak and hole   1.430 and –0.968 e. Å–3 
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(5S*,10R*)-Methyl 7,9-dibromo-10-hydroxy-8-methoxy-1-oxa-2-
azaspiro[4.5]deca-2,6,8-triene-3-carboxylate (21) 
 
Crystal data and structure refinement for sl1040 
  
Identification code    sl1040 
Empirical formula    C11H11Br2NO5 
Formula weight    397.03 
Temperature     180(2) K 
Wavelength     0.71073 Å 
Crystal system    Triclinic 
Space group     P-1 
Unit cell dimensions    a = 6.5189(1) Å α = 65.732(1)º 
     b = 10.7194(2) Å β = 77.573(1)º 
      c  = 11.0482(2) Å γ = 80.693º 
Volume     684.99(2) Å3 
Z      2 
Density (calculated)    1.925 Mg/m3 
Absorption coefficient   5.932 mm–1 
F(000)      388 
Crystal size     0.21 × 0.12 × 0.07 mm3 
Theta range for data collection  3.51 to 33.74º 
Index ranges     -10<=h<=10, -16<=k<=16, -17<=1<=17 
Reflections collected    12983 
Independent reflections   5457 [R(int) = 0.0494] 
Completeness to theta = 33.74º  99.4% 
Absorption correction    Semi-empirical from equivalents 
Max. and min. transmission   0.663 and 0.447 
Refinement method    Full-matrix least-squares on F2 
Data / restraints / parameters   5457 / 0 / 177 
Goodness-of-fit on F2    1.010 
Final R indices [I>2sigma (I)]  R1 = 0.0379, wR2 = 0.0876 
R indices (all data)    R1 = 0.0590, wR2 = 0.0972  
Largest diff. peak and hole   0.590 and –1.088 e. Å–3 
 
Chapter 3: Total Syntheses of Subereamollines A and B 
 205 
(5S*,10S*)-Methyl 7,9-dibromo-10-hydroxy-8-methoxy-1-oxa-2-
azaspiro[4.5]deca-2,6,8-triene-3-carboxylate (21a) 
 
Crystal data and structure refinement for sl1041 
  
Identification code    sl1041 
Empirical formula    C11H11Br2NO5 
Formula weight    397.03 
Temperature     180(2) K 
Wavelength     0.71073 Å 
Crystal system    Monoclinic 
Space group     P-2(1)/c 
Unit cell dimensions    a = 10.9772(1) Å α = 90º 
     b = 25.2605(3) Å β = 104.60(3)º 
      c  = 10.1567(2) Å γ = 90º 
Volume     2725.4(3) Å3 
Z      8 
Density (calculated)    1.935 Mg/m3 
Absorption coefficient   5.963 mm–1 
F(000)      1552 
Crystal size     0.23 × 0.12 × 0.05 mm3 
Theta range for data collection  3.55 to 30.97º 
Index ranges     -15<=h<=15, -36<=k<=36, -14<=1<=14 
Reflections collected    30388 
Independent reflections   8610 [R(int) = 0.0660] 
Completeness to theta = 30.97º  99.3% 
Absorption correction    Semi-empirical from equivalents 
Max. and min. transmission   0.737 and 0.400 
Refinement method    Full-matrix least-squares on F2 
Data / restraints / parameters   8610 / 0 / 347 
Goodness-of-fit on F2    1.014 
Final R indices [I>2sigma (I)]  R1 = 0.0471, wR2 = 0.0928 
R indices (all data)    R1 = 0.0937, wR2 = 0.1063  
Largest diff. peak and hole   0.988 and –0.631 e. Å–3 
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Compound Numbering 
In this chapter, the atoms of the ceratamines are numbered according to the system 
outlined by Andersen and co-workers (Figure 37).1 
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MeHN
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R = Me: 
R = H:
Br Br
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Figure 37 Atom labeling of ceratamine A and B. 
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4.1 Introduction 
Currently, total synthesis represents the only feasible method to obtain sufficient 
quantities of the ceratamines (Figure 38) for further biological evaluation because, 
due to their low abundance from the natural source, re-harvesting the reef organism 
would inevitably have a negative ecological impact on the environment. Embarking 
on a total synthesis also provides the opportunity to develop new synthetic methods 
towards the construction of these unique molecules. 
OMe
N
O
N
N
MeHN
R
R = Me: 
R = H:
Br Br
Ceratamine A (1)
Ceratamine B (2)  
Figure 38 Structure of Ceratamine A (1) and B (2). 
The unprecedented structures of 1 and 2 along with their novel biological activity 
have garnered interest within the scientific community. During the course of this 
project the Coleman group disclosed the total syntheses of ceratamines A and B, and 
the Andersen group described the preparation of several ceratamine analogues. This 
research is reviewed in Sections 4.1.2 and 4.1.3. 
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4.1.2 Andersen Group Approaches to the Ceratamines 
Andersen and co-workers have investigated synthetic strategies towards the 
ceratamines ever since they were identified as a potential lead structure for the 
development of a novel class of microtubule-stabilising agents. Ultimately, these 
synthetic investigations, while not providing access to the natural products, have 
produced synthetic analogues that have proved valuable in gaining insight into the 
ceratamine A pharmacophore. The details of this SAR study will be discussed in 
Section 4.1.4.  
4.1.2.1 First-Generation Approach 
The first-generation approach proposed by Andersen and co-workers was to construct 
the heterocyclic core of the ceratamines by appending the aminoimidazole moiety 
onto a functionalised azepine ring.2 If successful, it was envisaged that oxidation of 
the intermediate 10 (Scheme 46) would be favoured as the fully dehydrogenated core 
present in the natural products is thought to have an aromatic character.  
Initially, five steps were required to convert commercially available butenoic acid (3) 
to caprolactam 4 (Scheme 46). Treatment of 4 with NBS followed by opening of the 
bromonium ion with water gave bromohydrin 5 in 98% yield. At this stage, oxidation 
of 5 to the corresponding α-bromoketone was performed with either DMP or IBX to 
furnish bromoenamide 6 and the fully saturated 8, respectively. Disappointingly, all 
attempts to condense guanidine derivatives with 6 and 8 only gave the eliminated 
products 7 and 9, respectively, albeit in good yield. Eventually, it was possible to 
access 10 via an alternative route (not shown), however, difficulties associated with 
its purification and instability led to this strategy being abandoned. 
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Scheme 46 First-generation strategy by Andersen and co-workers. 
Reagents and conditions: (a) NBS, acetone/H2O (3:1), rt, 72 h, 98%; (b) DMP, CH2Cl2, rt, 
24 h, 98%; (c) IBX, DMSO, rt, 5 h, 84%; (d) guanidine HCl or acetylguanidine, DMF, rt, 
48 h, 7, 71%; 9, 87%. 
4.1.2.2 Second-Generation Approach  
In light of the problems surrounding the feasibility of grafting the aminoimidazole 
ring to a preformed azepine, the second-generation approach aimed to construct the 
azepine ring onto a pre-existing imidazole. It was envisaged that this could be 
achieved by the intramolecular Buchwald vinyl amidation of a suitably functionalised 
precursor (13) (Scheme 47). With similar foresight to the first approach, it was 
expected that upon removal of the protecting group in 12, tautomerisation would 
occur to give the more thermodynamically stable product, 11. Late stage installation 
of the amino substituent and bromine functionality (given the difficulty in working 
with aminoimidazoles* and the tolerance of C-Br bonds to the planned transition 
metal chemistry) would give ceratamine A (1).† 
                                                
* Compounds possessing 2-aminoimidazoles are notoriously problematic to carry through multiple 
synthetic manipulations due to their intractability, poor solubility, and reactivity. 
† It is worth mentioning that this route was designed to give access to ceratamine A, the more active 
member of the family. 
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Scheme 47 Second-generation retrosynthesis by Andersen and co-workers. 
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Scheme 48 Second-generation strategy by Andersen and co-workers. 
Reagents and conditions: (a) i) DIC, HOBt, DMAP, CH2Cl2, 0 ºC to rt, 1 h; ii) MeNH2, THF, 
10 min, 95%; (b) Pd(PPh3)4, CuI, THF, rt, 20 h, 73%; (c) (bromomethyl)triphosphonium 
bromide, KOtBu, –78 ºC, then 18, 30 min, 80%; (d) CuI, Cs2CO3, DMEDA, THF, 70 ºC, 20 
h, 85%; (e) Ph3SiNH2, Pd2(dba)3, XPhos, LiHMDS, PhMe, 100 ºC, 1 h; (f) acetic formic 
anhydride, DMAP, THF, rt, 24 h, 54%; (g) MeI, K2CO3, DMF, rt, 24 h, 48% over 3 steps; (h) 
AlCl3, CH2Cl2, rt, 30 min; (i) HCl(g), 1,4-dioxane/H2O (1:1), 0 ºC, 3 min, 25, 25% over 2 
steps; (j) Br2, AcOH, rt, 1 h, 43%.  
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The stannane 17 and cinnamidyl bromide 15 required for synthesis of aldehyde 18 
were readily accessible from commercially available tribromoacetic acid (14) and 
2,4,5-tribromoimidazole (16), respectively (Scheme 48). Stille coupling of these 
partners at room temperature furnished 18 in good yield and this could then be 
converted to the desired Z-vinyl bromide amidation precursor 19 by a Stork–Zhao 
olefination. The pivotal copper(I)-catalysed intramolecular coupling between the Z-
vinyl bromide and N-methyl amide functionalities in 19 proceeded in excellent yield 
to furnish the 2-chloroimidazo[4,5-d]azepine 20.  
A three-step procedure installed the N-methylformamide which was required to mask 
the problematic 2-aminoimidazole functionality. The chloride 20 was converted to the 
corresponding amine by heating with triphenylsilylamine and LiHMDS in the 
presence of Pd2(dba)3 and Buchwald’s XPhos ligand. Formylation of the amine with 
acetic formic anhydride followed by N-methylation of the secondary formamide gave 
21 in a 48% yield over the 3 steps. Next, removal of the BOM group with AlCl3 was 
presumed to have occurred cleanly (by TLC and HRMS) to give 22 although the 
structure could not be explicitly confirmed by 1H NMR due to its rotameric nature.  
The penultimate step of removing the N-formyl group proved problematic. Prior 
mechanistic studies had indicated that once unmasked, the molecule could be oxidised 
at C-11 by atmospheric oxygen because of the electron-donating ability of the 2-
amino substituent. After extensive experimentation, it was found that sparging dry 
HCl gas through a solution of 22 in 1,4-dioxane/water (1:1) gave the desired 
desbromoceratamine A (24) in 25% yield with the formation of only minimal 
amounts of the C-11 oxygenated product 23. Attempts to convert 23 to 24 via 
hydrogenolysis and Barton deoxygenation procedures resulted in decomposition.  
The final stage bis-bromination of 24 required to give ceratamine A (1) could not be 
achieved; two equivalents of NBS or Br2/AcOH gave the 9-monobrominated 
compound 25 and the use of excess amounts of bromine led to complex mixtures. 
This highlights the fallible nature of a late-stage bromination strategy on a highly 
electron rich system and is an important consideration when attempting to synthesise 
such compounds.  
Despite these approaches failing to deliver the targeted natural product the value of 
total synthesis is evident as it has been possible to access molecules with 
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modifications that are inaccessible by traditional medicinal chemistry approaches. 
More recently, a variation on the second-generation route has been used for the 
synthesis of ceratamine analogues (see Section 4.1.4).3 
4.1.3 Coleman Group Total Synthesis  
To date, the only successful total synthesis of the ceratamines was reported by 
Coleman and co-workers in 2009. To allow for a convergent synthesis and in a 
remarkably similar approach to the first-generation strategy of Andersen and co-
workers, they planned to construct the imidazo[4,5-d]azepine ring system in 26 by a 
condensation reaction between an activated azepane-2,4-dione (27) and a nitrogen-
based nucleophile such as the protected guanidine derivative 28 (Scheme 49). 
However, the success of this strategy hinged on the ability to perform an 
unprecedented double dehydrogenation to access the oxidation state required for the 
ceratamines. 
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Scheme 49 Coleman’s retrosynthetic analysis of the ceratamines. 
The synthesis commenced from known lactam 294 which could be readily hydrolysed 
under acidic conditions to hydroazepinedione 31 (Scheme 50). A subsequent 
Knoevenagel condensation with 3,5-dibromo-4-methoxybenzaldehyde (30) gave 
adduct 32 which was then brominated to furnish the α-bromoketone 33. At this stage, 
attempts were made to append the imidazole ring by direct displacement of the 
bromide with N-Boc-guanidine but ultimately this proved unsuccessful as a 
competing Michael addition to C-11 took precedence over the desired substitution.  
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Scheme 50 Coleman’s synthesis of 37. 
Reagents and conditions: (a) HCl (10% aq), acetone, rt, 12 h, quant; (b) 30, AcOH, 
piperidine, CH2Cl2, 3 Å MS, rt, 4 h, quant; (c) NBS, Amberlyst-15, EtOAc, 48 h, 67%; (d) 
Hantzsch ester, EtOH/C6H6 (1:1), rt, 24 h, 88%; (e) NaN3, DMSO, rt, 1 h, quant; (f) H2, 5% 
Pd on BaSO4, conc. HCl, MeOH, rt, 2 h; (g) HgCl2, Et3N, bis-Boc-S-methylisothiourea, 0 ºC, 
1 h, 74% over 2 steps; (h) TFA, CH2Cl2, rt, 1 h, quant. 
In order to prevent this competing conjugate addition, α-bromoketone 33 was reduced 
to 34 using Hantzsch ester (diethyl-1,4-dihydro-2,6-dimethyl-3,5-pyridine 
carboxylate). Unexpectedly, reaction of this substrate (34) with N-Boc-guanidine did 
not lead to the desired imidazole annulation product but instead furnished guanidine 
amide 39 in 88% yield (Scheme 51). It is believed this occurred via a unprecedented 
Favorskii-type rearrangement whereby the protected guanidine promotes formation of 
an enolate which then cyclises to give the putative cyclopropanone 38. Finally, 
nucleophilic addition of the guanidine breaks open the cyclopropanone to give 39.  
Coleman and co-workers were able to bypass this issue by converting bromide 34 to 
the corresponding azide 35 (Scheme 50). Following hydrogenolysis of the azide, 
condensation of the resulting primary amine with bis-Boc-protected S-
methylisothiourea gave the desired annulation precursor 36. Construction of the 
imidazo[4,5-d]azepine ring system was achieved by treatment with TFA which gave 
the trifluoroacetate salt 37 in quantitative yield.  
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Scheme 51 Unprecedented Favorskii-type rearrangement. 
Reagents and conditions: (a) N-Boc-guanidine, MeCN, 70 ºC, 24 h, 88%. 
With the heterocyclic framework now in place the major challenge that remained was 
how to effect the double dehydrogenation needed to obtain the fully oxidised ring 
system present in the ceratamine core. Ultimately, this was achieved by the treatment 
of 37 with IBX and pyridine in DMSO to give des-methyl ceratamine B (40) in 
excellent yield (Scheme 52). This could then be converted to des-methyl ceratamine 
A (41) by methylation of the lactam nitrogen. Unfortunately, installation of the C-19 
methyl group by reductive alkylation failed due to the sensitive nature of the oxidised 
ring system to the reducing conditions. However, reversing the order of the 
transformations easily solved this problem. Treatment of 37 with triethylorthoformate 
followed by NaBH4 reduction of the resulting ethyl formimidate afforded 26 which, 
upon oxidation with IBX, furnished ceratamine B (2) in 67% over the two steps. 
Finally, methylation of the lactam nitrogen provided ceratamine A (1). 
In summary, this route represents the first and only total synthesis of both members of 
the ceratamine family. Starting from lactam 29, the synthesis of 2 and 1 was achieved 
in 10 and 11 steps in an overall yield of 28% and 12%, respectively, thus belying the 
concise and efficient nature of this strategy. 
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Scheme 52 Synthesis of ceratamine A (1) and B (2). 
Reagents and conditions: (a) IBX, DMSO, py, 35 ºC, 1 h, 86%; (b) NaHMDS, DMF/THF 
(1:1), 0 ºC, then MeI, –78 ºC to –10 ºC, 50%; (c) HC(OEt3), 80 ºC, 5 h, then NaBH4, 0 ºC to 
40 ºC, 1 h; (d) IBX, DMSO, py, 35 ºC, 1 h, 81%; (e) NaHMDS, DMF/THF (1:1), 0 ºC, then 
MeI, –78 ºC to –10 ºC, 44%. 
4.1.4 Ceratamine A Structure-Activity Relationship 
Synthetic analogues of ceratamine A (1) were screened against MCF-7mp53 cells‡ to 
evaluate their ability to arrest cells in a TG-3§ cell-based assay.3 In this assay, the 
activity of ceratamine A (IC50 ≈ 10.6 µM; 54% cells arrested in mitosis at optimal 
concentration)** was used as the benchmark. Synthetic analogues 42 to 45 (Figure 39) 
were inactive, indicating that a fully planarised dehydrogenated core and a 2-N-
methylamino substituent are required for activity. The desbromo analogues 46 and 47 
that possess C-11 oxygenation were also completely inactive. Compound 48 which 
differed from the natural product by loss of the C-14/16 bromides and the 2-N-
methylamino group showed no activity. Desbromoceratamine A (24) was the only 
member in the series that caused significant mitotic arrest (20%) albeit at a high 
                                                
‡ A breast cancer cell line expressing a p53 mutation which can inactivate endogenous p53 (a tumour 
suppressor gene) in a dominant-negative fashion.  
§ A monoclonal antibody that has an affinity for mitotically phosphorylated nucleolin and can therefore 
be used to identify mitotic cells (Cancer Res., 2000, 60, 5052). 
** The optimal concentration of 25 µg/mL is independent of the IC50 value and was used by Andersen 
and co-workers to compare efficacies of the tested compounds. 
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concentration (160 µM), indicating that the bromine atoms were necessary to impart 
the full biological activity. 
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Figure 39 Structures of ceratamine A analogues. 
To explore the role of bromine further, Andersen and co-workers sought initially to 
substitute the bromines in 1 for a moiety possessing similar steric bulk–hypothesising 
that the bromines were exploiting pockets of space in the binding site. As a methyl 
group aptly fitted this criteria (Van der Waals radius of 1.80 Å cf. 1.86 Å for bromine) 
a small library of compounds containing a 3,5-dimethyl-4-methoxy aryl motif (Figure 
40) was synthesised. Indeed, the dimethyl analogue 49 (IC50 ≈ 10.3 µM; 67% cells 
arrested in mitosis at optimal concentration) had comparable activity to the natural 
product. The analogues 51 (lacking the 2-N-methyl substitution), 52 (C-11 
hydroxylated) and 53 (acylated at N-2) were all inactive, giving further evidence that 
N-2 methylation is required and C-11 functionalisation is not tolerated. However, the 
dimethyl analogue 50 exhibited the greatest antimitotic activity (IC50 ≈ 8.5 µM; 82% 
cells arrested in mitosis at optimal concentration) of all the ceratamine compounds. 
More importantly, 50 was easier to synthesise than 49 and consequently has been 
selected as a candidate for in vivo mouse models; however, the results of this study 
are yet to be disclosed. 
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Figure 40 Dimethylated analogues of the ceratamines. 
4.1.5 Ley Group Strategy 
As highlighted in the previous sections, it was envisaged that the most challenging 
aspect of the ceratamine synthesis would be the construction of the heterocyclic core. 
Taking inspiration from the proposed biosynthesis of the ceratamines (Section 1.3.4) 
the Ley group strategy hinged on an ambitious intramolecular cyclisation between C-
4 and C-5 to form the core heterocycle. Importantly, it was planned that the 
cyclisation precursor (57) would also contain the fully elaborated 3,5-dibromo-4-
methoxyaryl appendage which would therefore negate the need for late stage 
installation of the bromine substituents.  
We planned to synthesise the cyclisation precursor 57 from the same α-oximino acid 
(62) that was used for the synthesis of (5)-bromoverongamine, ianthelline, and JBIR-
44 in Chapter 2 (Scheme 53). A proposed Buchwald amidation5 between the known 
vinyl iodide 606 and primary amide 61 would furnish the Z-enamide 59.†† Then, 
unmasking of the α-keto amide 58 and subsequent treatment with tosylhydrazine and 
base should furnish the α-diazo carbonyl cyclisation precursor 57.  
                                                
†† It should be noted that since this route was designed prior to the disclosure of the IBX-mediated 
double dehydrogenation (Scheme 52), we planned to install the C-8/C-9 unsaturation prior to 
cyclisation despite the fact that increasing the rigidity of the molecule may hinder the proposed 
cyclisaton.  
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Scheme 53 Ley group retrosynthetic analysis of the ceratamines. 
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Scheme 54 Proposed mechanism for the key step. 
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With the stage set for the key step, it was anticipated that following generation of an 
electrophilic Rh(II) carbenoid species (63), a Buchner-type cyclopropanation‡‡ would 
occur between the imidazole olefin and the electrophilic centre of the carbenoid α-
carbon atom (Scheme 54).7 It was then envisaged that ring-opening of the 
cyclopropane (62) and subsequent rearomatisation would give the desired product 56. 
This ring-opening would be favoured due to the electron donating imidazole and the 
electron accepting carbonyl functionality in the vicinal positions of the cyclopropane. 
Of relevance to this, a recent theoretical study of ring-enlargement reactions of donor-
acceptor cyclopropanes revealed that the transition state energy for this process is 
dramatically lowered with more electron-donating and withdrawing vicinal 
substituents.8  
Commencing the final steps, conversion of the methyl thioether 56 to azide 55, which 
following reduction, methylation and removal of the BOM protecting-group would 
give 54. Lastly, oxidation of the ring system would furnish ceratamine B (2) that in 
turn could be converted to ceratamine A (1) by methylation of the amide nitrogen. 
4.2 Results and Discussion 
A number of conditions were screened in an effort to find a convenient and high 
yielding method to convert the α-oximino acid 62 to the primary amide coupling 
partner 61 (Table 10). It is known that benzoic and aliphatic acids can be converted to 
the corresponding amides by heating them in the presence of urea and imidazole 
under microwave irradiation.9 Although this procedure worked on a simplified 
substrate, subjecting 62 to the same conditions resulted in decomposition (entry 1). A 
more conventional approach using DCC/HOBt as the coupling reagents and 
ammonium hydroxide as the ammonia source gave a complex mixture (entry 2).  
It was possible to isolate the desired product when CDI was used as the coupling 
reagent; however, the imidazole side product was difficult to remove (entry 3). 
Instead, the acid was activated with ethyl chloroformate and the acyl carbonate 
reacted cleanly with the ammonia source to give 61 in 80% yield (entry 4). 
Furthermore, the structure of the primary amide was confirmed by X-ray 
crystallography. 
                                                
‡‡ Mechanistically, this cyclopropanation could either proceed via a direct insertion or stepwise 
process. 
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Table 10 Conditions for primary amide formation. 
OMe
N
O
OH
PMBO
Br Br
OMe
N
O
NH2
PMBO
Br Br
Primary amide
 formation
62 61  
Entry Reagents Solvent Conditions Yield 
1 Urea/Imidazole Neat 200 ºC (µW) 
5 min 
Decomp. 
2 DCC, HOBt, NH4OH CH2Cl2 rt Complex mix 
3 CDI, NH4OH THF 0 ºC to rt 78% 
4 Ethyl chloroformate, Et3N, 
NH4OH 
THF 0 ºC to rt 80% 
 
Figure 41 X-ray crystal structure of primary amide 61. 
The vinyl iodide coupling partner (60) was synthesised from 2,4,5-tribromoimidazole 
(16) following a known literature procedure (Scheme 55).6 Regioselective 
transmetallation of the benzyloxymethyl-protected imidazole 63 and quenching the 
resulting carbanion with dimethyl disulfide gave sulfide 64. Next, in a one-pot 
procedure, 64 was firstly lithiated and silylated with trimethylsilyl chloride,§§ and then 
lithiated and formylated with DMF. Subsequent removal of the silyl protecting group 
afforded aldehyde 65. Lastly, a Stork–Zhao olefination of the aldehyde 65 with 
(iodomethyl)triphenylphosphonium iodide10 gave the Z-vinyl iodide 60 in 56% yield. 
It was also possible to isolate the corresponding alkyne (not shown) in 19% yield 
from the reaction mixture. 
                                                
§§ This was necessary to achieve the regiospecific formylation at C-10. 
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Scheme 55 Synthesis of vinyl iodide 60. 
Reagents and conditions: (a) BOM-Cl, K2CO3, DMF, rt, 24 h, 69%; (b) n-BuLi, THF, –78 ºC, 
10 min then MeSSMe, –78 ºC, 15 min then rt; (c) n-BuLi, THF, –78 ºC, 10 min then TMSCl, 
20 min then n-BuLi, 10 min then DMF, –78 ºC, 1 h then rt, K2CO3, 3 h, 74% over 2 steps; (d) 
(iodomethyl)triphenylphosphonium iodide, KOtBu, rt, 5 min then –78 ºC, 65, 30 min, 56%. 
The vinyl iodide and amide coupling partners were united with conditions developed 
by Buchwald and co-workers.5 The Z-enamide was obtained in excellent yield by 
heating 60 and 61 to 70 ºC in a sealed tube in the presence of 10 mol% copper(I) 
iodide and 20% N,N′-dimethylethylenediamine.  
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Scheme 56 Buchwald coupling of 60 and 61. 
Reagents and conditions: (a) Cs2CO3, CuI (10 mol%), DMEDA (20 mol%), THF, 70 ºC, 4 h, 
82%. 
The crystal structure of 59 not only confirmed the Z-geometry of the enamide but also 
revealed that (in the solid state), the imidazole nitrogen was hydrogen bonding to the 
amide hydrogen (Figure 42). As a result, this bonding locks the molecule in such a 
way that it distances the C-4/C-10 olefin in the imidazole ring from C-5. This has 
obvious implications for the intramolecular cyclisation since the proposed 
cyclopropanation requires these positions to be in proximity to one another. It may 
well be the case that this bonding interaction is not relevant when dealing with the 
solution phase chemistry of this molecule. Nevertheless, this should not be 
disregarded for the cyclisation reaction and an appropriate choice of solvent may be 
required to minimise this bonding interaction. 
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Figure 42 X-ray crystal structure of Z-enamide 59 co-crystallised with acetonitrile. 
It was anticipated that the removal of the PMB group with the previously mentioned 
Lewis acidic conditions (Chapter 2) would be problematic given the acid sensitive 
nature of the BOM group. Therefore, oxidative cleavage of the PMB ether with DDQ 
was attempted but unfortunately no conversion occurred. As expected, treatment of 59 
which aluminium trichloride and anisole for an extended reaction time (3 hours) led to 
a complex mixture of products and gave oxime 66 in 20% yield with 67 being the 
only other identifiable product. However, only minimal formation of 67 was observed 
when the substrate was exposed to the conditions for 1 minute and the desired product 
66 was obtained in a moderate yield of 59% (Scheme 57).  
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Scheme 57 PMB deprotection of Z-enamide 59. 
Reagents and conditions: (a) AlCl3, anisole, CH2Cl2, rt, 1 min, 59%. 
Despite being able to obtain small quantities of 66 via this method, the problems 
associated with this PMB deprotection led us to reconsider the synthetic strategy and 
explore other possibilities. Initially, this included investigating whether protection of 
the oxime was actually necessary. 
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It was envisaged that the primary amide with the free oxime (70) could be accessed 
from the α-oximino acid 68 whose synthesis has previously been reported in Chapter 
2. Unfortunately, subjecting this substrate to the amidation conditions described in 
Table 10 (entry 4) gave the nitrile 69. On closer inspection it was found that 69 was 
formed following treatment of 68 with ethyl chloroformate and triethylamine. 
Interestingly, 69 is a naturally occurring metabolite and has been isolated from 
Psammaplysilla purpurea.11 
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Scheme 58 Attempted synthesis of 70. 
Reagents and conditions: (a) ethyl chloroformate, Et3N, THF, 0 ºC, 1 h. 
Therefore, as protection of the free oxime was clearly necessary, a suitable protecting 
group that could be selectively cleaved in the presence of the BOM group was 
required. Making use of the research into the subereamollines (Chapter 3), it was 
decided that protecting the oxime as a benzyl ether would be a viable option since it 
could be cleaved smoothly by hydrogenolysis over palladium black. Starting with the 
phenylpyruvic acid derivative (71) described in Chapter 2, condensation with O-
benzylhydroxylamine gave the α-oximino acid 72 (Scheme 59). This was converted 
to the corresponding primary amide 73, which could then coupled to the vinyl iodide 
60 to form the Z-enamide 74 in 64% yield over the two steps. In this case, subjecting 
74 to the hydrogenolysis conditions did not lead to cleavage of the benzyl ether. 
Instead, it was possible to isolate the imidazole 75, which resulted from 
hydrogenolysis of the carbon–sulfur bond. This was not wholly unexpected, as it is 
known that palladium black can desulfurise hydrocarbons.12 It was perhaps surprising 
that no debenzylation or reduction of the C-8/C-9 olefin was observed however, 
poisoning of the palladium catalyst may account for this. It is worth bearing in mind 
that this procedure could be used in the latter stages of the ceratamine synthesis to 
affect the desulfurisation of 56 (Scheme 53). 
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Scheme 59 Attempted synthesis of 66 from 74. 
Reagents and conditions: (a) O-benzylhydroxylamine, NaOAc, EtOH, rt, 1 h, 98%; (b) ethyl 
chloroformate, Et3N, THF, 0 ºC, 45 min then NH4OH, 30 min then rt, 1 h, 78%; (c) 60, 
Cs2CO3, CuI (10 mol%), DMEDA (20 mol%), THF, 70 ºC, 9 h, 82%; (d) Pd-black, H2, 1,4-
dioxane/AcOH (1:1), rt, 4 h, 16%. 
We felt there was no value at this stage in pursuing an alternative oxime protecting 
group, as we were yet to attempt the cleavage of the oxime 66 to the corresponding 
carbonyl; any further research into a suitable protecting group would be futile if there 
was an inability to unmask the carbonyl functionality. 
A variety of methods for the deoximation of aldoximes and ketoximes to their 
carbonyl derivatives have been reported in the literature and include: acid-catalysed 
(e.g. Mg(HSO4)2,13 and HCl/TiCl3),14 reductive (e.g. Raney Ni/B(OH)3/H2),15 
oxidative (e.g. N2O4,16 HIO4,17 Mn(OAc)3,18 and t-BuOOH),19 and photosensitised 
oxidative cleavage (e.g. hν/O2/Pt(II) complex).20 Since the stability of oximes is 
relatively high (when compared to hydroxylamines and imines), these methods are 
usually harsh and require forcing conditions that are often not compatible with highly 
functionalised substrates. When considering oxime 66, we were concerned about the 
susceptibility of the C-8/C-9 olefin and thioether to oxidation and the lability of the 
BOM group towards acidic conditions. Therefore, a mild method to effect this 
transformation was desirable.  
Zard and co-workers reported the use of a tributylphosphine–diphenyl disulfide (TBP-
PDS) reagent system for the reduction of oximes to imines, which upon work-up 
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produced the corresponding ketones.21 Research by Lukin and co-workers provided 
further insight into this reaction mechanism.22 In the first step, TBP-PDS converts the 
oxime to a phenylthioimine with the loss of tributylphosphine oxide and thiophenol 
(Scheme 60). Tributylphosphine then reduces the thioimine, via attack of the sulfur 
atom, to give the imine that is subsequently hydrolysed upon work-up.  
N
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TBP-PDS
– Bu3PO and PhSH
N
SPh
NHPBu3 OH2O
 
Scheme 60 Reaction pathway for oxime cleavage with TBP-PDS. 
Disappointingly, using the reported conditions, treatment of oxime 66 with TBP-PDS 
gave no conversion. It appeared that 66 was unreactive towards this reagent system 
since using an excess of reagent or heating the mixture also proved unsuccessful. To 
account for this observation, we postulate that it was not possible for the 
phenylthioimine 77 to form due to unfavourable steric interactions. This is based on 
the work of Vilarrasa and co-workers who observed that, while acetophenone oxime 
(Z)-78 was readily converted to the corresponding phenylthioimine, (E)-78 gave only 
a trace amount of the product (Scheme 61).23 They reasoned that the difference in 
steric hindrance around the nitrogen atom lone pair could account for this reactivity. 
For the intermediate 79a, the molecule can adopt the necessary reactive conformation 
whereas, in the case of 79b this is not possible because of an unfavourable steric clash 
between the SPh group and the phenyl ring. In our system, as illustrated in the crystal 
structure in Figure 42, these steric effects are even more pronounced and it is 
therefore unlikely that, if formed, 76 could collapse to the phenylthioimine 75. 
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Scheme 61 The effects of steric hindrance in the formation of phenylthioimines. 
The deoximation of 66 was also unsuccessful using a mild oxidative method 
developed by Akamanchi and co-workers.24 The reaction of 66 with Dess–Martin 
periodinane in wet dichloromethane was monitored by HRMS which showed that, 
although no deoximation had occurred, 66 had been oxidized to the sulfoxide 80 
(Scheme 62). 
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Scheme 62 Reaction of 66 with Dess–Martin periodinane. 
Reagents and conditions: (a) Dess–Martin periodinane, CH2Cl2 (wet), rt, 30 min. 
Despite the fact that only a couple of methods had been attempted, it was clear that 
the complexity of oxime 66 was not conducive to performing an efficient and high 
yielding deoximation. In an effort to overcome this stumbling block the retrosynthetic 
strategy towards the ketone 58 was revised so as to remove the need for the oxime 
group altogether (Scheme 63). Instead of masking the carbonyl group, the aim of this 
new approach was to couple either an unprotected (81) or protected (82) α-keto 
primary amide with vinyl iodide 60. For the former, this would produce 58 directly 
whereas the coupled product from the latter would require an additional step to 
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selectively deprotect the enol hydroxyl. It is important to note that 58 would probably 
exist as its enol tautomer, akin to the phenylpyruvic acids from which it is derived.  
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Scheme 63 Revised retrosynthetic strategy towards 58. 
Commencing with the synthesis, it was anticipated that obtaining amide (81) directly 
from the acid 71 (using the optimised conditions in Table 10) would be difficult as the 
polarity of the product would make chromatographic purification challenging. 
Instead, 71 was methylated with trimethylsilyldiazomethane to give methyl ester 83 
with the hope that the primary amide could be accessed by ammonolysis of the ester 
functionality (Scheme 64). Upon stirring with methanolic ammonia (7 N) for 2 hours 
there was full conversion of 83 to a single product. This was presumed to be amide 
81, however, concentration of the reaction mixture led to significant 
decomposition.*** This phenomenon has also been observed with phenylpyruvic acid 
derivatives.25 
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Scheme 64 Attempted synthesis of 81. 
Reagents and conditions: (a) TMSCHN2, PhMe/MeOH (3:1), 0 ºC to rt, 3 h, 83%. 
This finding meant that protection of the enol hydroxyl was the only viable option. 
Further to this, the enol hydroxyl of methyl ester 83††† was protected using either TBS 
chloride26 or TIPS triflate to give the silyl enol ethers 84 and 85, respectively (Scheme 
65). We had previously discovered that the methyl ester 83 could be saponified with 
                                                
*** This decomposition was evident with both TLC and 1H NMR analysis. 
††† The methyl ester was used as it was not possible to protect the free acid.  
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lithium hydroxide to give the carboxylic acid 71 in quantitative yield. However, 
saponification of both 84 and 85 to 86 and 87, respectively, was unsuccessful. In the 
case of the TBS enol ether, there was loss of the silyl group under the reaction 
conditions. For 85, no reaction took place, presumably due to the sterically 
encumbering silyl group. 
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Scheme 65 Attempted syntheses of 86 and 87. 
Reagents and conditions: (a) TBSCl, DMAP, Et3N, CH2Cl2, rt, 30 min, 98%; (b) TIPSOTf, 
Et3N, CH2Cl2, rt, 30 min, 97%; (c) LiOH·H2O, MeOH/H2O (3:1), rt, 1 h, 71, quant. 
This result prompted us to explore other protecting group strategies. Protecting 71 as 
the enol acetate was the most appealing as the acetate would be easy to install and 
could be removed under relatively mild conditions. Initially, 71 was treated with 
sodium acetate in neat acetic anhydride until a white precipitate had formed after 
which water was added.27 However, the compound isolated after work-up turned out 
to be the bis-acetylated product (not shown) and not the desired mono-acetylated 
product 88. We reasoned that the precipitate was the sodium carboxylate salt of 88 
and that solubilising it (with water) in the presence of acetic anhydride resulted in the 
acetylation of the carboxylate moiety. Accordingly, the precipitate‡‡‡ was isolated 
from the reaction mixture and subsequently acidified to furnish 88 in 72% yield 
(Scheme 66). The structure was confirmed by crystallographic analysis (Figure 43). 
                                                
‡‡‡ IR analysis confirmed the precipitate was indeed the carboxylate salt. The characteristic signals at 
1603 cm–1 (antisymmetric) and 1400 cm–1 (symmetric) were observed. 
Chapter 4:Towards the Total Syntheses of the Ceratamines 
 233 
OMe
BrBr
OH
HO O
OMe
BrBr
O
HO O
O
OMe
BrBr
O
O O
O
O
EtO
OMe
BrBr
O
H2N O
O
a b
71 88 89 90  
Scheme 66 Synthesis of primary amide 90. 
Reagents and conditions: (a) Ac2O, NaOAc, 2 h, rt, 72%; ethyl chloroformate, Et3N, THF, 
0 ºC, 45 min then HMDS, 30 min, 54%. 
When attempting to convert acid 88 to primary amide 90 using our optimised 
conditions, a complex mixture of products was obtained. Further analysis revealed 
that formation of the carbonate 89 proceeded smoothly in quantitative yield but that 
this decomposed upon treatment with a solution of ammonium hydroxide. Since the 
enol acetate was not stable to these conditions, a milder source of ammonia was 
required. Hexamethyldisilazane has been used to convert acid chlorides28 and both 
DCC29 and TBTU30 activated acids to primary amides. Pleasingly, addition of a 10 
fold excess of HMDS to the activated acid 89 gave the desired primary amide 90 in 
54% yield (Scheme 66).§§§ To our knowledge this represents the first example of the 
use of HMDS in a chloroformate-mediated amidation process. 
 
Figure 43 X-ray crystal structure of enol acetate 88. 
The copper-catalysed Buchwald amidation between amide 90 and vinyl iodide 60 was 
attempted using the conditions described in Scheme 56. TLC and LCMS analysis 
                                                
§§§ This method could also be used to convert the PMB α-oximino acid 62 to the primary amide 61 in 
69% yield.  
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showed that the primary amide had been fully consumed although the starting vinyl 
iodide (60) was still present, along with its protodehalogenated product 91; the 
desired product (92) could not be detected (Scheme 67). A series of control reactions 
were performed and these revealed that although 90 was stable at the reaction 
temperature, it decomposed when treated with caesium carbonate. The reaction was 
repeated under strictly anhydrous conditions, as it is known that the hydrolysis of enol 
acetates can be achieved with potassium carbonate in aqueous methanol,31 but to no 
avail. 
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Scheme 67 Attempted synthesis of 92. 
Reagents and conditions: (a) Cs2CO3, CuI (10 mol%), DMEDA (20 mol%), THF, 70 ºC, 4 h. 
This outcome was disappointing especially since, in the development of this 
amidation reaction, Buchwald and co-workers had been able to couple vinyl iodides 
possessing ester functionalities to primary amides in moderate yields and without 
significant decomposition.5 
4.3 Conclusion and Future Work 
At the time of writing, no further progress has been made towards the synthesis of the 
ceratamines. To summarise, the major problem that we have encountered in our route 
towards the ceratamines has been the inability to access compound 58. So far, 
attempts to either unmask the carbonyl functionality from the oxime or to protect the 
ketone as its silyl enol ether/enol acetate have been unsuccessful.  
With regards to future synthetic studies, as it was possible to couple the amides 61 
and 73 to the vinyl iodide 60, it appears that masking the carbonyl as an oxime 
remains the most promising strategy. As previously mentioned, since the deoximation 
of ketoximes is heavily precedented in the literature, a rigorous screen of conditions 
(compatible with substrate 66) should uncover an optimal method to perform this 
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transformation. However, unmasking the carbonyl may not be necessary as it known 
that oximes can be converted directly to the corresponding diazo compound by 
treatment with chloramines (Förster reaction).32 This would also remove the step that 
would otherwise be necessary to transform the ketone 58 to the diazo compound 57. 
Interestingly, the Förster reaction is much underused in spite of its capabilities and the 
current interest in C-H activation within the chemistry community. Originally it was 
believed that this reaction was limited to the transformation of α-oximino ketones to 
α-diazo ketones based on the proposed mechanistic pathway whereby there is 
nucleophilic attack onto the oxime nitrogen (in a Michael fashion) by chloramine 
(Scheme 68 (I)). Meinwald and co-workers put forward an alternate mechanism in 
which the first step involves nucleophilic displacement at the chloramine nitrogen 
(Scheme 68 (II)).33 This was supported by experimental evidence, as it was possible 
to convert oximes lacking an α-carbonyl moiety (e.g. fluoreneone and benzophenone 
oxime) to their diazo derivatives.  
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Scheme 68 Proposed mechanisms for the Förster reaction. 
In conclusion, it is hoped that in the near future an appropriate route to the diazo 
compound 57 will be uncovered which will subsequently allow us to investigate the 
chemistry of the key intramolecular-cyclisation step.    
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4.4 Chemistry: Experimental 
General Experimental Details  
Refer to Section 2.1.6 for general experimental details.  
(E)-3-(3,5-Dibromo-4-methoxyphenyl)-2-(((4-ethoxybenzyl)oxy)imino) 
propanamide (61) 
OMe
Br Br
15
8
1
N
O
NH2
O
MeO
9
1'
8'
5'
2'
 
To a stirred solution of acid 62 (207 mg, 0.425 mmol) and Et3N (89.0 µL, 0.639 
mmol) in THF (8 mL) at 0 ºC was added ethyl chloroformate (45.0 µL, 0.471 mmol). 
After 45 min, ammonium hydroxide (35 %, 200 µL) was added and the reaction 
mixture was stirred for a further 30 min at 0 ºC. The reaction mixture was allowed to 
warm to room temperature and, after 1 h, EtOAc (25 mL) and H2O (25 mL) were 
added and the organic layer separated. The aqueous layer was extracted with EtOAc 
(2 x 25 mL) and the combined organic extracts were dried and concentrated in vacuo. 
The residue was purified by flash column chromatography (20-40% EtOAc/Petrol) to 
furnish 61 (165 mg, 0.339 mmol, 80%) as a white solid. 
Rf 0.77 (5% MeOH/CH2Cl2); νmax (thin film)/cm-1 3424m, 3221w, 2938w, 1684s, 
1611s, 1515s, 1251s; δH (400 MHz, CDCl3) 7.40 (2H, s, H-2/6), 7.25 (2H, d J 8.6 Hz, 
H-3'/7'), 6.91 (2H, d, J 8.6 Hz, H-4'/6'), 6.59 (1H, br s, NH), 5.34 (1H, br s, NH), 5.15 
(2H, s, H-1'), 3.84 (3H, s, H-15), 3.82 (3H, s, H-8'), 3.80 (2H, s, H-7); δC (100 MHz, 
CDCl3) 164.1 (C-9), 159.8 (C-5'), 152.6 (C-4), 150.5 (C-8), 134.7 (C-1), 133.4 (C-
2/6), 130.1 (C-3'/7'), 128.2 (C-2'), 117.7 (C-3/5), 114.1 (C-4'/6'), 77.5 (C-1'), 60.5 (C-
15), 55.3 (C-8'), 28.3 (C-7); m/z (ESI+) found 506.9509, [M+Na]+ C18H18Br2N2O4Na 
(79Br) requires 506.9531; m.p. 100-102 ºC. 
Crystals of 61 were obtained by slow evaporation from MeOH. The structure was 
confirmed by X-ray crystallographic analysis and given the unique identifier sl0854. 
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(E)-2-((Benzyloxy)imino)-3-(3,5-dibromo-4-methoxyphenyl)propanoic acid (70) 
OMe
Br Br
15
8
1
N
O
OH
O
9
1'
5'
2'
 
To a stirred solution of 71 (132 mg, 0.375 mmol) and O-benzylhydroxylamine (96%, 
45.5 µL, 0.375 mmol) in EtOH (3.8 mL) was added sodium acetate (92.3 mg, 
1.13 mmol). After 1 h, H2O (20 mL) was added, then the mixture was acidified (pH 0) 
by the addition of 3 N HCl and extracted with EtOAc (3 × 20 mL). The combined 
organic extracts were dried and evaporated to dryness in vacuo to furnish 70 (168 mg, 
0.368 mmol, 98%) as a white solid. 
Rf 0.41 (10% MeOH/CH2Cl2); νmax (thin film)/cm-1 3200-2800br, 1706s, 1471s, 
1257s; δH (400 MHz, CDCl3) 10.10 (1H, br s, OH), 7.42-7.37 (5H, m, H-3' to 7'), 7.40 
(2H, s, H-2/6), 5.33 (2H, s, H-1'), 3.85 (3H, s, H-15), 3.82 (2H, s, H-7); δC (100 MHz, 
CDCl3) 164.8 (C-9), 152.9 (C-4), 148.9 (C-8), 135.4 (C-2'), 133.7 (C-1), 133.3 (C-
2/6), 128.73 (C-4'/6'), 128.69 (C-5'), 128.5 (C-3'/7'), 117.9 (C-3/5), 78.7 (C-1'), 60.5 
(C-15), 29.3 (C-7); m/z (ESI+) found 499.9095, [M–H+2Na]+ C17H14Br2NO4Na2 
(79Br) requires 499.9079. 
Consistent with literature data.34 
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(E)-2-((Benzyloxy)imino)-3-(3,5-dibromo-4-methoxyphenyl)propanamide (73) 
OMe
Br Br
15
8
1
N
O
NH2
O
9
1'
5'
2'
 
To a stirred solution of acid 72 (168 mg, 0.368 mmol) and Et3N (77.0 µL, 0.552 
mmol) in THF (5 mL) at 0 ºC was added ethyl chloroformate (38 µL, 0.404 mmol). 
After 45 min, ammonium hydroxide (35%, 200 µL) was added and the reaction was 
stirred for a further 30 min at 0 ºC. The reaction was allowed to warm to room 
temperature and, after 1 h, EtOAc (25 mL) and H2O (25 mL) were added and the 
organic layer separated. The aqueous layer was extracted with EtOAc (2 x 25 mL) 
and the combined organic extracts were dried and concentrated in vacuo. The residue 
was purified by flash column chromatography (20-60% EtOAc/Petrol) to furnish 73 
(132 mg, 0.289 mmol, 79%) as a white solid. 
Rf 0.17 (20% EtOAc/Petrol); νmax (thin film)/cm-1 3464s, 3144br, 1698s, 1472s, 
1257s; δH (400 MHz, CDCl3) 7.43 (2H, s, H-2/6), 7.40-7.30 (5H, m, H-3' to 7'), 6.60 
(1H, br s, NH), 5.76 (1H, br s, NH), 5.23 (2H, s, H-1'), 3.84 (3H, s, H-15), 3.83 (2H, 
s, H-7); δC (100 MHz, CDCl3) 164.2 (C-9), 152.6 (C-4), 150.7 (C-8), 136.2 (C-2'), 
134.6 (C-1), 133.4 (C-2/6), 128.6 (C-4'/6'), 128.4 (C-5'), 128.2 (C-3'/7'), 117.7 (C-
3/5), 77.7 (C-1'), 60.5 (C-15), 28.3 (C-7); m/z (ESI+) found 454.9619, [M+H]+ 
C17H17Br2N2O3 (79Br) requires 454.9609. 
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(Z)-Methyl 3-(3,5-dibromo-4-methoxyphenyl)-2-hydroxyacrylate (83) 
OMe
Br Br
OH
MeO O
10
4
9
7
1
11  
To a stirred solution of 71 (500 mg, 1.42 mmol) in toluene/MeOH (3:1, 16 mL) at 
0 ºC was added trimethylsilyl diazomethane (2.0 M in hexane, 1.07 mL, 2.13 mmol) 
dropwise. The mixture was stirred for 3 h at room temperature and quenched by the 
addition of 3 N HCl (300 µL). The solvent was removed in vacuo and the residue 
partitioned between H2O (30 mL) and EtOAc (30 mL). The aqueous phase was 
extracted with EtOAc (30 mL × 2) and the combined organic layers were dried and 
concentrated in vacuo. The residue was purified by flash column chromatography 
(2.5–20% EtOAc/Petrol) to furnish 83 (433 mg, 1.18 mmol, 83%) as a white solid. 
Rf 0.27 (10% EtOAc/Petrol); νmax (thin film)/cm-1 3416s, 1687s, 1531m, 1431s, 
1242s; δH (400 MHz, CDCl3) 7.91 (2H, s, H-2/6), 6.52 (1H, d, J 1.6 Hz, OH), 6.34 
(1H, d, J 1.5 Hz, H-7), 3.92 (3H, s, H-10), 3.90 (3H, s, H-11); δC (100 MHz, CDCl3) 
166.0 (C-9), 153.4 (C-4), 140.0 (C-8), 133.7 (C-2/6), 132.8 (C-1), 118.0 (C-3/5), 
107.7 (C-7), 60.7 (C-10), 53.5 (C-11).  
It was not possible to obtain HRMS data for this compound. 
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(Z)-Methyl 2-((tert-butyldimethylsilyl)oxy)-3-(3,5-dibromo-4-
methoxyphenyl)acrylate (84) 
OMe
Br Br
O
MeO O
10
4
9
7
1
11
1'
Si
3'
 
To a stirred solution of methyl ester 83 (84.8 mg, 0.232 mmol), DMAP (5.70 mg, 
46.7 µmol) and Et3N (32.5 µL, 0.233 mmol) in CH2Cl2 (3 mL) was added a solution 
of TBSCl (38.5 mg, 0.255 mmol) in CH2Cl2 (300 µL) dropwise. After 30 min the 
solvent was removed in vacuo and the residue partitioned between H2O (10 mL) and 
Et2O (10 mL). The organic layer was separated, dried, and evaporated to dryness in 
vacuo to furnish 84 (109 mg, 0.227 mmol, 98%) as a colourless oil. 
Rf 0.67 (10% EtOAc/Petrol); νmax (thin film)/cm-1 2951m, 2930m, 2858w, 1724s, 
1630s, 1243s; δH (400 MHz, CDCl3) 7.86 (2H, s, H-2/6), 6.34 (1H, d, J 1.5 Hz, H-7), 
3.88 (3H, s, H-10), 3.81 (3H, s, H-11), 0.97 (9H, s, H-3'), 0.18 (6H, s, H-1'); δC (100 
MHz, CDCl3) 165.2 (C-9), 153.4 (C-4), 141.5 (C-8), 133.4 (C-2/6), 132.8 (C-1), 
117.7 (C-3/5), 115.1 (C-7), 60.7 (C-10), 52.3 (C-11), 25.8 (C-3'), 18.6 (C-2'), –3.87 
(C-1'). 
It was not possible to obtain HRMS data for this compound. 
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(Z)-Methyl 3-(3,5-dibromo-4-methoxyphenyl)-2-((triisopropylsilyl)oxy)acrylate 
(85) 
OMe
Br Br
O
MeO O
10
4
9
7
1
11
1'
Si 2'
 
To a stirred solution of methyl ester 83 (43.6 mg, 0.119 mmol), and Et3N (16.6 µL, 
0.119 mmol) in CH2Cl2 (1.5 mL) was added a solution of TIPSOTf (35.2 µL, 0.131 
mmol) dropwise. After 30 min the solvent was removed in vacuo and the residue 
partitioned between H2O (10 mL) and Et2O (10 mL). The organic layer was separated, 
dried, and evaporated to dryness in vacuo to furnish 85 (60.0 mg, 0.115 mmol, 97%) 
as a colourless oil. 
Rf 0.66 (10% EtOAc/Petrol); νmax (thin film)/cm-1 2944 s, 2866 s, 1726 s, 1629 m, 
1470 s, 1244 s; δH (400 MHz, CDCl3) 7.89 (2H, s, H-2/6), 6.57 (1H, d, J 1.5 Hz, H-
7), 3.88 (3H, s, H-10), 3.81 (3H, s, H-11), 1.34 (3H, quint, J 7.5 Hz, H-1') 1.09 (18H, 
d, J 7.5 Hz, H-2'); δC (100 MHz, CDCl3) 165.3 (C-9), 153.3 (C-4), 141.9 (C-8), 133.2 
(C-2/6), 133.1 (C-1), 117.8 (C-3/5), 113.8 (C-7), 60.7 (C-10), 52.3 (C-11), 17.9 (C-
2'), 13.9 (C-1'). 
It was not possible to obtain HRMS data for this compound. 
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1-((Benzyloxy)methyl)-2,4,5-tribromo-1H-imidazole (63) 
N
N
Br
Br
Br
O1
2
5
9
 
To a vigourously stirred suspension of 2,4,5-tribromoimidazole (16) (23.0 g, 75.5 
mmol) and anhydrous K2CO3 (94.9 g, 687 mmol) in DMF (200 mL) at room 
temperature was added benzyloxymethyl chloride (12.5 mL. 90.1 mmol). After 24 h, 
H2O (1 L) was added and the solution was extracted with EtOAc (3 × 600 mL). The 
combined organic extracts were washed with H2O (1 L), dried, and evaporated to 
dryness in vacuo to give an oil which slowly crystallised to furnish 63 (22.1 g, 
52.1 mmol, 69%) as colourless crystals. 
δH (400 MHz, CDCl3) 7.33 (5H, m, H-7 to 11), 5.42 (2H, s, H-4), 4.60 (2H, s, H-5); 
δC (100 MHz, CDCl3) 136.1 (C-6), 128.6 (C-8/10), 128.4 (C-9), 127.7 (C-7/11), 119.2 
C-3), 117.9 (C-1), 105.8 (C-2), 75.7 (C-5), 71.2 (C-4); m/z (ESI+) found 422.8343, 
[M+H]+ C11H10Br3N2O (79Br) requires 422.8343. 
Consistent with literature data35 
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1-((Benzyloxy)methyl)-2-(methylthio)-1H-imidazole-4-carbaldehyde (65) 
N
N
MeS
O1
2
5
9
O
13
 
To a solution of 63 (6.84 g, 16.1 mmol) in THF (100 mL) at –78 ºC was added n-
BuLi (6.71 mL of 2.4 M solution in hexanes, 16.1 mmol). After 10 min, 
dimethyldisulfide (1.45 mL, 16.1 mmol) was added dropwise and the reaction was 
stirred for a further 15 min at –78 ºC before warming to room temperature. The 
mixture was concentrated in vacuo and the residue was partitioned between EtOAc 
(250 mL) and H2O (250 mL). The organic layer was separated and the aqueous layer 
was extracted with EtOAc (3 × 250 mL). The combined organic extracts were washed 
with brine (500 mL), dried and evaporated to dryness in vacuo to give an orange oil 
(5.95 g) which was used without further purification. To a solution of the oil (5.95 g) 
in THF (90 mL) at –78 ºC was added n-BuLi (6.33 mL of 2.4 M solution in hexanes, 
15.2 mmol). After 10 min, trimethylsilyl chloride (1.93 mL, 15.2 mmol) was added 
dropwise and the mixture stirred for a further 20 min after which, n-BuLi (6.33 mL of 
2.4 M solution in hexanes, 15.2 mmol) was added dropwise. After 10 min, DMF (3.52 
mL, 45.5 mmol) was added dropwise and the mixture was stirred at –78 ºC for 1 h. 
After warming to room temperature, H2O (50 mL) was added and the mixture was 
extracted with CH2Cl2 (3 × 50 mL). The organic extracts were combined and MeOH 
(20 mL) and anhydrous K2CO3 (4.19 g, 30.3 mmol) were added. After stirring for 3 h, 
H2O (100 mL) was added and the mixture was extracted with CH2Cl2 (3 × 50 mL). 
The combined organic extracts were dried, and concentrated in vacuo. The residue 
was purified by flash column chromatography (30% EtOAc/hexane) to furnish 65 
(3.12 g, 11.9 mmol, 74%) as a yellow oil. 
δH (400 MHz, CDCl3) 9.76 (1H, s, H-13), 7.67 (1H, s, H-3), 7.30 (5H, m, H-7 to 11), 
5.29 (2H, s, H-4), 4.49 (2H, s, H-5), 2.66 (3H, s, H-12); δC (100 MHz, CDCl3) 184.8 
(C-13), 147.0 (C-1), 142.3 (C-6), 135.8 (C-8/10), 128.7 (C-9), 128.5 (C-7/11), 128.0 
(C-3), 127.3 (C-2), 75.1 (C-4), 71.0 (C-5), 15.6 (C-12). 
Consistent with literature data.6 
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(Z)-1-((Benzyloxy)methyl)-4-(2-iodovinyl)-2-(methylthio)-1H-imidazole (60) 
N
N
MeS
O1
2
5
9
14
I
12  
To a suspension of (iodomethyl)triphenylphosphonium iodide10 (3.10 g, 5.85 mmol) 
in THF (25 mL) was added KOtBu (656 mg, 5.85 mmol). After 5 min the mixture 
was cooled to –78 ºC and a solution of aldehyde 65 (766 mg, 2.92 mmol) in THF (6 
mL) was added dropwise. After 30 min, H2O (50 mL) was added and the mixture 
extracted with CH2Cl2 (3 × 40 mL). The combined organic extracts were washed with 
brine (200 mL), dried, and concentrated in vacuo. The residue was purified by flash 
column chromatography (10-30 % EtOAc/hexane) to furnish 60 (633 mg, 1.63 mmol, 
56%) as a yellow oil. 
Rf 0.23 (20% EtOAc/hexane); νmax (thin film)/cm-1 2929w, 1732w, 1615w, 1445m, 
1073s; δH (400 MHz, CDCl3) 8.02 (1H, s, H-3), 7.44 (1H, d, J 8.7 Hz, H-13), 7.35 
(5H, m, H-7 to 11), 6.41 (1H, d, J 8.7 Hz, H-14), 5.34 (2H, s, H-4), 4.53 (2H, s, H-5), 
2.63 (3H, s, H-12); δC (100 MHz, CDCl3) 143.6 (C-1), 139.5 (C-2), 136.1 (C-6), 
132.7 (C-3), 128.5 (C-8/10), 128.1 (C-9), 127.9 (C-7/11), 120.0 (C-14), 76.1 (C-13), 
74.6 (C-4), 70.3 (C-5), 16.2 (C-12); m/z (ESI+) found 387.0027, [M+H]+ 
C14H16IN2OS requires 387.0028.  
Consistent with literature data.6  
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(E)-N-((Z)-2-(1-((Benzyloxy)methyl)-2-(methylthio)-1H-imidazol-4-yl)vinyl)-3-
(3,5-dibromo-4-methoxyphenyl)-2-(((4-methoxybenzyl)oxy)imino)propanamide 
(59) 
1
8'
9
16
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O
N
H
OMe
Br Br
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MeS O
O
MeO
11
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14'
9'
1'
 
To a stirred mixture of primary amide 61 (277 mg, 0.570 mmol), Cs2CO3 (336 mg, 
1.03 mmol) and copper(I) iodide (9.85 mg, 51.7 µmol) and THF (1.5 mL) in a sealed 
microwave vial at room temperature was added vinyl iodide 60 (200 mg, 0.517 mmol) 
in THF (1 mL). Then, N,N′-dimethylethanediamine (11.2 µL, 0.104 mmol) was added 
and the mixture heated to 70 ºC for 4 h. Upon cooling the mixture was filtered 
through celite and washed with EtOAc (50 mL) and concentrated in vacuo. The 
residue was purified by flash column chromatography (10-30% EtOAc/Hexanes) to 
furnish 59 (314 mg, 0.422 mmol, 82%) as a yellow oil. 
Rf 0.24 (20% EtOAc/Hexanes); νmax (thin film)/cm-1 3287w, 2928w, 1658s, 1557s, 
1241s; δH (400 MHz, CDCl3) 11.72 (1H, d, J 10.8 Hz, NH), 7.42 (2H, s, H-2/6), 7.38-
7.29 (7H, m, H3'/7', H-11'/16', H-12'/15' and H-14'), 7.01 (1H, dd, J 10.8, 9.2 Hz, H-
10), 6.97 (1H, s, H-13), 6.91 (2H, d, J 8.6 Hz, H-4'/6') 5.57 (1H, d, J 9.2 Hz, H-11), 
5.32 (2H, s, H-9'), 5.27 (2H, s, H-1'), 4.48 (2H, s, H-10'), 3.90 (2H, s, H-7), 3.83 (3H, 
s, H-16), 3.82 (3H, s, H-8'), 2.70 (3H, s, H-15); δC (100 MHz, CDCl3) 159.8 (C-9), 
159.7 (C-5'), 152.5 (C-4), 151.5 (C-8), 143.6 (C-14), 140.2 (C-12), 136.2 (C-11'), 
134.9 (C-1), 133.4 (C-2/6), 130.0 (C-3'/7'), 128.5 (C-13'/15'), 128.1 (C-14'), 127.9 (C-
2'), 127.7 (C-12'/16'), 121.0 (C-10), 118.4 (C-13), 117.6 (C-3/5), 114.0 (C-4'/6'), 
101.0 (C-11), 77.5 (C-1'), 74.5 (C-9'), 70.3 (C-10'), 60.4 (C-16), 55.2 (C-8'), 28.9 (C-
7), 16.8 (C-15); m/z (ESI+) found 743.0553, [M+H]+ C32H33Br2N4O5S (79Br) requires 
743.0538.  
Crystals of 59 were obtained from a solution of MeCN/H2O (1:1). The structure was 
confirmed by X-ray crystallographic analysis and given the unique identifier sl0909. 
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(E)-N-((Z)-2-(1-((Benzyloxy)methyl)-2-(methylthio)-1H-imidazol-4-yl)vinyl)-3-
(3,5-dibromo-4-methoxyphenyl)-2-(hydroxyimino)propanamide (66) 
1
9
16
N
O
N
H
OMe
Br Br
N
N
MeS O
HO
11
13
15
14'
9'  
To a stirred solution of enamide 59 (22.8 mg, 30.6 µmol) and anisole (33.3 µL, 0.306 
mmol) in CH2Cl2 (2 mL) at room temperature was added aluminium trichloride 
(40.8 mg, 0.306 mmol). After 1 min, a saturated aqueous solution of NaHCO3 (3 mL) 
was added followed by a saturated aqueous solution of Rochelle’s salt (3 mL) and 
stirred for 10 min. The aqueous phase was extracted with CH2Cl2 (3 × 15 mL) and the 
combined organic layers were dried, and concentrated in vacuo. The residue was 
purified by flash column chromatography (10-40% CH2Cl2/MeOH) to furnish 66 
(11.2 mg, 17.9 µmol, 59%) as a yellow solid. 
Rf 0.19 (20% EtOAc/Petrol); νmax (thin film)/cm-1 s, 3247 br, 2927 w, 1642 s, 1610 m, 
1558 s, 1420 s, 1241 s; δH (400 MHz, CDCl3) 11.99 (1H, br d, J 9.9 Hz, NH), 7.52 
(2H, s, H-2/6), 7.47 (1H, s, OH), 7.37-7.29 (5H, m, H4'/8', H-5'/7' and H-6'), 6.98 
(1H, dd, J 10.7, 9.0 Hz, H-10), 6.92 (1H, s, H-13), 5.56 (1H, d, J 9.0 Hz, H-11), 5.26 
(2H, s, H-1'), 4.47 (2H, s, H-2'), 3.96 (2H, s, H-7), 3.84 (3H, s, H-16), 2.76 (3H, s, H-
15); δC (100 MHz, CDCl3) 159.7 (C-9), 153.2 (C-8), 152.7 (C-4), 144.2 (C-14), 140.1 
(C-12), 136.2 (C-3'), 134.7 (C-1), 133.5 (C-2/6), 128.6 (C-5'/7'), 128.2 (C-6'), 127.9 
(C-4'/8'), 121.0 (C-10), 118.2 (C-13), 117.8 (C-3/5), 101.2 (C-11), 74.4 (C-1'), 70.4 
(C-2'), 60.6 (C-16), 28.1 (C-7), 15.6 (C-15); m/z (ESI+) found 622.9960, [M+H]+ 
C24H25Br2N4O4S (79Br) requires 622.9963. 
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(E)-2-((Benzyloxy)imino)-N-((Z)-2-(1-((benzyloxy)methyl)-2-(methylthio)-1H-
imidazol-4-yl)vinyl)-3-(3,5-dibromo-4-methoxyphenyl)propanamide (74) 
1
9
16
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O
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N
MeS O
O
11
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15
13'
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To a stirred mixture of primary amide 73 (81.1 mg, 0.178 mmol), Cs2CO3 (106 mg, 
0.324 mmol), copper(I) iodide (7.29 mg, 38.3 µmol) and THF (1.0 mL) in a sealed 
microwave vial at room temperature was added vinyl iodide 60 (62.4 mg, 0.162 
mmol) in THF (1 mL). Then, N,N′-dimethylethanediamine (8.26 µL, 76.7 µmol) was 
added and the mixture heated to 70 ºC for 9 h. Upon cooling the mixture was filtered 
through celite and washed with EtOAc (50 mL) and concentrated in vacuo. The 
residue was purified by flash column chromatography (10-30% EtOAc/Hexanes) to 
furnish 74 (96.0 mg, 0.134 mmol, 83%) as a yellow oil. 
Rf 0.31 (20% EtOAc/Petrol); νmax (thin film)/cm-1 3276w, 2928w, 1656s, 1556s, 
1471s, 1421s, 1241s; δH (400 MHz, CDCl3) 11.74 (1H, d, J 10.8 Hz, NH), 7.47 (2H, 
s, H-2/6), 7.42-7.30 (10H, m, H-3' to H-7' and H-11' to 15'), 7.03 (1H, apparent t, J 
10.0 Hz, H-10), 6.96 (1H, s, H-13), 5.58 (1H, d, J 9.2 Hz, H-11), 5.37 (2H, s, H-8'), 
5.32 (2H, s, H-1'), 4.48 (2H, s, H-9'), 3.92 (2H, s, H-7), 3.84 (3H, s, H-16), 2.66 (3H, 
s, H-15); δC (100 MHz, CDCl3) 159.8 (C-9), 152.6 (C-4), 151.7 (C-8), 143.6 (C-14), 
140.2 (C-12), 136.2 (C-10'), 136.0 (C-2'), 134.8 (C-1), 133.5 (C-2/6), 128.7 (C-4'/6'), 
128.5 (C-12'/14'), 128.4 (C-5'), 128.20 (C-3'/7'), 128.15 (C-13'), 127.8 (C-11'/15'), 
121.1 (C-10), 118.4 (C-13), 117.7 (C-3/5), 101.1 (C-11), 77.8 (C-1'), 74.5 (C-8'), 70.4 
(C-9'), 60.5 (C-16), 29.0 (C-7), 16.8 (C-15); m/z (ESI+) found 713.0459, [M+H]+ 
C31H31Br2N4O4S (79Br) requires 713.0433. 
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(E)-2-((Benzyloxy)imino)-N-((Z)-2-(1-((benzyloxy)methyl)-1H-imidazol-4-
yl)vinyl)-3-(3,5-dibromo-4-methoxyphenyl)propanamide (75) 
1
9
16
N
O
N
H
OMe
Br Br
N
N
O
O
11
13
13'
8'
1'
5'
 
A mixture of 74 (76.0 mg, 0.106 mmol) and palladium black (66 mg, 0.620 mmol) in 
dioxane/AcOH (1:1, 3 mL) was stirred under an H2 atmosphere for 4 h. The mixture 
was filtered through a pad of celite and the solvent removed in vacuo. The residue 
was taken up in EtOAc (20 mL), washed with water (20 mL), dried and concentrated 
in vacuo. The residue was purified by flash column chromatography (10-30% 
EtOAc/Petrol) to furnish 75 (11.4 mg, 17.1 µmol, 16%) as a white solid. 
Rf 0.20 (20% EtOAc/Petrol); νmax (thin film)/cm-1 3251w, 2924w, 2853w, 1654s, 
1556s, 1468s, 1240s; δH (400 MHz, CDCl3) 12.1 (1H, d, J 10.8 Hz, NH), 7.55 (1H, br 
s, H-14), 7.48-7.46 (2H, m, Ph-H), 7.45 (2H, s, H-2/6), 7.40-7.28 (8H, m, Ph-H), 7.00 
(1H, dd, J 10.8, 9.2 Hz, H-10), 6.96 (1H, d, J 1.3 Hz, H-13), 5.61 (1H, d, J 9.1 Hz, H-
11), 5.35 (2H, s, H-8'), 5.31 (2H, s, H-1'), 4.44 (2H, s, H-9'), 3.89 (2H, s, H-7), 3.83 
(3H, s, H-16); δC (100 MHz, CDCl3) 159.9 (C-9), 152.6 (C-4), 151.0 (C-8), 141.0 (C-
12), 136.6 (C-14), 136.55 (C-2'), 135.9 (C-10'), 134.8 (C-1), 133.4 (C-2/6), 128.7 (C-
4'/6'), 128.6 (C-12'/14'), 128.4 (C-3'/7'), 128.38 (C-5'), 128.0 (C-11'/15'), 121.4 (C-
10), 117.7 (C-3/5), 116.0 (C-13), 101.0 (C-11), 77.9 (C-1'), 75.1 (C-8'), 70.1 (C-9'), 
60.5 (C-16), 28.7 (C-7); m/z (ESI+) found 667.0587, [M+H]+ C30H29Br2N4O4 (79Br) 
requires 667.0556. 
The 13C chemical shift for C-13' is hidden. 
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(Z)-2-Acetoxy-3-(3,5-dibromo-4-methoxyphenyl)acrylic acid (88) 
1
9
15
O
O
HO O
OMe
BrBr
11  
A mixture of acetic anhydride (10 mL, 106 mmol), 71 (1.00 g, 2.84 mmol) and 
sodium acetate (349 mg, 4.25 mmol) was stirred for 2 h. The resultant white 
precipitate was isolated by filtration, washed with Et2O (3 × 20 mL) and dissolved in 
H2O (100 mL). The aqueous solution was acidified to pH 0 by the dropwise addition 
of 3 N HCl followed by the addition of Et2O (100 mL). The organic layer was 
separated and the aqueous phase extracted with Et2O (2 × 100 mL). The combined 
organic layers were dried and evaporated to dryness in vacuo to furnish 88 (806 mg, 
2.04 mmol, 72%) as a white solid.  
Rf 0.53 (20% MeOH/CH2Cl2); νmax (thin film)/cm-1 2827br, 1773s, 1685s, 1649m, 
1471s, 1181s; δH (400 MHz, CD3OD) 7.80 (2H, s, H-2/6), 7.19 (1H, s, H-7), 3.87 
(3H, s, H-15), 2.30 (3H, s, H-11); δC (100 MHz, CD3OD) 169.7 (C-10), 164.8 (C-9), 
156.2 (C-4), 140.2 (C-8), 135.1 (C-2/6), 132.4 (C-1), 124.5 (C-7), 119.3 (C-3/5), 61.2 
(C-15), 20.5 (C-11); m/z (ESI+) found 392.8980, [M+H]+ C12H11Br2O5 (79Br) requires 
392.8973; m.p. 168-170 ºC. 
Crystals of 88 were obtained by slow evaporation from Et2O. The structure was 
confirmed by X-ray crystallographic analysis and given the unique identifier sl1035. 
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(Z)-2-Acetoxy-3-(3,5-dibromo-4-methoxyphenyl)acrylic (ethyl carbonic) 
anhydride (89) 
1
9
15
O
O
O O
O
O
OMe
BrBr
12
11
14  
To a stirred solution of acid 88 (100 mg, 0.254 mmol) and Et3N (53.1 µL, 0.381 
mmol) in THF (5 mL) at 0 ºC was added ethyl chloroformate (25.5 µL, 0.267 mmol). 
After 1 h, EtOAc (25 mL) and H2O (25 mL) were added, the organic layer separated, 
and the aqueous layer extracted with EtOAc (2 x 25 mL). The combined organic 
extracts were dried and evaporated to dryness in vacuo to furnish 89 (112 mg, 0.240 
mmol, 95%) as a colourless oil.  
Rf 0.45 (20% Et2O/PE 40-60); νmax (thin film)/cm-1 2984 w, 2933 w, 1808 s, 1775 s, 
1745 s, 1472 m, 1155 s; δH (400 MHz CDCl3) 7.77 (2H, s, H-2/6), 7.24 (1H, s, H-7), 
4.38 (2H, q, J 7.2 Hz, H-13), 3.91 (3H, s, H-15), 2.36 (3H, s, H-11), 1.39 (3H, t, J 7.2 
Hz, H-14); δC (100 MHz, CDCl3) 167.7 (C-10), 156.5 (C-9), 155.8 (C-4), 148.0 (C-
12), 136.0 (C-8), 134.4 (C-2/6), 129.8 (C-1), 127.3 (C-7), 118.6 (C-3/5), 66.2 (C-13), 
60.8 (C-15), 20.4 (C-11), 13.9 (C-14). 
Chapter 4:Towards the Total Syntheses of the Ceratamines 
 251 
(Z)-3-Amino-1-(3,5-dibromo-4-methoxyphenyl)-3-oxoprop-1-en-2-yl acetate (90) 
1
9
15
O
O
H2N O
OMe
BrBr
11
 
To a stirred solution of acid 88 (105 mg, 0.266 mmol) and Et3N (55.6 µL, 0.399 
mmol) in THF (5 mL) at 0 ºC was added ethyl chloroformate (26.8 µL, 0.280 mmol). 
After 45 min, HMDS (555 µL, 2.66 mmol) was added and the reaction mixture was 
stirred for a further 30 min at 0 ºC. The reaction mixture was allowed to warm to 
room temperature and after 1 h, EtOAc (25 mL) and H2O (25 mL) were added, the 
organic layer separated and the aqueous layer was extracted with EtOAc (2 x 25 mL). 
The combined organic extracts were dried, and concentrated in vacuo. The residue 
was purified by flash column chromatography (30-70% EtOAc/Petrol) to furnish 90 
(56.6 mg, 0.144 mmol, 54%) as a white solid.  
Rf 0.22 (40% Et2O/PE 40-60); νmax (thin film)/cm-1 3424m, 3163br, 1753s, 1692s, 
1644m, 1615m, 1185s; δH (400 MHz, d6-DMSO) 7.83 (2H, s, H-2/6), 7.82 (1H, br s, 
NH), 7.51 (1H, br s, NH), 7.11 (1H, s, H-7), 3.82 (3H, s, H-15), 2.29 (3H, s, H-11); δC 
(100 MHz, d6-DMSO) 168.2 (C-10), 163.0 (C-9), 153.6 (C-4), 141.8 (C-8), 133.2 (C-
2/6), 131.6 (C-1), 118.9 (C-7), 117.8 (C-3/5), 60.5 (C-15), 20.8 (C-11); m.p. 140-
142 ºC  
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4.5 Appendix 
4.5.1 Crystal Structure Data 
(E)-3-(3,5-Dibromo-4-methoxyphenyl)-2-
(((4methoxybenzyl)oxy)imino)propanamide (61) 
 
Crystal data and structure refinement for sl0854 
  
Identification code    sl0854 
Empirical formula    C18H18Br2N2O4 
Formula weight    486.16 
Temperature     180(2) K 
Wavelength     0.71073 Å 
Crystal system    Triclinic 
Space group     P-1 
Unit cell dimensions    a = 8.8998(1) Å α = 68.743º 
      b = 10.1559(2) Å β = 80.052(1)º 
      c  = 11.2089(2) Å γ = 86.219(1)º 
Volume     929.99(3) Å3 
Z      2 
Density (calculated)    1.736 Mg/m3 
Absorption coefficient   4.384 mm–1 
F(000)      484 
Crystal size     0.35 × 0.32 × 0.28 mm3 
Theta range for data collection  3.52 to 32.05º 
Index ranges     -13<=h<=13, -15<=k<=15, -16<=1<=16 
Reflections collected    18490 
Independent reflections   6462 [R(int) = 0.0605] 
Completeness to theta = 32.05º  99.4% 
Absorption correction    Semi-empirical from equivalents 
Max. and min. transmission   0.301 and 0.180 
Refinement method    Full-matrix least-squares on F2 
Data / restraints / parameters   6462 / 0 / 237 
Goodness-of-fit on F2    1.036 
Final R indices [I>2sigma (I)]  R1 = 0.0383, wR2 = 0.0962 
R indices (all data)    R1 = 0.0487, wR2 = 0.1028  
Largest diff. peak and hole   0.716 and –1.227 e. Å–3 
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(E)-N-((Z)-2-(1-((Benzyloxy)methyl)-1H-imidazol-4-yl)vinyl)-3-(3,5-dibromo-4-
methoxyphenyl)-2-(((4-methoxybenzyl)oxy)imino)propanamide (59) 
 
Crystal data and structure refinement for sl0909 
  
Identification code    sl0909 
Empirical formula    C34H35Br2N5O5S 
Formula weight    785.55 
Temperature     180(2) K 
Wavelength     0.71073 Å 
Crystal system    Monoclinic 
Space group     P2(1)/c 
Unit cell dimensions    a = 32.4143(4) Å α = 90º 
b = 4.3270(1) Å β = 114.087(1)º 
      c  = 26.7941(6) Å γ = 90º 
Volume     3430.82(12) Å3 
Z      4 
Density (calculated)    1.521 Mg/m3 
Absorption coefficient   2.472 mm–1 
F(000)      1600 
Crystal size     0.46 × 0.05 × 0.04 mm3 
Theta range for data collection  3.67 to 27.49º 
Index ranges     -28<=h<=41, -5<=k<=5, -34<=1<=34 
Reflections collected    23528 
Independent reflections   7569 [R(int) = 0.0784] 
Completeness to theta = 27.49º  95.7% 
Absorption correction    Semi-empirical from equivalents 
Max. and min. transmission   0.906 and 0.556 
Refinement method    Full-matrix least-squares on F2 
Data / restraints / parameters   7569 / 0 / 428 
Goodness-of-fit on F2    1.100 
Final R indices [I>2sigma (I)]  R1 = 0.0586, wR2 = 0.1091 
R indices (all data)    R1 = 0.1005, wR2 = 0.1254  
Largest diff. peak and hole   0.892 and –0.431 e. Å–3 
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(Z)-2-Acetoxy-3-(3,5-dibromo-4-methoxyphenyl)acrylic acid (88) 
 
Crystal data and structure refinement for sl1035 
  
Identification code    sl1035 
Empirical formula    C12H10Br2O5 
Formula weight    394.02 
Temperature     181(2) K 
Wavelength     0.71073 Å 
Crystal system    Triclinic 
Space group     P-1 
Unit cell dimensions    a = 8.1680(2) Å α = 103.985(1)º
      b = 8.6811(2) Å β = 109.084(1)º 
      c  = 10.6434(3) Å γ = 96.000(2)º 
Volume     678.07(3) Å3 
Z      2 
Density (calculated)    1.930 Mg/m3 
Absorption coefficient   5.990 mm–1 
F(000)      384 
Crystal size     0.23 × 0.23 × 0.12 mm3 
Theta range for data collection  3.64 to 32.02º 
Index ranges     -12<=h<=11, -12<=k<=12, -11<=1<=15 
Reflections collected    9902 
Independent reflections   4587 [R(int) = 0.0425] 
Completeness to theta = 32.02º  97.4% 
Absorption correction    Semi-empirical from equivalents 
Max. and min. transmission   0.490 and 0.326 
Refinement method    Full-matrix least-squares on F2 
Data / restraints / parameters   4587 / 0 / 177 
Goodness-of-fit on F2    1.036 
Final R indices [I>2sigma (I)]  R1 = 0.0337, wR2 = 0.0879 
R indices (all data)    R1 = 0.0455, wR2 = 0.0940  
Largest diff. peak and hole   0.740 and –1.026 e. Å–3 
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5 Publications 
Total synthesis of Subereamollines A and B; J. W. Shearman, R. M. Myers, J. D. 
Brenton and S. V. Ley, Org. Biomol. Chem., 2011, 9, 62-65. 
The first total syntheses of (+)- and (-)-subereamollines A and B are reported. The enantiomeric forms 
of the natural products were obtained by preparative chiral HPLC separation of the corresponding 
racemates. 
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Antivascular and Anticancer Activity of Dihalogenated A-ring Analogues of 
Combretastatin A-4; T. M. Beale, R. M. Myers, J. W. Shearman, D. S. Charnock-
Jones, J. D. Brenton, F. V. Gergeley and S. V. Ley, Med. Chem. Commun., 2010, 1, 
202-208. 
The generally accepted view is that the 3,4,5-trimethoxy-substituted aromatic A-ring of combretastatin 
A-4 (CA-4) and its analogues should be conserved in order to maintain biological activity through 
enforcing an active molecular conformation. Contrary to this, we have found that substituting the larger 
meta-methoxy groups of CA-4 with smaller halogen atoms results in compounds that are equipotent or 
more potent than CA-4 itself in vitro. 
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Total Syntheses of the Bromotyrosine-Derived Natural Products Ianthelline, 5-
Bromoverongamine and JBIR-44; J. W. Shearman, R. M. Myers, T. M. Beale, J. D. 
Brenton and S. V. Ley, Tetrahedron Lett., 2010, 51, 4812-4814. 
The total syntheses of the bromotyrosine-derived natural products ianthelline, 5-bromoverongamine 
and JBIR-44 are described and their cytotoxic activity in a cervical cancer (HeLa) cell line and human 
umbilical vein endothelial cells (HUVECs) are reported. 
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Cancer, Chemistry and the Cell: Molecules that Interact with the Neurotensin 
Receptors; R. M. Myers, J. W. Shearman, M. O. Kitching, A. Ramos-Montoya, D. E. 
Neal and S. V. Ley, ACS Chem. Biol., 2009, 4, 503-525. 
The literature covering neurotensin (NT) and its signalling pathways, receptors, and biological profile 
is complicated by the fact that the discovery of three NT receptor subtypes has come to light only in 
recent years. Moreover, a lot of this literature explores NT in the context of the central nervous system 
and behavioral studies. However, there is now good evidence that the up-regulation of NT is intimately 
involved in cancer development and progression. This Review aims to summarize the isolation, 
cloning, localization, and binding properties of the accepted receptor subtypes (NTR1, NTR2, and 
NTR3) and the molecules known to bind at these receptors. The growing role these targets are playing 
in cancer research is also discussed. We hope this Review will provide a useful overview and a one-
stop resource for new researchers engaged in this field at the chemistry-biology interface. 
 
 
